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Background: Amyotrophic lateral sclerosis (ALS) is an invariably fatal and relatively common 
neurodegenerative disorder without effective therapy. Identified genetic variants cluster in 
biological pathways including RNA processing, axonal transport, and protein homeostasis. 
Discovery of new genetic variants within new biological pathways highlights new disease 
biology, and can lead to novel therapeutic targets. This project will focus on the development 
of cell and animal models to characterise novel ALS-associated mutations associated with 
GLT8D1, CAV1 and CAV2.  
Aims and objectives: i) To evaluate the relative toxicity of ALS-associated GLT8D1 
mutations in neuronal and non-neuronal cell lines via MTT and lactate dehydrogenase assays. 
ii) To investigate the effect of mutations on the enzyme activity of GLT8D1 using a UDP-GloTM 
glycosyltransferase assay. iii) To test whether mutant GLT8D1 causes fragmentation of the 
Golgi network using immunocytochemistry. iv) To model GLT8D1 mutations in zebrafish 
larvae via RNA microinjection. v) To model CAV1/CAV2 enhancer mutations in neuronal and 
non-neuronal cells via CRISPR/Cas9 genome editing. vi) To measure ganglioside expression 
in human cells expressing GLT8D1, CAV1 and CAV2 mutations using live cell imaging. 
Results: I studied in detail two ALS-associated GLT8D1 mutations: R92C and G78W. The 
relative toxicity of the mutations in model systems mirrors the clinical severity. Mutated 
GLT8D1 exhibits in vitro cytotoxicity and induces motor deficits in zebrafish larvae consistent 
with ALS. Identified GLT8D1 mutations are proximal to the substrate-binding site; both R92C 
and G78W mutations impair GLT8D1 enzyme activity. An R92C mutation reduces membrane 
ganglioside expression, which is indicative of dysregulated neurotrophic signalling. 
Ganglioside biosynthesis occurs in the Golgi; GLT8D1 localises to the Golgi in neuronal and 
non-neuronal cells, and preliminary data suggests an R92C mutation causes Golgi 
fragmentation. The second stage of this project follows the identification of ALS-associated 
variation within an enhancer linked to expression of CAV1/CAV2. CAV1 and CAV2 encode 
major components of caveolae, which organise membrane lipid rafts (MLR) important for 
neurotrophic signalling. Gangliosides are a key component of MLR. Discovered enhancer 
mutations reduce CAV1/CAV2 expression and disrupt ganglioside expression within MLR in 
patient-derived cells; and CRISPR/Cas9 perturbation proximate to a patient-mutation is 
sufficient to reduce CAV1/CAV2 expression in neurons.  
Conclusions: These results place dysregulated ganglioside metabolism upstream in the 
pathogenesis of ALS. I propose that GLT8D1 and CAV1/CAV2 share a common pathway of 
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Chapter 1. Introduction  
 
 
1.1. Introduction to amyotrophic lateral sclerosis  
 
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease, 
accounting for roughly 66% of all cases (Gordon, 2013). It is a relentlessly progressive and 
incurable neurodegenerative disorder characterised by the loss of both upper and lower motor 
neurons within the brainstem and spinal cord. Death and injury to motor neurons leads to a 
breakdown of neuromuscular junctions resulting in muscular atrophy, paralysis, and death 
usually by respiratory failure within 2-5 years of the first symptom (Yang et al., 2014, Renton 
et al., 2014). ALS is a multifactorial disorder with a number of described genetic and 
environmental risk factors. Although phenotypically indistinguishable from one another, 10% 
of cases are familial (fALS), usually with an autosomal dominant inheritance pattern, whilst 
the remaining 90% are sporadic (sALS), defined as having no family history of the disease 
(Renton et al., 2014). It is notable that even sALS is significantly heritable; twin studies 
estimate the broad sense heritability of sALS to be as high as 61% (Al-Chalabi et al., 2010).  
 
ALS is an age-related disorder with an incidence of 1-2 per 100,000 people worldwide and an 
estimated lifetime risk of 1 in 400 (Barber et al., 2006, Ingre et al., 2015), although some 
estimates are as high as 1 in 350 (Alonso et al., 2009, Al-Chalabi and Hardiman, 2013). There 
are geographical variations in the number of ALS cases, with prevalence rates significantly 
lower in non-European countries; however, this may be due to a lack of reliable 
epidemiological data (Chio et al., 2013).   
 
 
1.2. Clinical presentation and disease management 
 
The presentation of ALS varies greatly between individuals depending on the population of 
neurons first affected: disease can be limb- or bulbar-onset and may affect upper or lower 
motor neurons to differing degrees (Hardiman et al., 2017). While traditionally regarded as a 
pure motor system disease, cognitive decline and behavioural disturbance are increasingly 
recognised as cardinal features of ALS. Indeed, as many as 30% of ALS patients meet the 
diagnostic criteria for frontotemporal dementia (FTD) (Hinz and Geschwind, 2017). There is a 
significant genetic overlap between ALS and FTD, and both disorders are heterogeneous at 
the clinical, neuropathological, and genetic levels (Ferrari et al., 2011). FTD is a collection of 
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neurocognitive syndromes characterised by the impairment of executive functioning, 
behavioural changes, and reduced language proficiency (Young et al., 2018). Diagnosis of 
ALS is clinical and is based on the El Escorial criteria. Neurophysiology and laboratory studies 
are used to exclude alternative diagnoses, particularly reversible ALS mimics such as 
entrapment neuropathies and multifocal motor neuropathy with conduction block (Hardiman 
et al., 2017). 
There is currently no cure for ALS; therefore, clinical management is largely supportive and 
requires a multidisciplinary approach. Symptoms such as dysphagia, spasticity, cramping, and 
sialorrhea are managed on an individual basis. Two disease-modifying medications are 
currently licensed by the Food and Drugs Administration. Riluzole, a sodium channel blocking 
agent, has been shown to modestly prolong survival by approximately three months, and has 
been used for many years (Hardiman et al., 2017). The more recent, Edaravone, is an 
antioxidant that has been shown to mildly prolong functional independence in selected 
patients (Abe et al., 2014, Hardiman and van den Berg, 2017). It is expected that significant 
advancements in the treatment of the disease will require personalised approaches to target 
specific causative genes and proteins. For example, Tofersen, an antisense oligonucleotide 
for SOD1 fALS, is currently undergoing phase III trials having shown promise in phase I and 
II studies (NCT02623699). 
 
 
1.3. Genetics of ALS  
 
The first discovered ALS-associated gene, SOD1, was first identified almost three decades 
ago, and since then over 50 ALS-associated genes have been described (Taylor et al., 2016). 
Despite this, a genetic cause still cannot be identified in many families; the search for new 
ALS genes is ongoing. The cause of sALS is not fully elucidated, but genetic and 
environmental factors are both predicted to be important. Indeed, a genetic cause can be 
observed in many sporadic patients, although genetic screening of these patients is not in 
widespread clinical practice at present. Environmental factors including diet, physical activity 
and toxins have been postulated as risk factors, but definitive proof for these has yet to emerge 
(Hardiman et al., 2017). Described genetic variants are associated with >68% fALS and >11% 
sALS cases (Renton et al., 2014). Whilst more than 50 potentially causative or disease-
modifying genes have been identified, mutations in SOD1, TARDBP, FUS, and C9ORF72 are 
most frequently associated with ALS (Boylan, 2015). The discovery and characterisation of 
new genetic risk factors for ALS helps to illuminate the upstream mechanisms leading to 





The first ALS-causative mutation was identified in 1993 in the Cu/Zn superoxide dismutase 
gene (SOD1). Due to the role of SOD1 in converting superoxide radicals into oxygen and 
hydrogen peroxide, it was initially thought that mutations within this gene caused ALS via a 
loss-of-function mechanism resulting in a decrease in radical scavenging activity (Rosen, 
1993). However, this was soon disputed as different SOD1 mutants show varying degrees of 
enzyme activity, and SOD1 knockout mice do not develop ALS (Reaume et al., 1996, Yim et 
al., 1996, Al-Chalabi et al., 2012, Saccon et al., 2013). Moreover, correlations were not found 
between SOD1 dismutase activity and the aggressiveness of clinical phenotypes (Ratovitski 
et al., 1999). The fact that SOD1 mutations are autosomal dominant is most consistent with a 
gain-of-function mechanism. ALS-causing SOD1 mutations increase the protein’s propensity 
to misfold, which leads to the accumulation of SOD1 protein aggregates that induce 
neurotoxicity through mechanisms including oxidative stress and mitochondrial dysfunction 
(Rakhit et al., 2004, Vassall et al., 2006, Stathopulos et al., 2006, Joyce et al., 2011, Magrane 
et al., 2012). Since its discovery, SOD1 mutations have been shown to account for 15-20% of 
fALS cases and ~2% sALS cases, although there is significant variability between populations 
with the highest incidence in Scandinavia. More than 170 missense mutations have been 
identified which affect each of the five exons of SOD1 (Da Cruz et al., 2017). It is notable that 
SOD1-ALS is clinically and pathologically distinct from the majority of ALS cases. Familial 
SOD1-ALS patients lack TDP-43 pathology and are less likely to have significant cognitive 
changes (Mackenzie et al., 2007, Wicks et al., 2009), which may explain the failure to translate 




In 2008, it was demonstrated that mutations within transactive response DNA binding protein 
43kDa (TARDBP), which encodes the TDP-43 protein (Sreedharan et al., 2008), are a cause 
of ALS. TDP-43 is a ubiquitously expressed ribonucleoprotein that is predominantly localised 
in the nucleus, where it performs a range of functions linked to RNA metabolism including 
transcription, mRNA splicing, mRNA stability, RNA transport, miRNA biogenesis, and stress 
granule dynamics (Buratti and Baralle, 2012). There are over 50 known ALS-causing 
mutations in TARDBP, which contribute to 4-5% of fALS cases and 1% of sALS cases 
(Millecamps et al., 2010, Buratti, 2015). The mislocalisation of TDP-43 from the nucleus to the 
cytoplasm and the formation of TDP-43-positive cytoplasmic inclusions is recognised as the 
pathological hallmark of ~97% of ALS cases, including patients with mutated TARDBP 
(Neumann et al., 2006). The discovery that mutations within this protein are a cause of ALS 
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was a powerful argument that this almost universal pathology is an upstream cause of disease 
and not simply a downstream consequence.    
 
It is unclear whether TDP-43 aggregates cause toxicity through gain-of-function and/or loss-
of-function mechanisms. Several lines of evidence have shown that loss of nuclear TDP-43 
causes splicing defects in cellular and animal models, as well as in motor neurons from 
TARDBP-ALS patients (De Conti et al., 2015, Highley et al., 2014, Ling et al., 2015). However, 
other lines of evidence suggest that the key change is loss of autoregulation leading to 




The following year, in 2009, ALS-causing mutations were identified within fused in sarcoma 
(FUS) (Kwiatkowski et al., 2009, Vance et al., 2009). FUS has a functional role in a range of 
metabolic processes including transcription, mRNA splicing, mRNA transport, stress granule 
formation, miRNA biogenesis, and genome integrity (Deng et al., 2014b). Similar to TDP-43, 
FUS is predominantly localised in the nucleus, but also shuttles between the nucleus and 
cytoplasm (Zinszner et al., 1997). Cytoplasmic aggregations of FUS are described; however, 
like TDP-43, it is unknown how these aggregates cause motor neuron toxicity. Although, there 
is strong evidence for a dominant negative mechanism of FUS mislocalisation, misfolding and 
aggregation, leading to depleted nuclear function (Deng et al., 2014a). Currently, there are 
more than 50 FUS mutations associated with 4-5% fALS and <1% sALS cases, and the 
majority of these mutations present with an autosomal dominant mode of inheritance. Clinically 
FUS-ALS patients are younger than most, and importantly TDP-43 pathology is absent from 




At 39% of fALS cases and 8% of sALS cases, the most common genetic cause of ALS was 
identified in 2011 as a (G4C2)n hexanucleotide repeat expansion in intron 1 of chromosome 9 
open reading frame 72 (C9ORF72) (DeJesus-Hernandez et al., 2011, Renton et al., 2011, 
Majounie et al., 2012). Whilst >30 (G4C2)n repeats are considered pathogenic (Byrne et al., 
2014, Beer et al., 2015), expansions of 500-2000 repeats are common in ALS patients 
(Cooper-Knock et al., 2014). It remains unclear as to how the (G4C2)n repeat expansion 
causes ALS, although it is thought to be a result of three mutually-inclusive mechanisms: 
C9ORF72 haploinsufficiency, dipeptide repeat protein toxicity, and RNA toxicity (Donnelly et 
al., 2013, Waite et al., 2014, Mori et al., 2013, Zu et al., 2013). The weight of evidence 
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suggests C9ORF72 repeat expansions cause ALS via a gain-of-function mechanism, whilst 
loss-of-function mechanisms are more likely to modulate the disease phenotype through 
dysregulated autophagy (Zhu et al., 2020). Patients with hexanucleotide-repeat expansions in 
the C9ORF72 gene tend to have aggressive disease and a higher prevalence of cognitive 
involvement and overlap with FTD (Hardiman et al., 2017). Crucially, C9ORF72-ALS overlaps 
clinically and pathologically with the more common sporadic disease (Cooper-Knock et al., 
2012), suggesting that study of C9ORF72-ALS may lead to discoveries applicable for the vast 
majority of ALS patients. This fact together with the relative frequency of C9ORF72-ALS 




1.4. ALS pathological mechanisms  
 
ALS is a multifactorial disorder with various mechanisms implicated in the disease 
pathogenesis. In most cases of ALS, it is difficult to separate the initial toxic insult and 
exacerbating secondary pathways that drive disease progression. Associated pathological 
mechanisms include oxidative stress, mitochondrial dysfunction, dysregulated axonal 
transport, aberrant RNA processing, and impaired protein homeostasis, as well as a non-cell 
autonomous toxicity.  
 
1.4.1. Oxidative stress 
 
Oxidative stress is a result of an imbalance in the production and removal of reactive oxygen 
species (ROS), and/or the inability to repair oxidative damage. Oxidative stress promotes 
tissue damage by interacting with other pathological mechanisms that promote the 
degeneration of motor neurons (Pollari et al., 2014). Oxidative stress in the form of free radical 
damage and abnormal free radical metabolism is well described in ALS patients (Shaw et al., 
1995, Ferrante et al., 1997, Smith et al., 1998, Chang et al., 2008). In certain SOD1-ALS 
mouse models, oxidative stress is shown to originate from the distal muscles in advance of 
disease onset (Kraft et al., 2007). ROS are shown to inhibit the release of neurotransmitters, 
thus interfering with synaptic transmission. Moreover, a rise in the level of ROS is 
demonstrated to inhibit the function of neuromuscular junctions (Naumenko et al., 2011), 
suggesting that oxidative damage may originate in peripheral tissues and progress in a 
retrograde manner to neurons. Indeed, the ALS gene most commonly associated with 
oxidative damage is SOD1 (Wiedau-Pazos et al., 1996, Crow et al., 1997), although mutant 
TDP-43 has also been implicated in this pathway (Duan et al., 2010).   
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1.4.2. Mitochondrial dysfunction 
 
The mitochondrion is a membrane-bound organelle that functions as the major hub to convert 
energy for cellular processes (Liu et al., 2020b). Impaired mitochondrial morphology and 
function are well-known phenomena of ALS and neurodegeneration more broadly (Johri and 
Beal, 2012). Mitochondrial dysfunction has been described in ALS patient spinal motor 
neurons and in various cell and animal models of the disease. These models have identified 
impaired ATP production, calcium buffering, redox balance, respiratory complexes and 
mitochondria-dependent apoptosis (Bowling et al., 1993, Dal Canto and Gurney, 1994, Fujita 
et al., 1996, Menzies et al., 2002, Ferri et al., 2006, Sasaki et al., 2007, Grosskreutz et al., 
2010, Shi et al., 2010, Cozzolino and Carri, 2012). Indeed, motor neurons have a high 
metabolic demand, making them particularly susceptible to dysregulated ATP production 
(Menzies et al., 2002). Moreover, impaired mitochondrial function has been shown to increase 
ROS production, resulting in a positive feedback loop characterised by enhanced oxidative 
damage to mitochondrial components and greater mitochondrial dysfunction. This process 
could be central to motor neuron degeneration in ALS (Kaal et al., 2000, Robberecht, 2000). 
 
1.4.3. Impaired axonal transport 
 
Motor neurons have extremely long axons extending from the CNS to the muscles in which 
they innervate. Any hypothesis to explain ALS needs to account for the specific vulnerability 
of motor neurons, and their anatomy is the most obvious candidate. These axons rely on the 
efficient transport of protein, lipids, RNA and organelles via the cytoskeleton and associated 
motor proteins. Various genes implicated in ALS including FUS, TARBP, and C9ORF72, are 
associated with axonal transport and the cytoskeleton, suggesting impaired axonal transport 
is a feature of ALS pathogenesis. Impaired axonal transport has been described in several 
different genetic models of ALS (Alami et al., 2014, De Vos et al., 2007, Morotz et al., 2012), 
and is proposed to occur early in the disease pathogenesis (De Vos et al., 2008). Indeed, 
axonal transport defects have been reported in pre-symptomatic SOD1G93A ALS mice (Bilsland 
et al., 2010).   
 
1.4.4. Dysregulated RNA metabolism 
 
It has become increasingly clear that aberrant RNA metabolism is central 
to ALS pathogenesis. The four major ALS genes: SOD1, TARDBP, FUS, and C9ORF72, have 
functional roles in aspects of RNA metabolism including mRNA transcription, alternative 
splicing, RNA transport, mRNA stabilization, and miRNA biogenesis (Butti and Patten, 2018). 
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In particular, TDP-43, which forms the characteristic cytoplasmic inclusions seen in the 
majority of ALS patients, is reported to regulate the expression of hundreds of mRNAs and 
the splicing of >1000 mRNAs (Polymenidou et al., 2011). Moreover, TDP-43 is transported 
along axons and co-localises with axonal mRNA binding proteins at synaptic terminals (Wang 
et al., 2008, Narayanan et al., 2013). TDP-43-mediated regulation of cytoplasmic mRNA in 
motor neurons is shown to influence axonal outgrowth (Fallini et al., 2012). Similarly, FUS is 
crucial for mRNA transport within axons and this function is disrupted in ALS (Butti and Patten, 
2018). Furthermore, the (G4C2)n repeat expansion in C9ORF72 is thought to directly exert 
RNA toxicity by disrupting RNA metabolism. Transcription of the repeat expansion leads to 
accumulations of RNA foci, which facilitate the recruitment, mislocalisation, and impaired 
function of RNA binding proteins (Gendron et al., 2013, Simon-Sanchez et al., 2012, Donnelly 
et al., 2013, Lee et al., 2013).  
 
1.4.5. Impaired protein homeostasis 
 
Insoluble protein aggregates are a hallmark neuropathological feature of ALS (Webster et al., 
2017). Protein inclusions have been identified in degenerating neurons and glial cells of the 
brainstem, spinal cord, cerebellum, hippocampus, as well as the frontal and temporal lobes 
(Piao et al., 2003, Nishihira et al., 2008, Zhang et al., 2008, Al-Chalabi et al., 2012). These 
inclusions are ubiquitinated, implying that the ubiquitin-proteasome and autophagy systems 
are impaired, which is suggestive of defects in protein turnover (Neumann et al., 2006, 
Blokhuis et al., 2013). Multiple lines of evidence implicate ER stress in ALS pathogenesis, 
suggesting an inability to manage misfolded proteins (Matus et al., 2013). A large number of 
ALS associated genes including VCP, OPTN, SOD1, TARDBP, FUS and C9ORF72, directly 
or indirectly regulate protein trafficking or degradation via the ubiquitin-proteasome or 
autophagy pathways (Webster et al., 2017), which strongly implicates impaired protein 
homeostasis in ALS pathogenesis.  
 
1.4.6. Non-cell autonomous toxicity and neuroinflammation  
 
Various studies have implicated glial cells in the pathogenesis of ALS. Astrocytes derived from 
the direct reprogramming of SOD1-ALS, C9ORF72-ALS, and sALS patient fibroblasts are 
selectively toxic to wild-type (WT) neurons in co-culture (Meyer et al., 2014, Nagai et al., 2007, 
Di Giorgio et al., 2007). It has been demonstrated that astrocyte-derived extracellular vesicles 
and associated miRNA cargo are responsible for astrocyte-mediated toxicity in C9ORF72-
ALS (Varcianna et al., 2019). In support of the non-cell autonomous nature of ALS, deletion 
of mutant-SOD1 exclusively from mouse astrocytes slowed late-stage disease progression 
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(Yamanaka et al., 2008). Moreover, astrocytes derived from fALS and sALS patient post-
mortem neural progenitor cells (NPCs) induce motor neuron death in vitro, irrespective of the 
mutation they carry (Haidet-Phillips et al., 2011).  
 
 
1.5. Animal models of ALS 
 
1.5.1. Mouse models 
 
The first animal model of ALS was the SOD1G93A mouse (Gurney et al., 1994), which harbours 
mutant human SOD1 cDNA randomly inserted into its genome. This transgenic line remains 
the most widely used animal model of human ALS. SOD1G93A mice present with hind limb 
weakness at ~90 days, concurrent with neurodegeneration that closely resembles human ALS 
pathology (Synofzik et al., 2010). Death occurs by ∼135 days; however, this is dependent on 
the genetic background. Despite its widespread use, the SOD1G93A mouse may display 
phenotypic traits that arise from overexpression of the SOD1 protein, as opposed to being an 
effect of the SOD1G93A mutation itself (Shibata, 2001). Indeed, overexpression of human WT 
SOD1 in mice causes an abnormal phenotype (Jaarsma et al., 2001).  
 
The discovery of the C9ORF72 hexanucleotide (G4C2)n repeat expansion (DeJesus-
Hernandez et al., 2011, Renton et al., 2011) has led to the generation of various ALS/FTD 
animal models. Some of the first ALS/FTD transgenic mouse models were developed using a 
bacterial artificial chromosome (BAC) to express the G4C2 expansion. Whilst these models 
displayed molecular phenotypes similar to human C9ORF72-associated ALS/FTD, the mice 
were clinically unaffected with no evidence of neurodegeneration (O'Rourke et al., 2015, 
Peters et al., 2015). Conversely, other BAC transgenic mouse models expressing a similar 
number of repeats have since been shown to present with an age-dependent development of 
cognitive and behavioural dysfunction (Liu et al., 2016, Jiang et al., 2016). Notably, the Liu 
model included much more of the original human genomic context for the repeat expansion, 
suggesting that the surrounding regulatory genome is necessary to drive pathogenesis. 
Coincident with this was a much higher level of antisense transcription, which the authors 
linked to neuronal loss. However, there is some ongoing debate as to the validity of this model 
as it demonstrates inconsistent behavioural phenotypes and TDP-43 pathology (Alrafiah, 
2018). Finally, when researchers utilised a viral-mediated delivery system to express the 
repeat expansion, mice not only displayed histopathological features, but also developed 




Whilst these models show contrasting results, they do all provide evidence for gain-of-function 
toxicity associated with the G4C2 expansion. Observed pathological effects are generally all 
characteristic of ALS/FTD. In contrast, pathogenic mechanisms associated with C9ORF72 
loss-of-function in transgenic mice appear to extend beyond the characteristic features of 
ALS/FTD. One of the earlier loss-of-function models generated by selective knockout of the 
C9ORF72 ortholog in mouse neurons and glia was shown to be insufficient to cause disease 
(Koppers et al., 2015). Conversely, mice harbouring loss-of-function mutations in the 
orthologue of C9ORF72 were shown to develop an array of complications in the 
haematopoietic system including splenomegaly, neutrophilia, thrombocytopenia, increased 
expression of inflammatory cytokines, and severe autoimmunity, which ultimately led to a high 
mortality rate (Burberry et al., 2016). A similar result was observed by Jiang and colleagues, 
who reported that a chronic 50% reduction in C9ORF72 led to splenomegaly and enlarged 
lymph nodes (Jiang et al., 2016). Whilst ALS/FTD are not considered autoimmune disorders, 
it is evident that C9ORF72 is a multifactorial gene that operates in pathways extending beyond 
the CNS. This is evidence that the function of the actual C9ORF72 protein may not be 
important for the development of ALS-FTD, although this does not explain why ALS has not 
been linked to similar GC-rich expansions at other sites within the genome.    
 
The identification of ALS-causing TARDBP mutations has led to the generation of a wide range 
of TDP-43 ALS/FTD mouse models. A limitation of these models is that observed phenotypes 
may be artefacts of TDP-43 overexpression. Indeed, overexpression of WT TDP-43 has been 
shown to cause an ALS phenotype (Xu et al., 2010). Recently, issues regarding 
overexpression were circumvented through the use of CRISPR/Cas9 genome editing; 
however, this model did not display a robust phenotype nor show signs of TDP-43 
mislocalisation (White et al., 2018). Interestingly, TDP-43 was overexpressed in this model 
due to a circumventing of the normal autoregulation mechanism responsible for precise control 
of TDP-43 levels. The model developed by Wegorzewska and colleagues in 2009 accurately 
recapitulated clinical hallmarks of ALS/FTD, but lacked typical TDP-43-positive pathology 
(Wegorzewska et al., 2009). 
 
 
1.5.2. Zebrafish models 
 
Contrary to previous findings in mice (Koppers et al., 2015), haploinsufficiency 
of C9orf72 orthologues in zebrafish cause motor axon and behaviour deficits (Ciura et al., 
2013). Furthermore, expression of the G4C2 repeat expansion in zebrafish recapitulated key 
pathological hallmarks associated with ALS/FTD, commensurate with motor and cognitive 
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impairment as well as premature death (Shaw et al., 2018). Similar results were observed in 
a study of the same year, which showed that the expression of a comparable number of G4C2 
repeats correlated with motor neuron toxicity; however, behavioural effects were not reported 
(Swinnen et al., 2018). 
 
The zebrafish genome contains two orthologues of human TDP-43: tardbp and tardbpl. 
Transient knockdown of tardbp using morpholino oligonucleotides was shown to induce a 
motor phenotype concurrent with the shortening of motor neuron axons. In the same study, 
microinjection of human mRNA encoding known TDP-43 mutations (A315T, G348C and 
A382T) led to a similar phenotype (Kabashi et al., 2010). However, subsequent studies 
observed more profound effects associated with mutant TDP-43. Whilst tardbp-mutants 
showed no phenotype, Schmid et al. reported that double mutants for tardbp and its 
paralogue displayed muscle degeneration, strongly reduced blood circulation, mispatterning 
of vessels, impaired axon outgrowth, and premature death (Schmid et al., 2013). These results 
were reflected in a study of the same year; however, there was no report of circulatory defects 
(Hewamadduma et al., 2013). A more detailed discussion of zebrafish models of ALS is 







1.6. A literature review in the context of the present study: disrupted 
glycosyltransferase function is a cause of neurodegeneration  
 
 
This following sections of this chapter are an extended version of work which I published 
during my PhD (Moll et al., 2020). It is evident that the pathophysiological mechanisms 
underpinning ALS are multifactorial, and there is complex interplay between genetic factors 
and molecular pathways. The main focus of my project was to experimentally evaluate a novel 
glycosyltransferase enzyme implicated in ALS. Therefore, the following sections of this 
introductory chapter will review dysregulated glycosyltransferase function as a cause of 
neurodegeneration in the context of Alzheimer’s disease (AD), Parkinson’s disease (PD), 
Huntington’s disease (HD), and ALS.   
 
Glycosyltransferases represent a large family of enzymes that catalyse biosynthesis of 
oligosaccharides, polysaccharides, and glycoconjugates. Sugar moieties are transferred from 
activated sugar donors to specific acceptor molecules via the formation of glycosidic bonds 
(Chuh et al., 2016). Acceptor molecules include other sugars, nucleic acids, lipids, and 
proteins. Glycosyltransferases reside predominantly within the Golgi apparatus of eukaryotes 
as type II transmembrane proteins. Over 90 glycosyltransferase families have been described 
(www.cazy.org/GlycosylTransferases.html). Sequence alignment tools have been useful for 
predicting glycosyltransferase function, including a metal-binding motif important for 
configuration of substrate within the active site (Lairson et al., 2008). However, even closely 
related sequences have been shown to exhibit different catalytic activity (Breton et al., 2006).  
Glycosyltransferases are classified as either ‘retaining’ or ‘inverting’ enzymes according to 




1.6.1. Genetic mutations in glycosyltransferases are associated with 
neurodegeneration 
 
Changes in expression levels of glycosyltransferases have been strongly linked with 
neurodegeneration (Ludemann et al., 2005, Desplats et al., 2007, Schneider, 2018), but 
determining whether these effects are upstream of neurotoxicity is difficult. Two distinct 
glycosyltransferase-associated mechanisms are prominent in the neurodegeneration 
literature: ganglioside synthesis and the addition of O-linked β-N-acetyl glucosamine to 
proteins (O-GlcNAcylation). Genetic mutations in the development of an age-associated 
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neurodegenerative disease are, by definition, upstream causes or risk factors rather than 
secondary to the disease process. Mutations discovered within glycosyltransferases and their 
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Table 1.1. Defects affecting specific glycosyltransferase enzymes observed in 
neurodegenerative disease. Glycosyltransferase genes, functional consequences, 
associated neurodegenerative disorders, observed defects, and references are shown. Table 






1.6.1.1. UDP glycosyltransferase 8 (UGT8)  
 
UGT8 is a member of glycosyltransferase family 8. UGT8 functions in the biosynthesis of 
galactocerebroside, a sphingolipid that forms the myelin membrane in the central and 
peripheral nervous systems. Rare and potentially pathogenic copy number variants have been 
identified in the promotor region of UGT8 following an unbiased genome-wide screen for de 
novo DNA mutations in twelve trios, including sALS patients and unaffected parents 
(Pamphlett et al., 2011). Abnormal lipid biosynthesis and metabolism is a pathological 
hallmark of ALS (Dupuis et al., 2008, Dorst et al., 2011); therefore, it is possible that UGT8 
plays a role in the hypolipidemia observed in ALS patients and the SOD1G93A ALS mouse 
model (Kim et al., 2011, Yang et al., 2013). Mice lacking ugt8a, the ortholog of UGT8, exhibit 
impaired locomotor activity and disruption in nerve conduction, followed by degeneration of 
the myelin sheath (Bosio et al., 1996, Coetzee et al., 1996), which is rescued following 
transgenic expression of ugt8a (Zoller et al., 2005). Interestingly the rescue occurred with 
expression of ugt8a under a promoter exclusively expressed within oligodendrocytes, which 
is consistent with other evidence implicating these cells in ALS-associated neurodegeneration 
(Morrison et al., 2013).  
 
 
1.6.1.2. ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 1 (ST6GAL1)  
 
ST6GAL1 is an ‘inverting’ enzyme and a member of glycosyltransferase family 29. ST6GAL1 
catalyses the transfer of sialic acid onto galactose-containing substrates including cell-surface 
signalling lipids and proteins (Garnham et al., 2019). A genome-wide association study 
implicated polymorphisms within ST6GAL1 in the conversion of mild cognitive impairment into 
clinical AD (Lee et al., 2017).  Interestingly, ST6GAL1 is cleaved and occurs in a soluble form; 
this cleavage is mediated by BACE1 (Kitazume et al., 2001), which is also involved in the 
cleavage of APP to form β-amyloid. Indeed, overexpression of ST6GAL1 increases APP 
secretion (Nakagawa et al., 2006), suggesting that the activity of ST6GAL1 can directly modify 




1.6.2. Glycosyltransferases regulate ganglioside synthesis 
 
Major gangliosides are sialic acid-containing glycosphingolipids. Within the mammalian brain 
they are synthesized in the endoplasmic reticulum from a lactosylceramide precursor before 
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remodelling during transit from the cis- to the trans-Golgi network by a series of 
glycosyltransferase enzymes (Figure 1.1). Mature gangliosides are expressed on the plasma 
membrane of most vertebrate cells and within bodily fluids. They are particularly abundant on 
neuronal and glial cells within the CNS where they are thought to function prominently in cell 
signalling (Vajn et al., 2013).  
 
 
1.6.3. Gangliosides are differentially distributed in the mammalian CNS 
 
Mapping ganglioside distribution patterns in the CNS may be crucial to understanding the 
functional properties of the various ganglioside sub-species. Ganglioside-monosialic acid 1 
(GM1), ganglioside-di-sialic acid 1a (GD1a), ganglioside-di-sialic acid 1b (GD1b), and 
ganglioside-tri-sialic acid 1b (GT1b) are all derived from a common precursor (GM3) and 
constitute over 90% of total gangliosides within the typical mammalian brain. Their abundance 
is attributed to the high activity of the synthesising enzyme, β-1,4-N-acetylegalactosaminyl 
transferase 1 (B4GALNT1). Synthesis occurs via two primary pathways, designated a-series 
and b-series (Figure 1.1) (Ledeen, 1966, Yao et al., 2014).   
 
Rodent-based studies have revealed cell type-specific expression of major CNS gangliosides 
during adulthood. By way of illustration, GD1b is specific to granule neurons throughout all 
layers of the cerebellar cortex, whilst GD1a is localised exclusively to the molecular layer 
(Kotani et al., 1993, Kawashima et al., 1996, Vajn et al., 2013). Immuno-labelling of GD1a, 
GD1b, and GT1b in the adult mouse CNS revealed high expression across all layers of the 
cerebral cortex. Conversely, GM1 was restricted to myelinated fibres within the lower layers 
(Vajn et al., 2013). The variability of ganglioside composition throughout nervous tissue is 
consistent with an important role in the formation and function of the CNS.   
 
Region-specific alterations in ganglioside distribution within the mammalian brain are known 
to occur during development and ageing, with ganglioside composition changing from simple 
(e.g. GM3) to complex (e.g. GM1), compliant with the degree of neurogenesis, 
synaptogenesis, and axonal branching. Knowledge of how such alterations are regulated is 
limited, but it is thought to be modulated at the level of glycosyltransferase gene expression 







1.6.4. Gangliosides regulate neuroinflammation and neurotrophic action 
 
Studies using genetically modified mice have shed light on the biological importance of 
gangliosides to nervous system function. A double knockout of genes encoding key 
glycosyltransferase enzymes involved in ganglioside biosynthesis, GM2- and GD3-synthase, 
displayed up-regulation of complement genes and their receptors in mouse cerebellum (Ohmi 
et al., 2009). This infers that gangliosides prevent the destruction of nervous tissue through 
complement-mediated neurodegeneration. The rise in complement activity coincided with 
impairments in the structure and function of lipid rafts, which anchor complement proteins to 
membrane bilayers. A follow-up study confirmed that maintenance of lipid rafts is key to the 
neuroprotective properties of gangliosides (Ohmi et al., 2011).   
 
Gangliosides have also been shown to exhibit neurotrophic properties by enhancing neurite 
outgrowth and alleviating the deterioration of nervous tissue following injury (Kittaka et al., 
2008, Ohmi et al., 2009). For example, GD3 synthase-deficient mice lacking b-series 
gangliosides showed a reduction in the regenerative capacity of axotomised hypoglossal 
nerves (Okada et al., 2002). A study of GM2 synthase-deficient mice has suggested that this 
is also true of a-series gangliosides, concurrent with a decrease in the expression of known 
neurotrophic factors compared to WT controls, supporting the notion that gangliosides 
regulate neuronal integrity (Kittaka et al., 2008).   
 
Ganglioside function has been investigated in axon-glial junctions at the nodes of Ranvier in 
myelinated central and peripheral motor nerve fibres of GM2 synthase-deficient mice. Mutant 
mice presented with mislocalisation of ion channels and a reduction in motor nerve conduction, 
suggesting a role for gangliosides in stabilising the interactions between neurons and glia at 
paranodal junctions (Susuki et al., 2007). It has been suggested that gangliosides indirectly 
perpetuate nerve integrity by increasing the neuroprotective properties of astrocytes, the most 
abundant glial cell type within the CNS. In support of the knockout mouse models, a study 
found that ganglioside-depleted astrocytes were less able to augment the survival of 
hippocampal neurons in vitro. In the same study, neurotrophic activity was rescued following 
treatment with ganglioside GM3, suggesting it is involved in glial cell-mediated neuronal 
maintenance (Akasako et al., 2011). However, a more recent study argued that glial 
gangliosides are less significant to the age-related maintenance of neuronal integrity; a rescue 
experiment on GM2 synthase-deficient mice was performed by driving GalNAcT expression 
in a cell-restricted manner. Neuronal-specific expression of GalNAcT in these mice led to a 
lasting WT phenotype, whereas mice with glial-specific GalNAcT expression exhibited 
progressive tremor, weakness, and ataxia with ageing (Yao et al., 2014). Irrespective of this, 
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these studies form a compelling argument to support the various mechanisms through which 






Figure 1.1. Schematic overview of the biosynthesis and function of major gangliosides 
within the mammalian brain. Lactosylceramide is synthesised at the cytoplasmic leaflet of 
the ER membrane from its ceramide precursor. De novo ceramide is transported to the Golgi 
apparatus and is converted to glycosphingolipids and sphingomyelin through the addition of 
saccharides and phosphocholine, respectively. Glycosphingolipids are transported in vesicles 
to the outer leaflet of the plasma membrane. Sialic acid-enriched glycosphingolipids form 
gangliosides, which are anchored to the membrane via their ceramide-lipid moiety. Four major 
gangliosides comprise >90% of total gangliosides within the brain. A-series gangliosides (red) 
are derived from GM3. B-series gangliosides (purple) are synthesised from GM3 by GD3 
synthase (St8sia1). Nomenclature: the letter G denotes the “ganglioside” core; the second 
letter designates the quantity of sialic acid residues (M - mono; D - di; T - tri). Gangliosides 
are essential to maintaining neuronal integrity with functions including, but not limited to, 
increasing the neuroprotective properties of astrocytes, stabilising interactions between 
neurons and glia, enhancing neurite outgrowth, and negatively regulating neuroinflammation 





1.6.5. Impaired ganglioside synthesis is linked to neurodegeneration 
 
Altered levels of gangliosides have been reported in animal models of ALS and in post-mortem 
CNS tissue from ALS patients (Ariga, 2014, Dodge et al., 2015); similar findings have been 
reported in PD (Wu et al., 2012), HD (Desplats et al., 2007), and AD (Gylys et al., 2007).  
 
 
1.6.5.1. Parkinson’s disease  
 
Reduced glycosyltransferase function with subsequent reduction in ganglioside synthesis has 
been implicated in the pathogenesis of PD. A recent report described a reduction in gene 
expression of the glycosyltransferases B3GALT4 and ST3GAL2 in neuromelanin-containing 
neurons in the substantia nigra pars compacta (SNpc) of PD patients, compared to controls 
(Schneider, 2018). These genes are key players in the ganglioside biosynthesis pathway 
(Figure 1.1). It is proposed that reduced B3GALT4 and ST3GAL2 expression leads to 
vulnerability of dopaminergic neurons via aberrant ganglioside synthesis. Consistent with this 
hypothesis, the number of GM1 ganglioside-expressing cells in the PD SNpc are reduced (Wu 
et al., 2012), and levels of the major brain gangliosides - GM1, GD1a, GD1b and GT1b - are 
decreased in whole SN homogenates from PD patients (Seyfried et al., 2018). Model systems 
provide evidence that dysfunction of ganglioside synthesis is a cause and not just an 
association of typical PD pathology. Genetically engineered mice lacking major brain 
gangliosides display overt motor impairment with increasing age, which is accompanied by 
loss of dopaminergic neurons from the SNpc and aggregation of α-synuclein (Wu et al., 2012).  
 
1.6.5.2. Huntington’s disease 
 
In a similar manner to PD, reduced expression of glycosyltransferases involved in ganglioside 
synthesis has also been described in the R6/1 mouse model of HD and in human HD patients 
(Desplats et al., 2007). In this study >80% of gene expression changes observed in the 
striatum of R6/1 mice were also observed in the post-mortem caudate of human HD subjects. 
Overlapping genes were significantly enriched with glycosyltransferases involved in 
ganglioside synthesis including ST3GAL5, ST8SIA3, B4GALNT1 and ST3GAL2 (Figure 1.1).  
Consistent with impaired ganglioside synthesis, the same study reported reduced ganglioside 






1.6.5.3. Alzheimer’s disease  
 
There is good evidence for perturbed ganglioside metabolism in patients with AD, and in the 
development of β-amyloid pathology in particular (Barrier et al., 2007). In contrast to the 
findings in PD and HD, the key observation appears to be increased ganglioside synthesis.  
Elevated GM1, GM2 and GM3 levels have been reported in the cerebral cortices of AD brains 
(Kracun et al., 1992, Gylys et al., 2007). Development of β-amyloid deposition is the defining 
pathology of AD and within brains exhibiting early AD pathology, a significant proportion of β-
amyloid is bound to ganglioside species (Yanagisawa and Ihara, 1998). It has even been 
suggested that insoluble GM1-bound β-amyloid is the key toxin leading to neuronal death 
(Hayashi et al., 2004), as a result of high affinity binding between GM1 and β-amyloid, which 
facilitates formation of insoluble β-pleated sheets (Yamamoto et al., 2007). With increasing 
age, GM1 is localised to pre-synaptic nerve terminals and this may have a role in directing β-
amyloid deposition to the same locations (Yamamoto et al., 2008). Unlike evidence regarding 
gangliosides, reports of altered glycosyltransferase expression in AD are more limited. There 
is evidence that glycosyltransferase activity may modify AD pathology. Overexpression of the 
glycosyltransferase, B4GALNT1, leads to increased ganglioside expression but also 
increases APP cleavage to form β-amyloid pathology through suppression of lysosomal 
degradation of BACE1 (Yamaguchi et al., 2016). Currently, transgenic mouse models of AD 
do not mirror changes in ganglioside distribution seen in human post-mortem tissue (Barrier 
et al., 2007).  
 
1.6.5.4. Amyotrophic lateral sclerosis  
 
ALS has been linked to abnormal lipid metabolism (Desport et al., 2005) and in particular, 
gangliosides and their ceramide precursors are thought to be modulators of disease 
progression (Salazar-Grueso et al., 1990, Stevens et al., 1993). Whether ganglioside 
production is increased or decreased is controversial. As early as 1985, a 10% reduction in b-
series gangliosides was identified within the motor cortex of ALS brains compared to non-ALS 
controls (Rapport et al., 1985). More recently, elevated levels of gangliosides GM1 and GM3 
were reported within ALS post-mortem spinal cords compared to age-matched controls; 
findings were corroborated in the SOD1G93A transgenic ALS mouse model (Dodge et al., 2015). 
Interestingly, autoantibodies against specific gangliosides produce an inflammatory disease 
of spinal motor neurons known as multifocal motor neuropathy with conduction block 
(Harschnitz et al., 2014), which is a frequent differential diagnosis of ALS. ALS specifically 
inflicts pathology on the upper and lower motor neurons within the corticospinal tract, the 
neuromuscular junction, and muscle. The accessibility of this system in disease models 
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facilitates the differentiation of up- and downstream disease associations. For example, 
increased expression of glycosphingolipids is observed in muscle tissue from end-stage 
mutant SOD1-ALS mice compared to controls, but similar changes were observed in response 
to surgically induced muscle denervation suggesting a downstream effect (Henriques et al., 
2015). Moreover, neurotransmission at the neuromuscular junction is unchanged in aged GM2 
and GD3-deficient mice, compared to controls (Zitman et al., 2011). The recent discovery that 
mutations in the glycosyltransferase GLT8D1 are associated with fALS is a step forward that 
places glycosyltransferase activity irrefutably upstream in the development of disease 
(Cooper-Knock et al., 2019).  
 
 
1.6.6. Gangliosides as a therapeutic target  
 
A growing body of evidence supports the role of gangliosides in the pathogenesis of 
neurodegenerative disease. With this came the realisation that gangliosides may offer a 
potential new class of therapeutic targets, although it is unclear whether they should be added 
or removed and in what context. The pharmacological use of gangliosides for targeting 
neurodegenerative disease processes is becoming increasingly well-documented (Schneider 
et al., 2015a, Schneider et al., 2015b, Knight et al., 2015, Henriques et al., 2015). The following 
sections of this introductory chapter will discuss the use of gangliosides for the treatment of 
AD, PD and ALS.   
 
1.6.6.1. Alzheimer’s disease  
 
In 1994, a double-blind placebo-controlled trial of intramuscularly administered GM1 for the 
treatment of AD patients, found that GM1 did not significantly affect cognitive performance. 
This suggested it was not a viable approach for targeting cognitive deficits in AD (Flicker et 
al., 1994). However, a later study tested the effects of intracerebroventricular administration 
of GM1 to 5 early-onset AD patients, and identified improvements in the patients’ ability to 
perform routine daily activities (Augustinsson et al., 1997). This was supported by a 
subsequent study of 5 early-onset AD patients, reporting that a continuous injection of GM1 
into the frontal horns of the lateral ventricles for a twelve-month period improved motor function 
and neuropsychological ability (Svennerholm et al., 2002). All studies are limited by the low 
number of participants, but the positive effects observed in the latter two studies suggest that 




The therapeutic value of gangliosides to AD is difficult to determine, due to conflicting reports 
coupled with reported studies having enrolled a relatively low number of participants. That 
said, a recent study reported symptomatic improvements in a Dutch APPE693Q mouse model 
of AD following targeted depletion of ganglioside GM2. Based on the hypothesis that GM2 
accelerates the aggregation and accumulation of amyloid-β in AD (Yamamoto et al., 2005), 
Knight and colleagues increased the activity of a known GM2 catabolising enzyme, β-
hexosaminidase. They observed a reduction in the level of ganglioside-bound amyloid-β, as 
well as improvements in learning behaviour and a reduction in anxiety (Knight et al., 2015). 
 
1.6.6.2. Parkinson’s disease  
 
Having shown promise in preclinical animal models of PD through the rescue of SNpc neurons 
and an increase in dopamine synthesis (Schneider et al., 1995), the therapeutic potential of 
ganglioside GM1 has since been tested in human subjects. In 1995, Schneider and colleagues 
confirmed the safety and efficacy of GM1 treatment in PD patients (Schneider et al., 1995). 
This led to a randomised double-blind placebo-controlled study in 1998, during which 
significant improvements in the motor performance of PD patients were observed following 
GM1 treatment (Schneider et al., 1998). Since then, positron emission tomography scans of 
PD patients receiving GM1 treatment coincided with improvement in the efficacy of the PD 
drug, Ritalin, in striatal regions compared to controls. Correspondingly, the GM1-treated 
cohort displayed symptomatic improvement and a reduction in symptomatic progression over 
the course of the study. Although limited by the low number of participants (n=40), this pilot 
study provides additional data to support the therapeutic potential of GM1 in PD (Schneider et 
al., 2015a). However, the disease modifying potential of GM1 is limited by its lack of blood-
brain barrier penetrability following systemic administration, indicating the need for membrane-
permeable analogues. A previous study has addressed this issue, and the treatment of PD 
mice with a membrane-permeable analogue of GM1 was shown to attenuate prior 
manifestations of Parkinsonism (Wu et al., 2012).   
 
Due to limits in bioavailability, methods of enhancing endogenous levels of GM1 in the brain 
have been explored. Sialidase enzymes were injected into the dorsal third ventricle in a mouse 
model of PD to catalyse the conversion of GD1a, GD1b and GT1b gangliosides into GM1. A 
significant increase in ganglioside expression levels was subsequently observed, marked with 
a reduction in the loss of dopaminergic neurons (Schneider et al., 2015b). With clinical trials 
still ongoing, research into the use of gangliosides to treat PD is showing more promise than 




1.6.6.3. Amyotrophic lateral sclerosis  
 
Studies on the therapeutic potential of gangliosides in ALS have been ongoing for decades, 
yet with inconsistent results. In 1984, a 6-month double-blind controlled trial of intramuscularly 
administered gangliosides was conducted in ALS patients. No differences were observed in 
the progression of muscle weakness between the group receiving ganglioside treatment 
compared to those receiving placebo, suggesting gangliosides are an ineffective treatment 
option (Harrington et al., 1984). These findings may have been limited by the route of 
administration, as observed in the AD studies. However, some years later, a patient that also 
underwent intramuscularly administered ganglioside therapy displayed a high anti-GM2 titre 
and developed ALS-like disorder. A subsequent decrease in anti-GM2 titre saw symptoms 
improve, suggesting the anti-GM2 was particularly reactive with motor neurons in the patient, 
potentially causing motor neuron-specific impairment (Yuki et al., 1991). However, this was 
an isolated case and it is not conclusive that ganglioside therapy caused ALS. In 1995, 
Matsumoto and colleagues identified GM2 as a major ganglioside in a neuroblastoma-spinal 
cord hybrid cell line, suggesting GM2 displays motor neuron specificity. Based on these 
reports, GM2 might serve as a potential target antigen in ALS (Matsumoto et al., 1995). An 
interesting follow-up study would be to analyse the presence of GM2 in the serum of a motor 
neuron disease patient cohort.   
 
A potentially pathogenic role for anti-GM2 antibodies in ALS is inconsistent with reports on 
other anti-ganglioside antibodies. In 1988, a moderate increase in IgM anti-GM1 antibody titre 
was reported in the sera of ALS patients. These findings were replicated by the same research 
group a year later (Pestronk et al., 1988, Pestronk et al., 1989). However, when this concept 
was revisited in 2015, similar anti-GM1 antibody levels were identified between ALS patients 
and healthy controls (Kollewe et al., 2015), suggesting the expression of anti-ganglioside 
antibodies may not bear an impact on disease progression.   
 
In recent years, gangliosides have shown promise as a therapeutic target in murine models of 
human ALS. rHIgM12 is a recombinant human immunoglobulin M, shown to bind with high 
affinity to gangliosides GD1a and GT1b. Administration of rHIgM12 in two SOD1 ALS mouse 
models (G93A and G86R) coincided with a 16-day delay in the onset of neurological deficits 
and a 5-day delay in weight loss compared to untreated controls (Xu et al., 2015). The 
therapeutic potential of gangliosides is supported by another study of the same SOD1 ALS 
mouse model (G93A). The disease course in this model was initially accelerated by inhibiting 
the synthesis of a complex ganglioside precursor, glucosylceramide. Subsequent infusion of 
exogenous ganglioside, GM3, delayed the onset of motor deficits and increased viability of 
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the mice (Dodge et al., 2015). Following on from these reports, a recent study sought to treat 
SOD1G86R ALS mice with Conduritol B epoxide to increase the concentration of 
glucosylceramide, the precursor for all complex glycosphingolipids. Ganglioside distribution at 
neuromuscular junctions was maintained at a level that coincided with a reduction in motor 
neuron degeneration and a delay in disease onset. Whilst this study supports a role for 
complex glycosphingolipids in muscle innervation, it also suggests that the targeting of 
ganglioside precursors is a viable therapeutic approach for ALS (Henriques et al., 2017).   
 
The efficacy of gangliosides as a treatment option has differed between neurodegenerative 
diseases and is likely influenced by factors such as the route of administration and 
bioavailability. However, attempts to overcome these limitations have proven successful and 
the recent targeting of a major ganglioside precursor in ALS is an exciting leap towards 
preventing the detrimental effects of perturbed ganglioside metabolism. Studies such as this 
highlight the considerable progress that has been made since the discovery of gangliosides 
85 years ago (Figure 1.2). The future is likely to see more nuanced manipulation of 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.6.7. Glycosyltransferase O-GlcNAcylation: a key regulator of 
neurodegeneration? 
 
1.6.7.1. O-GlcNAcylation is implicated in neurodegenerative disease 
 
O-GlcNAcylation occurs predominantly in the brain and is regulated by the 
glycosyltransferases O-Linked N-Acetylglucosamine Transferase (OGT) and EGF Domain 
Specific O-Linked N-Acetylglucosamine Transferase (EOGT), which attach the GlcNAc moiety 
to acceptor proteins at specific serine/threonine residues via an O-linked glycosidic bond; the 
reverse reaction is catalysed by O-GlcNAcase (OGA). OGT acts intracellularly whereas EOGT 
acts extracellularly on secreted and membrane proteins. Together these reactions constitute 
a dynamic and reversible process (Figure 1.3).  
 
Protein glycosylation, and more specifically the addition of O-GlcNAc groups to CNS proteins 
important for axonal and synaptic function, is significantly reduced in animal models of 
neurodegenerative diseases and in patient tissue from diseases including PD, HD, AD, and 
ALS (Liu et al., 2004, Ludemann et al., 2005, Kumar et al., 2014, Frenkel-Pinter et al., 2017, 
Wani et al., 2017) (Table 1.1). O-GlcNAcylation is reported to negatively regulate tau 
phosphorylation (Liu et al., 2004), which is key in the pathogenesis of a number of 
neurodegenerative diseases including AD. In contrast, an increase in O-GlcNAcylation is 
observed in the post-mortem temporal cortex of PD patients and is postulated to contribute to 
neurodegeneration through the inhibition of autophagy, leading to an increase in α-synuclein 
accumulation (Wani et al., 2017).  
 
Neurofilaments are critical components of the neuronal cytoskeleton that can undergo O-
GlcNAcylation (Yuan et al., 2012). Neurofilament levels are significantly higher in the serum 
and cerebrospinal fluid of ALS patients compared to controls (Benatar et al., 2018). This 
increase is thought to be a consequence of axonal damage. However, there is evidence that 
neurofilament damage may be upstream in the pathogenesis of ALS, including the observation 
that increased phosphorylation of neurofilaments is associated with neurotoxicity (Julien, 
1997). It is thought that phosphorylation and O-GlcNAcylation are reciprocal, meaning that 
reduced O-GlcNAcylation could precipitate harmful phosphorylation; indeed, this has been 
observed in a transgenic rat model of SOD1-ALS (Ludemann et al., 2005).  
 
OGT is an inverting enzyme and a member of glycosyltransferase family 41. OGT is highly 
enriched in the brain, where it is ten times more active than in peripheral tissue (Okuyama and 
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Marshall, 2003). OGT is localised to the nucleus, soma, dendrites, and pre-synaptic terminals 
of neurons (Akimoto et al., 2003). Removal of post-synaptic OGT from primary neurons inhibits 
both synapse formation and the development of dendritic spines (Lagerlof et al., 2017). This 
highlights the importance of OGT in maintaining synaptic stability, and notably loss of synaptic 
stability is a unifying feature of neurodegenerative disease. EOGT is an inverting enzyme and 
a member of glycosyltransferase family 61. Despite distinct sites of action, OGT and EOGT 
are both regulated via the hexosamine biosynthetic pathway (Ogawa et al., 2015). EOGT 
activity is involved in Notch signalling, which is important for neurodevelopment. Indeed, 
homozygous loss-of-function mutations in EOGT produce Adams-Oliver syndrome, a 










Figure 1.3. O-GlcNAcylation is implicated the pathophysiology of neurodegenerative 
disease. An overview of O-GlcNAcylation, a post-translational modification of O-GlcNAc, 
which has been implicated in neurodegenerative diseases: HD, AD, PD, and ALS. O-
GlcNAcylation occurs predominantly in the brain and is regulated by the glycosyltransferases 
OGT and EOGT, which attach the O-GlcNAc moiety to acceptor proteins at specific serine / 
threonine residues via an O-linked glycosidic bond. OGT acts intracellularly whereas EOGT 









1.6.7.2. ALS-associated genetic variants within O-GlcNAcylation pathway enzymes  
 
As part of this literature review, we investigated EOGT mutations in the context of ALS. While 
homozygous EOGT mutations affect neurodevelopment, we hypothesised that heterozygous 
mutations within EOGT might negatively impact on the maintenance of axon integrity and 
increase the risk of developing ALS. To test this hypothesis, we performed rare-variant burden 
testing (Cirulli et al., 2015) within EOGT to check for a genetic association with ALS (Moll et 
al., 2020). We used whole genome sequencing data from 4493 sALS patients and 1924 
control subjects (van der Spek et al., 2019), and identified 32 missense rare (MAF <1%) 
variants within EOGT that were exclusively or predominantly found in ALS cases (see 
appendix 1). When considering all rare missense variants found in cases and controls across 
all exons of EOGT, there was a significant enrichment of such mutations in ALS patients (Firth 
logistic regression, p=0.007). Similar testing did not identify an enrichment of ALS-associated 
mutations within OGT; indeed, we only identified two rare missense mutations within OGT in 
4493 sALS patients. It should be noted that OGT is encoded on the X chromosome and 
therefore males are necessarily hemizygous, which may predispose to a neurodevelopmental 
phenotype rather than a late age-of-onset disease; for example, mutations within N terminal 
tetratricopeptide repeats of OGT are associated with X-linked intellectual disability (Gundogdu 
et al., 2018). There was no significant burden of ALS-associated mutations within OGA 





Overall there is substantial evidence for dysfunction of glycosyltransferases in 
neurodegenerative diseases including ALS, AD, HD, and PD. There are diverse functions 
associated with glycosyltransferase activity and for many of the enzymes the biological 
pathway associated with their activity is not yet clear. However, in our analysis, dysfunction 
associated with neurodegenerative disease can be seen to converge on the ganglioside 
synthesis pathway and altered O-GlcNAcylation. The exact nature of the defect appears to be 
variable in different diseases; for example, ganglioside concentrations are reduced in PD and 
HD, increased in AD, and there is evidence for change in both directions in ALS. Similarly, 
increased O-GlcNAcylation is associated with the development of PD pathology but reduced 
O-GlcNAcylation is associated with the development of tau pathology. We suggest that 
consensus will arise via efforts to position glycosyltransferase dysfunction within the cascade 
of pathogenesis leading to neuronal death. It is not glycosyltransferase dysfunction per se that 
is interesting, but rather upstream changes in glycosyltransferase function that initiate toxicity. 
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With this in mind, we have highlighted genetic associations between mutations in 
glycosyltransferases and neurodegenerative disease, and we have revealed a new 
association between ALS and mutations in EOGT. Glycosyltransferases are likely to be an 
important therapeutic target in the effort to develop disease-modifying therapies for 
neurodegenerative disease.  
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1.7. Work leading up to this study: GLT8D1 
 
 
1.7.1. Exome sequencing in an autosomal dominant ALS pedigree identifies candidate 
deleterious variants 
 
The following sections are adapted from work published as part of my PhD (Cooper-Knock et 
al., 2019). Exome sequencing in two related individuals with autosomal dominant ALS 
(Figure 1.4a) identified five potential causal variants. Candidate monogenic causal variants 
were shared by both affected individuals, rare, and predicted deleterious. Variants were 
selected for further analysis if the Exome Aggregation Consortium (ExAC) frequency was 
<1/10,000 controls (Lek et al., 2016) and the Phred-scaled Combined Annotation Dependent 
Depletion (CADD) score was >25 (Kircher et al., 2014). Heterozygous variants in five genes 
met the filtering criteria: p.R92C (GenBank: NM_018446: c.274C>T) in GLT8D1, p.P529L 
(GenBank: NM_001267619: c.1586C>T) in ARPP21, p.A266T (GenBank: NM_003848: 
c.796G>A) in SUCLG2, p.R1252H (GenBank: NM_173689: c.3755G>A) in CRB2, and 
p.C116R (GenBank: NM_052837: c.346T>C) in SCAMP3. Subsequently, another family 
member developed unilateral weakness and upper motor neuron dysfunction suggestive of 
ALS. Detailed neurological investigation did not fulfil El-Escorial diagnostic criteria, but no 
alternative cause was identified. Screening this individual for the five candidate mutations 
revealed only p.R92C in GLT8D1 and p.P529L in ARPP21 (Cooper-Knock et al., 2019). 
 
 
1.7.2. Targeted sequencing supports pathogenicity of variants within exon 4 of 
GLT8D1 
 
Targeted DNA sequencing of the five candidate genes was performed in a cohort of 103 fALS 
and young sALS cases from the North of England. The cohort included 34 fALS patients in 
whom a genetic cause had not been identified, despite screening for ALS-associated 
mutations in SOD1, C9ORF72, TARDBP, and FUS; 61 young-onset sALS patients; and 13 
C9ORF72-ALS patients. SUCLG2, CRB2, and SCAMP3 were not mutated in any additional 
cases and were excluded from further analysis. In addition to the two individuals from the 
index pedigree, four of the screened patients also carried p.R92C (GenBank: NM_018446: 
c.274C>T) within GLT8D1 exon 4 (Tables 1.2, 1.3). Another patient carried a rare deleterious 
p.G78W (GenBank: NM_018446: c.232C>A) change within the same exon of GLT8D1, 
suggesting a common pathogenic effect (Figure 1.4b, Table 1.2). Mutations were confirmed 
by Sanger sequencing by using independent DNA samples. In addition to an ExAC frequency 
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of <1/10,000 controls, similar mutations are absent from North of England controls (n = 220) 
and from unaffected family members within the index pedigree (Figure 1.4a). No patient with 
a mutation in GLT8D1 carried an additional ALS-associated mutation, as determined from the 
ALS Online Genetics Database (Abel et al., 2012). No additional patients were identified with 
a mutation in ARPP21 (Cooper-Knock et al., 2019).  
 
GLT8D1 encodes a glycosyltransferase enzyme of unknown function, which is widely 
expressed (http://www.gtexportal.org/home/). Importantly, this class of proteins has not 
previously been associated with neurodegeneration, although GLT8D1 has been identified as 
a schizophrenia risk gene (Sasayama et al., 2014, Yang et al., 2018). It is noteworthy that ALS 
and schizophrenia share common genetic risk (McLaughlin et al., 2017). Four of five identified 
GLT8D1 mutations affect amino acids that show high evolutionary conservation, as 
determined by relative entropy using the NCBI “Conserved Domains Tool” 
(https://www.ncbi.nlm.nih.gov/Structure/cdd/cddsrv.cgi) (Figure 1.4c). All mutations are 
closely associated with the proposed GLT8D1 ligand-binding site involving amino acid 
residues 71–76 (Bourne and Henrissat, 2001), suggesting that the discovered mutations may 










Figure 1.4. Discovery of ALS-Associated Mutations within Exon 4 of GLT8D1 in Close 
Proximity to the Putative Substrate Binding Site. (A) Original pedigree in which p.R92C 
mutations were discovered. Exome sequencing was performed in two related individuals with 
ALS (*). Sanger sequencing (of red shapes) confirmed the p.R92C mutation is carried by ALS 
patients (shaded grey) and absent from unaffected individuals. (B) Identified structural and 
topological domains within GLT8D1, including the site of identified mutations within exon 4. 
(C) Sequence homology analysis within exon 4 localises ALS-associated mutations to close 
proximity with the substrate binding site of GLT8D1. ALS-associated amino acid changes 
(yellow highlight) affect evolutionary conserved bases (red text) with one exception. Amino 
acids which form the putative substrate binding site are indicated (blue highlight). Displayed 
sequence is glycosyltransferase domain encoded by exon 4 (amino acid [aa] 66–aa116). 




Of the six cases carrying the p.R92C mutation in GLT8D1, five cases including the two index 
cases also carried a p.P529L change (GenBank: NM_001267619: c.1586C>T) within cyclic 
AMP (cAMP)-regulated phosphoprotein 21 (ARPP21). In support of pathogenicity of the 
p.R92C GLT8D1 mutation in the absence of the ARPP21 variant, one patient carried only the 
GLT8D1 mutation without an ARPP21 change. Subsequent analysis of Project MinE whole-
genome sequencing data from 4,493 ALS patients (Project MinE ALS Sequencing 
Consortium, 2018) identified two additional patients carrying the p.R92C mutation without a 
variant in ARPP21. Comparison between the 4,493 Project MinE patients and 60,706 controls 
sequenced by the ExAC (http://exac.broadinstitute.org/) revealed that the p.R92C change is 
significantly associated with ALS (Fisher exact test, odds ratio [OR] = 54.1, p = 2.03E-08), and 
this association remains significant when cases carrying a variant in ARPP21 are excluded 
(Fisher exact test, OR = 20.3, p = 0.0029) (Cooper-Knock et al., 2019).  
 
 
1.7.3. Exon 4 of GLT8D1 is significantly enriched with ALS-associated rare deleterious 
variants affecting conserved amino acids 
 
Burden analysis was performed using Sequence Kernal Association Test-Optimal Unified Test 
(SKAT-O) (Lee et al., 2012) to compare rate of genetic variation within exon 4 of GLT8D1 in 
a cohort of 1,138 fALS patients and 19,450 controls (as described in (Kenna et al., 2016)). 
Rare deleterious variants are significantly enriched in exon 4 in the fALS cohort (SKAT-O, 
p=0.0025); there is no significant ALS-association within GLT8D1 when exon 4 is excluded 
(see appendix 2). Across all cohorts, five distinct rare deleterious mutations of GLT8D1 exon 
4 were identified in fourteen ALS patients (Table 1.2). Identification of additional fALS cases 
from an independent population with similar mutations in GLT8D1 strongly suggests that 






Table 1.2. Mutations identified with exon 4 of GLT8D1. DNA change, protein change, 
number of ALS patients, ExAC frequency, CADD score, average disease duration, disease 




1.7.4. Clinical characteristics of patients with mutated GLT8D1 
 
Clinical characteristics of cases carrying a mutation in GLT8D1 are summarised in Table 1.3. 
Overall, disease characteristics are within the expected spectrum of ALS (Cooper-Knock et 
al., 2012). Phenotype data were not available from all cases; however, eight patients with 
p.R92C mutations suffered a particularly aggressive disease course with average survival of 
21 months, but patients with p.G78W or p.I70T mutations lived >5 years. Average age of onset 
across all patients was 49.3 years, and three patients developed symptoms in their fourth 






Table 1.3. Phenotype information for patients carrying ALS-associated mutations in 
GLT8D1. Case number, disease characterisation, sex, age of onset, average disease 
duration, site of disease onset, GLT8D1 mutation, and population cohort, are shown. # 
denotes patients that underwent exome sequencing. Table adapted from (Cooper-Knock et 







1.8. Work leading up to this study: CAV1 and CAV2 
 
 
1.8.1. Discovery of ALS-linked CAV1/CAV2 enhancer mutations 
 
The following sections are adapted from work currently submitted for publication as part of my 
PhD (available at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3606796). Non-
coding regulatory sequence includes enhancers, which are cis-acting DNA sequences that 
modulate expression of target genes primarily through binding of transcription factors (TFs) 
(Koch et al., 2011). Physical interaction between an enhancer and the promoter of the target 
gene is mediated by DNA looping (Pennacchio et al., 2013). A novel pipeline was designed 
for the identification of disease-associated variation within enhancers (Figure 1.5a).  
 
Sets of enhancers which regulate a common coding gene were aggregated. As previously 
described (Fishilevich et al., 2017), high quality manually curated links were identified between 
enhancers and coding genes based on corroboration between: correlated expression between 
genes, enhancer-RNAs (eRNAs), and TFs; expression quantitative trait loci (eQTL) within 
enhancers; capture Hi-C; and gene–enhancer genomic distances.  
 
Following the aggregation of enhancers linked to individual coding genes, enhancer variants 
were filtered to remove those unlikely to be pathogenic prior to association testing. Enhancer 
variants were included if minor allele frequency (MAF) was <0.01 (Lek et al., 2016, van 
Rheenen et al., 2016), and LINSIGHT (Huang et al., 2017) score was >0.8. A LINSIGHT 
score >0.8 is consistent with strong evolutionary selection (Huang et al., 2017). Following 
filtering, case and control variant frequencies for each set of enhancers were collapsed into a 
single SKAT burden test (Lee et al., 2012). 
 
The pipeline was tested using whole genome sequencing (WGS) data from 4,495 ALS cases 
and 1,925 controls (Project MinE, Data-Freeze-1). Firstly, it was hypothesised correctly that 
aggregated enhancers linked to all genes within the ‘amyotrophic lateral sclerosis’ KEGG 
(Kyoto Encyclopaedia of Genes and Genomes) pathway (Kanehisa et al., 2017) would be 
enriched with ALS-associated genetic variation (SKAT-O, p=0.02, 377 variants, see appendix 
3). Secondly, it was hypothesised that pathogenic enhancer variants are likely to cause 
reduced transcription of their target coding gene, which might be expected to mimic a 
haploinsufficiency mechanism. Therefore, variants were examined within enhancers linked to 
expression of TBK1, which is known to cause ALS via haploinsufficiency (Freischmidt et al., 
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2015). Consistent with this hypothesis, genetic variation within TBK1 enhancers is significantly 
associated with ALS (p=0.003, SKAT-O, 12 variants, see appendix 4). 
 
The pipeline was applied to test for genetic association within enhancers linked to CAV1 and 
CAV2 expression. A significant enrichment of ALS-associated genetic variation was 
discovered within enhancers linked to CAV1 (p=3.88E-05, SKAT-O, 40 variants) and CAV2 
(p=1.52E- 05, 57 variants). In total, 56 (1.2%) sALS patients carry one or more ALS-associated 
variants within CAV1/CAV2 enhancers compared to 2 (0.1%) of controls. There is significant 
overlap between enhancers and ALS-associated variants linked to CAV1 and CAV2 (see 
appendix 5), which reflects shared function between the two proteins. 
 
 
1.8.2. Genetic variation within CAV1 coding sequence is associated with ALS 
 
It is likely that genetic variation within linked enhancer and coding regions can produce similar 
phenotypes. ALS-associated genetic variation within CAV1 and CAV2 exons was assessed 
by rare-variant burden testing using WGS data from 4,495 ALS cases and 1,925 controls 
(Project MinE Data-Freeze-1). In addition to filtering by MAF<0.01 (van Rheenen et al., 2016), 
a functional filter was introduced to identify variants which alter protein function (Cingolani et 
al., 2012). In CAV1, but not CAV2, coding sequence a significant enrichment of functional 
genetic variation in ALS patients was identified (p=0.03, 12 variants, Firth logistic regression, 
beta=1.47, Figure 1.5). Coding and enhancer mutations occurred in independent individuals, 




1.8.3. CAV1/CAV2 function and association with ALS 
 
Caveolin 1 (CAV1) and caveolin 2 (CAV2) are scaffolding proteins and the main component 
of the caveolae plasma membranes. CAV1 and CAV2 are expressed in most cell types, 
except striated muscle cells, where caveolin 3 is predominant. In motor neurons, CAV1 and 
CAV2 are expressed together in a hetero-oligomeric complex (de Almeida, 2017) within 
membrane lipid rafts (MLRs) on the cell surface and have a key role in organization of 
intercellular signalling (Sawada et al., 2019; Schmick and Bastiaens, 2014). CAV1 activity 
promotes neurotrophic signalling, leading to enhanced neuronal survival (Head et al., 
2011; Mandyam et al., 2017). In contrast, loss of CAV1 accelerates neurodegeneration (Head 
et al., 2010, 2011). Abnormal neurotrophic signalling is well documented in ALS (Mutoh et al., 
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2000; Turner et al., 2004), and in particular, deficient neurotrophic signalling is associated with 
an increased vulnerability to neuronal injury (Bemelmans et al., 2006; Ghavami et al., 





Figure 1.5. Significant enrichment of ALS genetic-risk within enhancers and coding 
regions linked to CAV1 and CAV2. (A) Pipeline for variant filtering and burden testing; 
enhancers are first associated with genes based on epigenetic and transcriptome data 
(Fishilevich et al., 2017); enhancer variants are prioritised for further analysis if they are rare 
(MAF<0.01, (Lek et al., 2016) and evolutionary conserved (LINSIGHT score >0.8, (Huang et 
al., 2017). (B) Quantity of genetic material (bp) relative to CNS enhancers derived from Hi-C 
data (Rhie et al., 2018); CNS enhancers = 100. Upper two bars denote total genetic material; 
lower two bars denote ALS-associated genetic variants only. Grey shading denotes material 
unique to CNS or tissue-agnostic enhancers versus material shared by both (white). (C, D) 
CAV1-coding variants passing filtering criteria are depicted in the table and figure. One variant 
is present at higher frequency in controls (orange arrow) and one variant is present in multiple 









1. Mutations in the glycosyltransferase domain of GLT8D1 cause ALS via dysregulated 
ganglioside biosynthesis.  
2. ALS-associated enhancer mutations linked to CAV1 and CAV2 cause downregulation 
of CAV1 and CAV2 expression and disrupt membrane lipid rafts. 
 
 
1.9.2. Overall objectives: 
 
1. Investigate the relative toxicity caused by overexpressing ALS-associated GLT8D1 
mutations in neuronal and non-neuronal cells. 
2. Measure the effect of ALS-associated GLT8D1 mutations on the glycosyltransferase 
activity of the enzyme. 
3. Assess motor function in zebrafish larvae following targeted knockdown of the 
endogenous glt8d1 orthologue using antisense morpholino oligonucleotides, and 
following overexpression of mutant human GLT8D1 mRNA. 
4. Evaluate the effect of an ALS-linked R92C mutation on membrane lipid raft integrity. 
5. Investigate whether an ALS-linked R92C mutation causes fragmentation of the Golgi 
network. 
6. Assess the relative expression of CAV1/CAV2 mRNA and protein in patient-derived 
cells carrying an ALS-associated CAV1/CAV2 enhancer variant. 
7. Use CRISPR/Cas9 genome editing to disrupt the WT CAV1/CAV2 enhancer sequence 
in a human neuronal cell model, and evaluate the effect on CAV1/CAV2 mRNA 
expression. 
8. Evaluate the effect of ALS-associated CAV1/CAV2 enhancer variants on membrane 




Chapter 2. Materials and Methods 
 
2.1. Materials 
2.1.1. General materials 
Bromophenol blue powder, glycerol, sodium chloride (NaCl) analytical grade, 
dimethylformamide (DMF), sodium dodecyl sulphate (SDS), Ethylenediaminetetraacetic acid 
(EDTA), Oxoid™ Phosphate Buffered Saline (PBS) Tablets (Dulbecco A), Hanks Balanced 
Salt Solution (HBSS) and nitrocellulose membranes were all purchased from ThermoFisher 
Scientific. SDS [Lauryl Sulphate] and HEPES free acid and Tris (molecular grade) were 
purchased from Melford. Acetic acid; Ammonium Persulphate (APS); β-Mercaptoethanol; 
Dithiothreitol (DTT); TEMED; Triton™ X-100; Trizma® base; and Tween® 20 were all 
purchased from Sigma-Aldrich.    
 
2.1.2. General buffers and solutions  
 PBS: 137mM NaCl, 3mM KCl, 8mM Na2HPO4, and 1.5mM KH2PO4, at pH 7.3. 
Oxoid™ PBS tablets were dissolved in 1L dH2O, and the solution was autoclaved.  
 1x Tris Acetate EDTA (TAE) buffer: 40mM Tris, 40mM acetate, 1mM EDTA, at pH 8.0.  
 1x Tris-Buffered saline, 0.1% Tween® 20 Detergent (TBST): 20mM Tris, 137mM NaCl, 
0.2% (v/v) Tween® 20, at pH 7.6.  
 
Solutions for RNA work were pre-treated with (Diethylpyrocarbonate) DEPC to inhibit RNase 
activity. 0.001 volumes of DEPC was added to the appropriate solution and mixed for 1 hour. 
The solution was subsequently autoclaved to degrade the DEPC. For sterilisation, solutions 
were autoclaved in an MP25 autoclave (Rodwell) at 121°C, 15psi for 15 minutes. 
 
2.1.3. Cell culture materials 
Dulbecco’s Modified Eagle Medium (DMEM), RPMI 1640, DMEM/F-12 GlutaMAXTM, 
Penicillin/Streptomycin and 10x Trypsin were all purchased from Lonza. Neurobasal medium, 
foetal bovine serum (FBS), L-glutamine, sodium pyruvate, N-2 supplement, B-27 supplement, 
and Opti-MEMⓇ Reduced Serum Medium were all purchased from ThermoFisher Scientific. 
Tetracycline-free FBS was purchased from Biosera. Flp-InTM T-RExTM Core Kit, Flp-InTM T-
RExTM HEK293 cells, Blasticidin-S and Hygromycin-B, ZeocinTM and Tetracycline were all 
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purchased from Invitrogen. Plasma fibronectin was purchased from Merck. Gelatin powder 
was purchased from BDH Biochemical. Polyethylenimine (PEI) was purchased from Sigma-
Aldrich. Epidermal growth factor (EGF), Heparin and fibroblast growth factor (FGF) were 
purchased from PeproTech. Smoothened agonist (SAG) was purchased from Millipore. All-
trans retinoic acid (RA) and forskolin were purchased from Sigma-Aldrich.  
  
2.1.4. Molecular biology materials  
HyperLadder™ I, II, III, IV and V molecular weight markers, and accuzyme were purchased 
from Bioline. Pre-stained protein ladder (broad molecular weight) was purchased from Abcam. 
Agarose (molecular grade) was purchased from Melford. LB Broth, Miller (molecular genetics 
granular); and LB Agar, Miller (powder) were purchased from Fisher Scientific. DNA 
Polymerase I was purchased from Invitrogen. DH5-α Competent E.coli was purchased from 
New England BioLabs. T4 DNA Ligase and 10x Ligase Buffer were purchased from Promega. 
Ethidium bromide, phenol-chloroform and ampicillin were purchased from Sigma-Aldrich.  
BamHI, XbaI, NheI, HindIII, BcII, and XhoI FastDigest restriction enzymes were purchased 
from ThermoFisher Scientific. 10x FastDigest green buffer, M-MLV reverse transcriptase, 5x 
first strand buffer, 0.1M dithiothreitol, random hexamer primer and DNTP mix were all 
purchased from ThermoFisher Scientific. Ethidium bromide was purchased from Sigma-
Aldrich. 2x Brilliant III qPCR Master Mix; and 2x Brilliant III SYBR Green qPCR Master Mix 
were purchased from Agilent Technologies. Protein Assay Dye Reagent Concentrate 
(Bradford Reagent) was purchased from Bio-Rad. Bovine serum albumin (BSA) powder was 
purchased from Fisher Scientific. FLAGⓇ Magnetic Beads were purchased from Sigma-
Aldrich. Ultra-Pure ProtoGel® 30% (w/v) Acrylamide, 0.8% (w/v) Bis-Acrylamide Stock 
Solution (37.5:1) and EZ-ECL Kit were purchased from Geneflow. Original dried skimmed milk 
powder was purchased from Marvel. Paraformaldehyde (PFA), SIGMAFAST™ EDTA-free 
Protease Inhibitor Cocktail (PIC) tablets, Sodium Azide and Thiozolyl Blue Tetrazolium 
Bromide (MTT) powder were purchased from Sigma-Aldrich. PMSF protease inhibitor and 
TRIzol® LS Reagent were purchased from ThermoFisher Scientific. Fluorescent mounting 
medium (DAKO) was purchased from Aligent. Hoechst (33342) was purchased from 
ThermoFisher Scientific. Alt-R® S.p. Cas9 Nuclease V3, Alt-R® Cas9 Electroporation 
Enhancer and TracrRNA were purchased from Integrated DNA Technologies. VeriFi mix red 







Table 2.2. Primary antibodies used for immunoblotting (WB) and 
immunocytochemistry (ICC). Antibody specificity, molecular weight (kDa), source, 















Rabbit/polyclonal 1:200 for ICC 
TGN-46 47 Abcam/ab50595 Mouse/monoclonal 1:500 for ICC 
GM130 112 Abcam/ab52649 Rabbit/monoclonal 1:250 for ICC 
α-Tubulin 50 Sigma-Aldrich/T9026 Mouse/monoclonal 
1:5000 for 
WB/ICC 
Table 2.1. Molecular biology kit product details. Name, source and assay ID are shown. 
Kit Source Identifier 
mMESSAGE mMACHINETM 
SP6 Transcription Kit 
ThermoFisher Scientific #AM1340 
PierceTM LDH Cytotoxicity Assay 
Kit 
ThermoFisher Scientific #88953 
Plasmid Mini Kit QIAGEN #12125 




PierceTM BCA Protein Assay Kit ThermoFisher Scientific #23225 
NeonTM Transfection System 
Starter Pack Kit 
Invitrogen #MPK5000S 
4D NucleofectorTM System Lonza 
#AAF-1002B  
#AAF-1002X 
GenElute Mammalian Genomic 
DNA Miniprep Kit 
Sigma-Aldrich #G1N350 
Direct-zol RNA Miniprep Kit Zymo Research #R2050 
Alt-R CRISPR-Cas9 Control Kit, 
Human, 2 nmol 
Integrated DNA technologies #1072554 
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JL-8 32 Takara Bio/632380 Mouse/monoclonal 
1:5000 for 
ICC/WB 
FLAG M2 - Sigma-Aldrich/F3165 Mouse/monoclonal 1:500 for WB 
Caveolin1 22 GeneTex/GTX100205 Rabbit/polyclonal 1:1000 for WB 
Caveolin1 22 Abcam/ab2910 Rabbit/polyclonal 1:500 for ICC 
Caveolin2 21 Abcam/ab3417 Rabbit/polyclonal 1:500 for WB 





Table 2.3. Secondary antibodies and molecular probes. Antibody specificity, source, 





Donkey anti-mouse (AlexaFluorTM 
568)  
Life Technologies 1:1000 for ICC 
Donkey anti-rabbit (AlexaFluorTM 
488) 
Life Technologies 1:1000 for ICC 
Goat anti-mouse (AlexaFluorTM 
568) 
Life Technologies 1:1000 for ICC 
Goat anti-rabbit (AlexaFluorTM 488) Life Technologies 1:1000 for ICC 
Wheat Germ Agglutinin, 
AlexaFluorTM 488 Conjugate, 
fluorescent probe 
Invitrogen/11261 2µg/mL for live imaging 
Cholera Toxin Subunit B 
(Recombinant) AlexaFluorTM 555 
Conjugate, fluorescent probe 
Invitrogen/C22843 1µg/mL for live imaging 
Anti-mouse-IgG HRP conjugate Promega/W4021 1:5000 for WB 










Table 2.4. PCR primer sequences for molecular cloning and site-directed 
mutagenesis. Gene and reference ID, plasmid type, restriction endonuclease and primer 
sequences are shown. All oligonucleotides were purchased from Sigma-Aldrich.  






Oligonucleotide sequence for 















































Table 2.5. Media compositions. Cell lines, media and supplements are shown.  
Cell line Media/source Supplements 
HEK293 / SH-SY5Y DMEM, Lonza 10% (v/v) FBS and 50 U/mL Pen/Strep 
N2A DMEM, Lonza 
10% (v/v) FBS, 50 U/mL Pen/Strep, 
500mM sodium pyruvate 
HEK293 stable DMEM, Lonza 
10% (v/v) tetracycline-free FBS, 50 
U/mL Pen/Strep, 150ug/mL Hygromycin 
B, and 15ug/mL Blasticidin S 
Fibroblast DMEM, Lonza 10% (v/v) FBS and 50 U/mL Pen/Strep 




1% (v/v) B-27, 1% (v/v) N-2, 20ng/mL 











2% (v/v) B-27, 1% (v/v N-2) 
iAstrocyte DMEM, Lonza 
10% (v/v) FBS, 0.3% (v/v) N-2, 50 U/mL 
Pen/Strep 
Mouse primary  
NeurobasalTM, 
ThermoFisher Scientific 






Table 2.6. Plasmid manipulations and origins. Plasmid ID, manipulations and the source 
are shown. The individuals who provided the plasmid or performed the manipulation are 
referred to by their initials: Dr Guillaume Hautbergue (GH); Dr Tennore Ramesh (TR); 
Tobias Moll (TM).  
Plasmid Manipulation Company/origin 
pcDNA5/FRT/TO_GFP N/A Addgene 
pEGFP-N1 N/A Clontech 
PCS2+ N/A Addgene 
pEGFP-N1_GLT8D1 
GLT8D1 (IMAGE: 
40116197) inserted into 
NheI and XhoI 
restriction sites of 
pEGFP-N1. 
Generated by GH/TM 
pEGFP-N1_GLT8D1-G78W 




Generated by GH/TM 
pEGFP-N1_GLT8D1-R92C 




Generated by GH/TM 
pcDNA5/FRT/TO_3xFLAG 
3xFLAG-M2 tag cloned 
into HindIII/BamHI sites 
of 
pcDNA5/FRT/TO_GFP. 






40116197) cloned into 
BamHI/XhoI restriction 
sites. 
Generated by GH/TM 
pcDNA5/FRT/TO_3xFLAG-
GLT8D1-G78W 





Generated by GH/TM 
pcDNA5/FRT/TO_3xFLAG-
GLT8D1-R92C 





Generated by GH/TM 
PCS2+_GLT8D1 
GLT8D1 cloned into 
BcII/XbaI restriction 
sites of PCS2+. 
Generated by TR/TM 
PCS2+_GLT8D1-G78W 
GLT8D1-G78W cloned 
into BcII/XbaI restriction 
sites of PCS2+. 
Generated by TR/TM 
PCS2+_GLT8D1-R92C 
GLT8D1-R92C cloned 
into BcII/XbaI restriction 
sites of PCS2+. 





Table 2.7. Oligonucleotide sequences for GLT8D1 cloning and knockdown in 
zebrafish. Label, relevant procedure and nucleotide sequence are shown. 
Label Relevant procedure Sequence 
























































GLT8D1_RT_Rvs RT-PCR primers for 
GLT8D1 
TAACCACATTCACTCTGCGT 
GLT8D1_Fwd RT-PCR primers for 
assessing Glt8d1 
knockdown in zebrafish 
AGCCGGAGAGAGTCCAGTTT 
GLT8D1_Rvs RT-PCR primers for 
assessing Glt8d1 


































































2.2.1. Cell culture  
2.2.1.1. HEK293, Neuro-2A and SH-SY5Y cell line maintenance 
Human embryonic kidney 293 (HEK293) and human neuroblastoma SH-SY5Y cell lines used 
in this project were cultured in 10mL Dulbecco's Modified Eagle’s Medium (DMEM) 
supplemented with 10% (v/v) foetal bovine serum (FBS) and 50 U/mL Penicillin/Streptomycin 
in T75 culture flasks. Neuro-2A (N2A) cell medium was supplemented with an additional 
500mM sodium pyruvate. Cell lines were maintained at 37°C, 5% CO2 and split every 3-4 
days. For sub-culturing, media was removed and the cells were washed with sterile phosphate 
buffered saline (PBS). 2mL 1x trypsin was added to the adherent cells in a T75 and incubated 
for 3 minutes at 37°C. Flasks were tapped to dislodge trypsinized cells and 10mL of 
supplemented DMEM was added. Cells were centrifuged at 400xg for 4 minutes at room 
temperature (RT) and the supernatant was discarded. The cell pellet was re-suspended in 
fresh DMEM and ~1x106 cells were transferred to a fresh T75 flask. Supplemented DMEM 
was added to create a final volume of 10mL. All adherent cell lines were seeded at ~20% 
confluency and sub-cultured when ~90% confluent. All experimental work was performed 
using HEK-293, N2A, and SH-SY5Y cells within the range of 7-32 passages. 
 
2.2.1.2. HEK293 Sham and HEK293_GLT8D1-WT/R92C cell line generation   
Stable HEK293 cells exhibiting tetracycline-inducible expression of wild type (WT) and mutant 
(p.R92C) GLT8D1 were generated using the Flp-InTM T-RExTM system. The pGKFLPobpA 
vector (Addgene) encoding a recombinase was co-transfected with either pcDNA5/FRT/TO, 
pcDNA5/FRT/TO_3xFLAG-GLT8D1, or pcDNA5/FRT/TO_3xFLAG-GLT8D1-R92C plasmids 
into the HEK293 Flp-InTM T-RExTM CVCL_U427 line in a ratio of 4:6 using polyethylenimine 
(PEI). Resulting clones were screened for ZeocinTM sensitivity, and Blasticidin-S/Hygromycin-
B resistance, to ensure isogenic. Clones that were Blasticidin-S/Hygromycin-B-resistant but 
ZeocinTM-sensitive were expanded and cryopreserved (see section 2.2.1.9.). HEK293 Sham 







2.2.1.3. HEK293 Sham and HEK293_GLT8D1-WT/R92C stable cell line maintenance  
HEK293 Sham and HEK293_GLT8D1-WT/R92C stable cell lines were cultured in 10mL 
DMEM supplemented with 10% (v/v) tetracycline-free FBS, 50 U/mL Penicillin/Streptomycin, 
100µg/mL Hygromycin B and 15µg/mL Blasticidin S in 10cm plates at 37°C, 5% CO2 and split 
every 3-4 days as previously described (see section 2.2.1.1).   
 
2.2.1.4. Fibroblast cell maintenance 
Human fibroblasts were initially cultured in 10mL Eagle’s Minimum Essential Medium (EMEM) 
supplemented with 10% FBS, 1% MEM non-essential amino acids (Lonza), 1% MEM vitamins 
(Lonza), 1% Penicillin-Streptomycin, 1% Sodium Pyruvate and 1% Uridine (Sigma) in T75 
culture flasks at 37°C, 5% CO2, prior to cryopreservation (see section 2.2.1.11). Cells 
underwent a medium change every 2 days and were split when approaching confluence. Cells 
were split as previously described (see section 2.2.1.1) aside from centrifugation which was 
performed at 550xg for 4 minutes at RT. The cell pellet was re-suspended in fresh EMEM and 
1/3 of the cell suspension was transferred to a fresh T75 flask. Supplemented EMEM was 
added to create a final volume of 10mL. 
 
2.2.1.5. Lymphoblastoid cell maintenance 
 
Human lymphoblastoid cell lines (LCLs) derived from Caucasian ALS patients (n=5) and 
neurologically normal controls (n=3), all of Northern European descent, were obtained from 
the UK Motor Neurone Disease Association (MNDA) DNA Bank. LCLs were cultured in 
suspension in 30mL RPMI 1640 medium (Lonza) supplemented with 2mM L-glutamine and 
10% (v/v) FBS (Table 2.5) in T175 culture flasks at 37°C, 5% CO2. Cells were seeded at a 
concentration of 2x105 viable cells/mL and split every 3-4 days. For splitting, cells were 
centrifuged at 400xg for 4 minutes at RT and the supernatant was discarded. The cell pellet 
was re-suspended in fresh supplemented RPMI 1640 medium and ~6x106 cells were 
transferred to a fresh T175 culture flask. Supplemented RPMI 1640 media was added to 
create a final volume of 30mL.   
 
2.2.1.6. Generation of induced neural progenitor cells (iNPCs) from human fibroblasts 
Prior to transduction, fibroblasts were cultured in 10mL DMEM supplemented with 10% (v/v) 
FBS and 50 U/mL Penicillin/Streptomycin in T75 culture flasks at 37°C, 5% CO2 for a minimum 
of 1 week. Fibroblasts underwent a medium change every 2 days, and were split as previously 
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described (see section 2.2.1.4). 6-well culture plates were coated in plasma fibronectin 
(5µg/mL in PBS) for 5-30 minutes prior to seeding. Excess fibronectin was removed 
immediately before seeding ~2x105 fibroblasts per well. Fibroblasts were incubated for 24 
hours at 37°C, 5% CO2. Fibroblasts were transduced using retroviral vectors (MOI 5-10) 
expressing Kruppel-like factor 4 (Klf4), POU transcription factor Oct-3/4 (Oct3/4), SRY-related 
HMG-Box Gene 2 (Sox2), and a c-Myc substitute (Dr Laura Ferraiuolo personal 
communication). Culture media was changed 16 hours post-transduction to fibroblast media 
(see Table 2.5). After 24 hours, the media was changed to pre-iNPC media (see Table 2.5) 
containing epidermal growth factor (EGF, 20ng/mL), heparin (5ng/mL) and fibroblast growth 
factor (FGF, 20ng/mL). Media changes were performed every 2 days; EGF and heparin were 
removed 10 days post-transduction, and the concentration of FGF was increased to 40ng/mL. 
iNPCs were generated in collaboration with Dr Laura Ferraiuolo and Allan Shaw.    
 
2.2.1.7. iNPC maintenance 
 
iNPCs were cultured in DMEM/F-12 GlutaMAXTM supplemented with 1% (v/v) B-27, 1% (v/v) 
N-2, and FGF (20ng/mL) (see Table 2.5) at 37oC, 5% CO2 in 10cm petri-dishes. 10cm dishes 
were pre-coated using plasma fibronectin (5µg/mL in PBS) for 30 minutes at RT prior to 
seeding. iNPCs underwent media changes every two days and were split when ~90% 
confluent. For splitting, media was removed and cells were incubated in 1mL accutase until 
they dislodged. Cells were re-suspended in iNPC-conditioned medium and centrifuged at 
200xg for 4 minutes at RT. The supernatant was discarded and cells were re-suspended in 
fresh iNPC media. Excess fibronectin was removed from a fresh, pre-coated 10cm plate and 
iNPCs were re-plated at a suitable density to encourage contact-mediated recovery.  
 
2.2.1.8. Differentiation of iNPCs into iNeurons 
6-well culture plates were coated in fibronectin (5ug/mL in PBS) for 5-30 minutes prior to 
seeding. Excess fibronectin was removed and iNPCs were seeded into 6-well plates at a 
density of 2x105 cells per well. iNPCs were cultured in 2mL supplemented DMEM/F-12 
GlutaMAXTM (see Table 2.5). Media was changed to a FGF-free iNeuron media (DMEM/F-12 
GlutaMAXTM, 1% (v/v) B-27, 1% (v/v) N-2) (see Table 2.5) 24 hours after seeding. After 48 
hours, the media was changed to iNeuron media + γ-secretase inhibitor IX (DAPT, 2.5µM; 
Tocris). After 48 hours, media was changed to iNeuron media + smoothened agonist (SAG, 
0.5µM) + all-trans retinoic acid (RA, 1µM) + forskolin (2.5µM) for 6 days with a media change 
every 2 days. At day 11, cells were cultured in iNeuron media + SAG (0.5µM) + RA (1µM) + 
forskolin (2.5µM) + growth factors: brain-derived neurotrophic factor (BDNF, 20ng/mL), ciliary 
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neurotrophic factor (CNTF, 20ng/mL) and glial cell-line derived neurotrophic factor (GDNF, 
10ng/mL) for 4 days. iNeurons were fully differentiated at day 16.   
 
2.2.1.9. Differentiation of iNPCs into iAstrocytes 
For iAstrocyte differentiation, iNPCs were seeded as previously described (see section 
2.2.1.7) but at a lower density of ~1x105 cells per well in iNPC media (see Table 2.5). The 
following day, the media was changed to iAstrocyte media (DMEM supplemented with 10% 
(v/v) FBS, 0.3% (v/v) N-2) (see Table 2.5). iAstrocytes were allowed to mature for a minimum 
of 7 days until fully differentiated.  
 
2.2.1.10. SH-SY5Y neuronal differentiation 
Human SH-SY5Y neuroblastoma cells were seeded at densities of either 5x104 cells per well 
of a 6-well culture plate, or 2x103 cells per well of a 96-well culture plate in DMEM 
supplemented with 10% (v/v) FBS, 50 units/mL penicillin and 50μg/mL of streptomycin. 24 
hours after seeding the media was changed to DMEM supplemented with 5% (v/v) FBS, 50 
units/mL penicillin, 50μg/mL of streptomycin, 4mM L-glutamine, and 10μM retinoic acid. After 
72 hours, the medium was switched to neurobasal media containing 1% (v/v) N-2 supplement 
100x, 50 units/mL penicillin, 50μg/mL of streptomycin, 1% L-glutamine and 50ng/mL human 
BDNF. Cells were cultured for an additional 3 days until fully differentiated.  
 
To confirm neuronal differentiation blinded, semi-automated analysis of neurite length was 
performed using the SimpleNeuriteTracer plugin for FIJI (Longair et al., 2011). 2D images 
were converted to 8-bit grayscale and successive points along the midline of a neural process 
were selected. The software automatically identified the path between the two points. Tracing 
accuracy was improved using Hessian-based analysis of image curvatures. The 
AnalyzeSkeleton plugin (Arganda-Carreras et al., 2010) was used to quantify the morphology 
of the traces. 
   
2.2.1.11. Cryopreservation of Cell Lines 
Unless stated otherwise, all cell lines were cryopreserved in freezing medium containing 90% 
(v/v) FBS + 10% (v/v) dimethyl sulfoxide (DMSO). Cells were pelleted as previously described 
(see section 2.2.1), and ~5x106 cells were re-suspended in 1mL freezing medium. iNPCs were 
re-suspended in 1mL 90% (v/v) supplemented DMEM/F-12 GlutaMAXTM + 10% DMSO. Cells 
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were transferred to a cryogenic vial and were slowly frozen at -80oC in a CoolCell® SV2 
(BioCision) overnight, then transferred to liquid nitrogen for long-term storage.  
 
2.2.1.12. Tetracycline induction of stable HEK293 cell lines  
 
To induce expression of the pcDNA5/FRT/TO_3xFLAG-GLT8D1-WT/R92C construct, cells 
were cultured in Blasticidin-S-free supplemented DMEM for 24 hours (refer to section 2.2.1.3), 
after which, tetracycline (stock concentration: 10µg/mL in 70% ETOH) was added to the 
culture media to create a final concentration of 10mg/mL. Induction pressure was stable for at 
least 48 hours.      
 
2.2.1.13. Preparation and maintenance of dissociated primary mouse cortical neurons 
 
The following protocol was performed under a Home Office project licence (I5BBF6E32) and 
in accordance with the Animals (Scientific Procedures) Act of 1986 (ASPA). Initially, culture 
plates were coated in an appropriate volume of poly-D-lysine (50µg/mL in dH2O) overnight at 
37°C, 5% CO2. C57BL/6 mice were bred at the University of Sheffield Biological Services Unit 
and females were sacrificed by cervical dislocation. Cerebral cortices were isolated from 
embryonic day 14 embryos whilst submersed in cold HBSS-/-. Meninges were manually 
removed using dissecting forceps and the tissue was washed 1x in 10mL HBSS-/-, then 
resuspended in 5mL HBSS. Trypsin was added to a final concentration of 0.025% and 
incubated for 13 minutes at 37°C to encourage tissue dissociation. 5mL DNAse (10μg/mL 
DNAse in HBSS+/+) was added for 2 minutes and the supernatant was aspirated. Tissue was 
resuspended in 1mL triturating solution (1% albumax, 25mg trypsin inhibitor, 10μg/mL DNAse) 
and triturated through flame-polished glass Pasteur pipettes with progressively smaller 
openings to obtain a single cell suspension. Cells were re-suspended in supplemented 
neurobasal media (1x B27-supplement, 1x GlutaMax, 50 U/mL Penicillin/Streptomycin) and 
maintained at 37°C, 5% CO2. A half media change was performed every 3-4 days until the 
day of experiment. Mouse primary cortical neurons were harvested by David Burrows and Dr 
Agnieszka Urbanek. 
 
2.2.1.14. CRISPR editing of mammalian cell lines  
 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology was 
utilised for genome editing in HEK293 and SH-SY5Y cell lines. gRNA duplexes were 
assembled from tracrRNA and crRNA in a thermocycler according to the manufacturer’s 
instructions under RNAse-free conditions. Cells were cultured to 70-90% confluent on the day 
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of transfection. 1mL antibiotic-free DMEM was prepared and incubated in 24-well plates at 
37°C. CRISPR/Cas9 Ribonucleoproteins were formed by complexing 240ng gRNA duplex 
with 1250ng Alt-R V3 Cas9 Protein (IDT) in 10μL buffer R (from 10μL Neon transfection kit) - 
a 1:1 molar ratio - for 10 minutes. 1x105 viable cells were aliquoted per transfection and 
centrifuged at 400xg for 4 minutes. Cells were washed in Ca2+ and Mg2+-free PBS (Sigma) 
and centrifuged at 400xg for 4 minutes. Cell pellets were resuspended in the 10μL buffer R 
containing Cas9 protein and gRNA duplexes. 2μL of 10.8μM electroporation enhancer (IDT) 
was added and the solution mixed thoroughly to ensure a suspension of single cells. 10μL of 
this mixture was loaded into a Neon transfection system and electroporated according to 
manufacturer’s instructions (refer to section 2.2.3.2). Cells were then transferred to pre-
warmed media in 24-well plates.   
 
2.2.1.15. Determining CRISPR editing efficiency 
 
Genomic DNA was isolated from CRISPR-edited and control cells using a GenElute 
Mammalian DNA Miniprep Kit (Sigma) according to manufacturer’s instructions.  A ~400bp 
region around the expected cas9 cut site was amplified by PCR using VeriFi mix (PCRbio).  
Expected amplification was confirmed using gel electrophoresis, and the products were 
Sanger-sequenced (Core Genomic Facility, University of Sheffield). Sequencing trace files 
were uploaded to TIDE (available at: https://tide.deskgen.com/) and an indel efficiency was 
calculated.  
 
2.2.1.16. Liposome-mediated cell transfection 
HEK293 and N2A cells were transfected 24 hours after seeding. Transection conditions were 
adjusted according to the plate size, experiment, cell type, and cell density (see Table 2.8). 
Plasmid DNA was mixed with polyethylenimine (PEI) to promote endocytosis. The reaction 
mixture was diluted using Gibco™ Opti-MEM® I Reduced Serum Media and the samples were 
vortexed 14-16 times and incubated for 10 minutes at RT to allow DNA-liposome complexes 
to form. The reaction mixture was added to the culture media in a dropwise manner and cells 








Table 2.8. Transfection conditions according to plate size, experiment, cell type and 










T75 1x106 10 35 333µL 
T175 5x106 30 105 1mL 
10cm plate 2x106 15 52 500µL 
6-well plate (HEK) 2x105 2 7 200µL 
6-well plate (N2A) 3x105 2 6 200µL 
24-well plate (HEK) 
immunoblotting 
5x104 0.7 1.75 50µL 
24-well plate (N2A) 
immunoblotting 
7.5x104 0.7 2.1 50µL 
24-well plate (HEK) 
MTT / ICC 
2.5x104 0.5 1.75 50µL 
24-well plate (N2A) 
MTT / ICC 
3x104 0.5 1.75 50µL 
 
 
2.2.1.17. Electroporation-mediated cell transfection   
2.2.1.17.1. Neon® Transfection System  
 
Electroporation was performed using a Neon® Transfection System (Invitrogen) according to 
the manufacturers’ guidelines. In brief, a Neon® Tube was filled with 3mL of Electrolytic Buffer 
and inserted into a Neon® Pipette Station. Cells were harvested as previously described (see 
section 2.2.1.1). Cells were centrifuged at 400xg for 4 minutes at RT and the media was 
removed. Cells were washed with Ca2+ and Mg2+-free PBS and re-centrifuged at 400xg for 4 
minutes at RT. The PBS was aspirated and the cells were re-suspended in Resuspension 
Buffer R at a final density of 1×107 cells/mL. The amount of DNA used for transfection was 
dependent on cell concentration and the size of the culture plate used for subsequent seeding 
(see Table 2.9). DNA was gently mixed with the cell suspension and 10µL was aspirated into 
a Neon® Tip using a Neon® Pipette, avoiding the formation of air bubbles. The Neon® Pipette 
containing the sample was inserted vertically into the Neon® Tube and electroporation was 
performed at 3 pulses of 1200V with a pulse width of 20ms. Following electroporation, cells 
were seeded into an appropriate culture plate and incubated at 37°C, 5% CO2.  
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Table 2.9. Nucleofection conditions using the Neon® Transfection System (adapted 
from Invitrogen). 
Plate DNA (µg) 
Volume of plating 
medium 
Cell number 
96-well 0.25 - 0.5 100µL 1-2 x 104 
48-well 0.25 – 1.0 250µL 2.5-5 x 104 
24-well 0.5 – 2.0 500µL 0.5-1 x 105 
12-well 0.5 – 3.0 1mL 1-2 x 105 
6-well 0.5 – 3.0 2mL 2-4 x 105 
10cm 5.0 – 30.0 10mL 1-2 x 106 
 
 
2.2.1.17.2. 4D NucleofectorTM System  
 
Nucleofection was performed following the dissociation of primary mouse cortical neurons 
(refer to section 2.2.1.13). Excess poly-D-lysine was removed from the culture plate, and the 
wells were washed 2x in dH2O and 1x in sterile PBS. An appropriate volume of pre-warmed 
neurobasal media was added to the wells and the plates were incubated at 37°C, 5% CO2. 
Fresh, dissociated cortical neurons were electroporated using a 4D NucleofectorTM System 
(Lonza) according to the manufacturer’s instructions. In brief, 100µL reactions were 
assembled by mixing 82µL NucleofectorTM Solution with 18µL Supplement (sample contents 
confidential) to create the NucleofectorTM X Solution. 4-5x106 cells were centrifuged at 80xg at 
RT, and the pellet was resuspended in 90µL NucleofectorTM X Solution. 10µL of plasmid DNA 
(2µg) was added and the reaction was mixed gently. Samples were transferred to a single 
NucleovetteTM and electroporated using a randomly selected pre-programmed setting 
recommended by the manufacturer (voltage and pulse width were encrypted). The sample 
was incubated at RT for 10 minutes post-nucleofection, resuspended in pre-warmed 
neurobasal medium, and transferred to the culture plate which was pre-coated using poly-D-







2.2.2. Molecular cloning 
2.2.2.1. Plasmid cloning by polymerase chain reaction (PCR) 
PCR reactions (50µL total) for the amplification of I.M.A.G.E. clones were assembled 
accordingly: 
- 1µL DNA I.M.A.G.E. clone (100ng/µL) 
- 34.5µL Milli-Q H2O 
- 5µL 10x Accuzyme™ reaction buffer  
- 1µL Accuzyme™ DNA Polymerase  
- 1µL DMSO 
- 5µL 10x DNTP Mix (each at 10mM)  
- 1.25µL forward primer (10µM) 
- 1.25µL reverse primer (10µM) 
 
PCR reactions were performed in a thermocycler according to the following parameters 
outlined in Table 2.10: 
Table 2.10. PCR programme for I.M.A.G.E clone amplification. 
Stage  Temperature Time 
Heated lid 110 oC - 
Pre-cycle step 95 oC 1 minute 
Start cycle 30x 
Temperature step 1 95 oC 20 seconds 
Temperature step 2 53 oC 20 seconds 
Temperature step 3 72 oC 3 minutes 
End cycle 
Post-cycle step 68 oC 4 minutes 
Hold 10 oC Infinite 
 
 
2.2.2.2. Agarose gel electrophoresis  
Agarose gel electrophoresis was used to separate linear DNA fragments produced by PCR or 
restriction digest. 1% agarose gels were prepared by dissolving 1g agarose powder in 100mL 
1x Tris-acetate-EDTA (TAE) buffer (40mM Tris; 20mM NaOAc; 1mM EDTA; pH8.0) (w/v). The 
agarose solution was heated until fully dissolved, cooled, and 100ng/mL of ethidium bromide 
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was added to enable visualisation of the nucleic acid under ultraviolet (UV) light. The mixture 
was cooled slightly and poured onto a casting tray containing 30-well combs. The gel was left 
for 30 minutes to cool and set, then transferred to an electrophoresis tank and submerged in 
1x TAE buffer. Combs were removed and samples were loaded consecutively alongside 5µL 
of a HyperLadder™ molecular weight marker. Electrophoresis was performed at 80V for 45-
60 minutes, and gels were imaged using the GENI UV light imaging system (Syngene). For 
DNA extraction, bands were visualised on a UV-trans illuminator, excised using a scalpel and 
transferred to an Eppendorf tube.  
 
2.2.2.3. DNA extraction from agarose gels 
DNA was extracted from agarose gels using a QIAquick Gel Extraction Kit (QIAGEN), 
according to the manufacturers’ instructions. In brief, 100μL Buffer QG (solubilisation and 
binding buffer) was added per 100mg gel and incubated at 50°C for 10 minutes with vortexing 
every 2-3 minutes until the gel completely dissolved. One gel volume of isopropanol was 
added to the sample and mixed. The sample was then transferred to a QIAquick spin column 
and drawn through via vacuum suction. 750μL Buffer PE (wash buffer) was applied to and 
drawn through the column. Excess Buffer PE was removed via centrifugation at 13,300xg for 
1 minute at RT. 50μL Buffer EB (elution buffer) was added to the column and left to stand for 
3 minutes at RT. DNA was eluted into an Eppendorf tube via centrifugation at 13,300xg for 1 
minute at RT.   
 
2.2.2.4. Restriction digests for PCR insert  
Restriction digests were assembled accordingly: 
- 50μL DNA (500ng/μL) 
- 30μL Milli-Q H2O 
- 10μL 10x restriction buffer (NEB) 
- 50 units of each restriction enzyme (see Table 2.6) 
Reactions were incubated on a heat block overnight at 37°C.  
 
2.2.2.5. Phenol-chloroform extraction for DNA purification 
100μL of phenol-chloroform was added to the restriction digest reaction and vortexed for 1 
minute at RT. Samples were centrifuged at 13,300xg for 3 minutes at RT and the supernatant 
was transferred to a fresh Eppendorf tube. 3M NaOAc was added (10% of total volume) and 
the sample was vortexed briefly. Twice the volume of 100% ETOH was added and the sample 
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was incubated at -20°C for 2-3 hours to precipitate the DNA. Samples were centrifuged at 
13,300xg for 20 minutes at RT and the supernatant was discarded. The DNA pellet was 
washed in 70% ETOH to remove excess salts and left to air-dry for 1 hour at RT, then re-
suspended in 16μL Milli-Q H2O.  
 
2.2.2.6. Plasmid ligation   
Digestion reactions for the linearization of plasmids were assembled accordingly: 2μL plasmid 
DNA (500ng/μL); 2μL 10x restriction buffer; 1μL of each restriction enzyme (10 units / μg DNA) 
(see Table 2.6); 14μL Milli-Q H2O. Reactions were incubated at 37°C for 2 hours. During the 
final 10 minutes of the digest, 1 unit of calf intestinal alkaline phosphatase (CIP) was added 
for every 1 pmol of DNA ends, to dephosphorylate DNA 5’-ends and ensure the vector did not 
re-circularise during ligation. A ligation reaction was then assembled accordingly: 
- 16μL DNA (500ng/μL)  
- 0.5μg pre-cut vector  
- 5μL 5x ligation buffer  
- 1μL T4 DNA ligase 
- 2μL Milli-Q H2O 
Ligation reactions were incubated overnight at 16°C in a thermocycler.   
 
2.2.2.7. Site-directed mutagenesis 
50μL PCR reactions for site-directed mutagenesis were assembled accordingly: 
- 0.5μL plasmid DNA (100ng/μL) 
- 1.25μL forward oligonucleotide (125ng) 
- 1.25μL reverse oligonucleotide (125ng)  
- 5μL 10x dNTPs (each at 10mM) 
- 5μL 10x PFU turbo buffer (2mM) 
- 36μL Milli-Q H2O 
- 1μL PfuTurbo DNA polymerase 
  
PCR reactions were run in a thermocycler according to the following parameters outlined in 
Table 2.11: 
Table 2.11. PCR programme for site-directed mutagenesis. 
Stage  Temperature Time 
Heated lid 110 oC - 
59 
 
Pre-cycle step 95 oC 30 seconds 
Start cycle 26x 
Temperature step 1 95 oC 10 seconds 
Temperature step 2 53 oC 1 minute 
Temperature step 3 72 oC 15 seconds 
End cycle 
Post-cycle step 72 oC 10 minutes 
Hold 10 oC Infinite 
 
Mutated inserts were subsequently validated by Sanger sequencing (Core Genomic Facility, 
University of Sheffield).  
 
 
2.2.2.8. LB agar plates 
Lysogeny broth (LB) agar (10g/L Tryptone, 5g/L Yeast extract, 10g/L NaCl, 15g/L Agar) was 
prepared by re-suspending 40g LB agar powder in 1L dH2O, and autoclaving. The following 
steps were performed aseptically to avoid contamination. LB agar was heated until completely 
melted and left to cool for 15 minutes at RT. 50μg/mL ampicillin or 50μg/mL kanamycin 
selection antibiotic was added to the melted LB agar. The LB agar solution was then mixed, 
poured onto 10cm petri dishes, left to set at RT, and stored at 4°C. 
 
2.2.2.9. Plasmid transformation into competent E. coli  
The following steps were performed aseptically to avoid contamination: DH5-α competent 
Escherichia coli (E. coli) cells and plasmid DNA were thawed on ice. 1μL of plasmid DNA 
(500ng/μL) was added to 50μL of DH5- α cells and incubated on ice for 10 minutes. Samples 
were then heated for 5 minutes at 37°C before adding 1mL Lysogeny broth (LB) to stimulate 
bacterial growth. Samples were then incubated at 37°C for 1 hour, during which agar plates 
containing 50μg/mL of ampicillin were dried at 37°C. 100μL of each sample was transferred 
to an agar plate, streaked using a sterile cell spreader, and incubated overnight at 37°C. The 
following day, a single bacterial colony was selected and transferred to either 100mL (for 
Midiprep) or 2mL (for Miniprep) of liquid LB containing 50μg/mL of appropriate antibiotic 
(depending on the antibiotic resistance gene in the plasmid of interest) and incubated 





2.2.2.10. DNA extraction and purification from bacterial cultures 
2.2.2.10.1. Plasmid Miniprep 
 
Minipreps were performed using a QIAGEN® Plasmid Mini Kit, according to the 
manufacturer’s instructions. In brief, 1.5mL of bacterial cultures were harvested by 
centrifugation at 10,000xg for 1 minute at RT. The supernatant was discarded and the bacterial 
pellet was re-suspended in 200µL buffer P1. 200µL buffer P2 was added, the sample was 
gently inverted 5 times and incubated for 5 minutes at RT. 300µL Buffer S3 was added and 
inverted 10 times, then centrifuged at 10,000xg for 1 minute at RT. The supernatant was 
transferred to a fresh Eppendorf tube, mixed with 700µL isopropanol and incubated at RT for 
10 minutes. Samples were centrifuged at 10,000xg for 10 minutes at RT and the supernatant 
was completely removed. The pellet was air dried for 10 minutes then re-suspended in 50µL 
buffer EB.      
 
2.2.2.10.2. Plasmid Midiprep 
 
Bacterial cultures were harvested by centrifugation at 6000xg for 15 minutes at 4°C. Plasmid 
purification was performed using the QIAGEN® Plasmid Plus Midi Kit, according to the 
manufacturer’s instructions. For maximum DNA yield, pelleted bacteria was re-suspended in 
4mL resuspension buffer (buffer P1) (50mM Tris·Cl, pH 8.0; 10mM EDTA; 100 µg/ml RNase 
A). 4mL lysis buffer (buffer P2) (200mM NaOH, 1% SDS) was added and mixed by inversion 
until a viscous lysate formed, and was incubated at RT for 3 minutes. 4mL neutralisation buffer 
(buffer P3) (3.0 M potassium acetate, pH 5.5) was added to the lysate, mixed 4-6 times by 
inversion and incubated at RT for 10 minutes. 2mL binding buffer (buffer BB) was added, 
mixed by inversion, and incubated at -20°C for 15 minutes to increase the yield of DNA further. 
The lysate was transferred to a QIAGEN Plasmid Plus spin column and drawn through via 
vacuum suction at ~300 mbar. 700µL endotoxin removal buffer (buffer ETR) was applied to 
the column and centrifuged at 10,000xg for 1 minute at RT. 700µL wash buffer (buffer PE) 
(10mM Tris-HCl pH 7.5, 80% ETOH) was subsequently applied to the column and centrifuged 
at 10,000xg for 1 minute at RT. Any residual wash buffer was removed by centrifugation at 
10,000xg for 1 minute. To elute the DNA, 200µL elution buffer (buffer EB) (10mM Tris-Cl, pH 
8.5) was applied to the columns, incubated at RT for 2 minutes, and centrifuged at 10,000xg 
for 1 minute. DNA was quantified using a NanoDropTM 1000 Spectrophotometer 
(ThermoFisher Scientific) and sequence identity was confirmed via Sanger sequencing (Core 




2.2.2.11. Restriction digests for plasmid characterisation 
The following components were added to a clean Eppendorf tube in the order shown: 1µg 
digested DNA; 10 units of each restriction enzyme (see Table 2.6); 1µL 10x FastDigest Green 
Buffer. Volumes were adjusted to create a 10µL reaction by adding an appropriate volume of 
Milli-Q H2O. The reaction mix was incubated at 37°C for 1 hour, after which the DNA fragments 
were separated via agarose gel electrophoresis (see section 2.2.2.2). 
 
2.2.2.12. Quantitative Real-Time PCR (qRT-PCR) 
 
Cells were cultured until at least 70% confluent, lysed on ice using an appropriate volume of 
Tri Reagent (Sigma) for 5 minutes and transferred to 1.5mL RNAse-free tubes. Total RNA was 
extracted using a Direct-zol RNA Miniprep Kit (Zymo) according to manufacturer’s instructions. 
During RNA purification, samples were treated with DNase (6 U/μL) to degrade genomic DNA 
prior to reverse transcription. RNA concentration was confirmed using a NanoDropTM 1000 
Spectrophotometer (ThermoFisher Scientific). 2μg of total RNA was then converted to cDNA 
by adding 1μL dNTPs (2mM each), 1μL 40μM random hexamer primer (ThermoFisher 
Scientific), and DNAse/RNAse-free water to a total volume of 14μL. This mixture was heated 
for 5 minutes at 70°C then incubated on ice for 5 minutes. 4μL of 5x FS buffer, 2μL 0.1M DTT, 
and 1μL M-MLV reverse transcriptase (ThermoFisher Scientific) were then added and the 
cDNA conversion was performed in a PCR thermocycler (37°C for 50 minutes, 70°C for 10 
minutes). cDNA was amplified using RT-PCR with Brilliant III SYBR Green (Agilent) as per the 
manufacturer’s instructions. CT analysis was performed using CFX Maestro software 
(BioRad).  
 
2.2.3. Biochemical methods  
 
2.2.3.1. Sodium dodecyl sulphate-polyacrylamide gel preparation  
Spacer plates were assembled onto Mini-PROTEAN® Tetra Cell Casting Modules (BioRad). 
Resolving gels containing 12% polyacrylamide were prepared (w/v) (see Table 2.12) and 
transferred into the 1mm space separating the two spacer plates. Resolving gels were sealed 
with a layer of isopropanol for 15 minutes, which was subsequently removed before pouring a 
5% stacking gel (see table 2.12) onto the surface. Mini-PROTEAN® Combs were inserted 
into the surface of the stacking gels and left to set for 15 minutes at RT.  
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Table 2.12. Composition of 12% resolving and 5% stacking polyacrylamide gels. 
Reagent  5% stacking 12% resolving 
dH2O 5.8mL 3.5mL 
30% (w/v) Acrylamide 1.7mL 4.0mL 
Resolving buffer (1.5M Trizma®, 
13.9mM sodium dodecyl 
sulphate (SDS), pH 8.8, filtered) 
- 2.5mL 
Stacking buffer (0.5 M Trizma®, 
13.9mM SDS, pH6.8, filtered) 
2.5mL - 
10% (w/v) APS 50uL 50uL 
TEMED 20uL 20uL 
 
 
2.2.3.2. Cell lysis for immunoblotting 
2.2.3.2.1. IP lysis buffer 
 
HEK293 and N2A cell lysis was performed on ice to minimise protein degradation. DMEM was 
removed from cultured cells, and cells were washed with ice-cold PBS. PBS was aspirated 
and replaced with ice-cold IP lysis buffer (150mM NaCl, 50mM HEPES, 1mM EDTA, 1mM 
DTT, 0.5% (v/v) Triton™ X-100, pH 8.0) containing an EDTA-free protease inhibitor cocktail 
(PIC) (SIGMAFASTTM Sigma-Aldrich) at 1% of the total volume (20µL/mL). 50µL IP lysis buffer 
was added per well of a 24-well plate, 200µL per well of a 6-well plate, and 500µL per 10cm 
plate. Cells were scraped into the IP lysis buffer and incubated on ice for 15 minutes. The 
lysate was transferred to pre-cooled micro-centrifuge tubes and centrifuged at 17,000xg for 5 
minutes at 4°C. The supernatant was transferred to fresh pre-cooled Eppendorf tubes and the 
cell debris pellet was discarded.  
 
2.2.3.2.2. Bradford protein assay  
A Bradford assay was used to quantify total protein levels within cells lysed in IP lysis buffer. 
1µL cell lysate was mixed with 1mL Bradford reagent (Bio-Rad) (pre-diluted 1:5 in dH2O) and 
incubated at RT for 2 minutes. The sample was transferred to an optically clear polystyrene 
cuvette and the absorbance was read at 595nm, relative to a blank control, using a WPA 
S1200 Diode Array Spectrophotometer (Biochrom Ltd.). Protein concentrations were 
calculated using the Beer-Lambert law (OD595nm = ε×l×c; where ε = 1/15, and l = 1cm) and 
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normalised to the least concentrated sample by adding the necessary volumes of complete IP 
lysis buffer. 
 
2.2.3.2.3. Urea lysis buffer 
 
Lymphoblastoid cell lysis was performed using urea lysis buffer [8M urea; 1% (w/v) DTT; 20% 
(w/v) SDS; 1.5M Tris pH 6.8; + dH2O) (+ PIC [20µL/mL] + 1mM phenylmethylsulfonyl fluoride 
(PMSF) at RT to avoid precipitation of the urea out of solution. Media was removed from 
pelleted lymphoblastoid cells and the pellet was re-suspended in an appropriate volume of 
urea lysis buffer. Samples were syringed 10x using 25-guage needles and incubated at RT 
for 15 minutes. Samples were further lysed by sonication (Soniprep 150, MSE) for 10 seconds 
at 50% amplitude followed by a 30-second incubation at RT; this process was repeated 3 
times. Lysates were then centrifuged at 13,000xg for 5 minutes at RT, the supernatant was 
transferred to a fresh Eppendorf tube, and the pellet of debris was discarded.   
 
 
2.2.3.2.4. Bicinchoninic acid (BCA) assay  
BCA assays were used to quantify total protein levels within lymphoblastoid cell lysates. BCA 
assays were performed using a Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific), 
according to the manufacturers’ instructions. In short, a standard curve was created by diluting 
albumin standards in PBS at RT. A working reagent (WR) was then prepared by mixing BCA 
Reagent A with BCA Reagent B (50:1, Reagent A:B). Protein lysates were mixed thoroughly 
then diluted in PBS (1:10). 25µL of each standard or unknown sample was added per well of 
an optically clear 96-well plate, in triplicate. 200µL of the WR was added to each well and the 
plate was mixed thoroughly on a plate shaker for 30 seconds at RT. The plate was then 
incubated in the dark at 37°C for 30 minutes. The plate was cooled to RT and the absorbance 
was measured at 562nm on a PHERAstar® FS spectrophotometer (BMG Labtech). 
Absorbance data from the unknown samples were plotted against a standard curve and the 
concentrations were calculated.  
 
2.2.3.3. SDS-polyacrylamide gel electrophoresis    
Cell lysates were mixed with 4x Laemmli buffer (277.8mM Tris-HCl; 44.4% (v/v) glycerol; 4.4% 
SDS; 0.02% bromophenol blue; 355mM 2-mercaptoethanol; pH 6.8) and heated at 95°C for 5 
minutes to denature the proteins. 12% SDS polyacrylamide gels were assembled into a Mini-
PROTEAN® Tetra Vertical Electrophoresis Cell (Bio-Rad) and submerged in running buffer 
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(25mM Tris, 3.5mM SDS, 20mM glycine). 25µg of each denatured protein sample was loaded 
per well, alongside 2µL of a pre-stained protein ladder (ab116028, Abcam) to serve as a 
molecular weight marker. Gel electrophoresis was performed at 120V for approximately 1 
hour, or until the dye front had reached the bottom of the gel. For immunoblotting of 
nitrocellulose membranes, gels were moved to a semi-dry transfer apparatus and assembled 
with nitrocellulose membranes (Bio-Rad) and transfer buffer (47.9mM Tris, 38.6mM glycine, 
1.38mM SDS, 20% (v/v) methanol)-saturated Whatman® filter paper (Sigma-Aldrich). Protein 
within the gel was electrophoretically transferred to the nitrocellulose membranes at 0.15A per 
gel for 1 hour.   
 
2.2.3.4. Immunoblotting  
Nitrocellulose membranes were stained with Ponceau stain (0.1% (w/v) Ponceau S, 5% (v/v) 
acetic acid) for the rapid detection of protein bands. Membranes were blocked in 5% (w/v) milk 
(Marvel)/Tris Buffered Saline, with Tween® 20 (TBST) (20mM Tris, 137mM NaCl, 0.2% (v/v) 
Tween® 20, pH 7.6) overnight at 4°C. Membranes were then incubated with primary antibody 
(see Table 2.2) in 5% milk/TBST for 1 hour at RT. Membranes were washed 3x in TBST (10 
minutes per wash) at RT, then incubated with a secondary antibody (see Table 2.3) 
conjugated to horseradish peroxidase (HRP) in 5% milk/TBST for 1 hour at RT. The 
membranes were washed 3x in TBST (10 minutes per wash) at RT and incubated with a 
chemiluminescent substrate and oxidising agent (1:1) (PierceTM ECL, ThermoFisher Scientific) 
for 1 minute. The chemiluminescence signal was imaged using a G:BOX (Syngene).  
 
2.2.3.5. Coomassie blue staining 
12% polyacrylamide gels were prepared as previously described (see section 2.2.3.1). 
Following electrophoresis (see section 2.2.3.3), gels were submerged in 100mL Coomassie® 
Blue R-250 (ThermoFisher Scientific) staining solution (0.1% (v/v) Coomassie® R-250, 40% 
(v/v) ETOH, 10% (v/v) acetic acid) for 1 hour at RT on an orbital shaker. The staining solution 
was decanted and gels were rinsed 1x in dH2O. Gels were submerged in 100mL destain 
solution (10% (v/v) ETOH, 7.5% (v/v) acetic acid) overnight at RT and imaged the following 
day using a white light illuminator.   
 
2.2.3.6. Immunoprecipitation (IP) of FLAG-tagged GLT8D1 
HEK293 cells were seeded at a density of 1x106 cells per 10cm petri dish and cultured for 24 
hours. Cells were subsequently transfected with pcDNA/FRT/TO_3xFLAG-GLT8D1 wild-type 
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and mutant vectors as previously described (see section 2.2.1.16). For the 
immunoprecipitation of GLT8D1 from stable HEK293 lines, cells were cultured in Blasticidin 
S-free supplemented DMEM for 24 hours prior to induction with 10mg/mL tetracycline for 48 
hours (refer to section 2.2.1.12). 25x 10cm dishes were assembled for each condition to 
maximise protein yield. Prior to cell lysis, 300µL anti-FLAG® M2 magnetic beads 
(ThermoFisher) were blocked in BSA (1% in PBS) in 1.5mL Eppendorf tubes at 4°C on a 
rotating mixer. 48 hours post-transfection, media was removed, cells were washed in ice-cold 
PBS, and lysed in 500µL ice-cold IP lysis buffer (+ PIC [20µL/mL] + 1mM PMSF) for 3 minutes. 
Cells were removed using a cell scraper, transferred to pre-cooled Eppendorf tubes, and 
syringed 10x using 25-guage needles. Lysates were centrifuged at 13,300xg for 5 minutes at 
4°C. 50µL of the supernatant was retained as a reference for protein input. Total protein 
concentration within cell lysates was determined using a Bradford assay (see section 
2.2.3.2.2). 1% BSA was separated from the anti-FLAG® M2 magnetic beads using a 
DynaMag™-2 Magnet (ThermoFisher) and replaced with the protein lysate. Samples were 
then incubated for 2-3 hours on a rotating mixer at 4°C. Protein lysate was separated from the 
magnetic beads using a DynaMag™-2 Magnet, and the supernatant was retained as a 
reference for flow-through. The magnetic beads were washed 3x in 1M NaCl (diluted in an 
appropriate volume of IP lysis buffer) followed by 2x washes in IP lysis buffer. Anti-FLAG® M2 
magnetic beads were incubated with a FLAG® peptide (100µg/mL in lysis buffer) (Millipore) 
overnight at 4°C on a rotating mixer to purify FLAG-tagged products via competitive elution. 
Anti-FLAG® M2 magnetic beads were removed and the purified protein was fractionated on 
12% polyacrylamide gels (see section 2.2.3.3) alongside the input and flow-through for either 
Coomassie blue staining (see section 2.2.3.5) or immunoblotting (see section 2.2.3.4). Purified 
protein was stored at -80°C.   
 
2.2.3.7. Glycosyltransferase activity assay   
Glycosyltransferase assays were performed in opaque, white 96-well plates using a UDP-
Glo™ Glycosyltransferase Assay kit (Promega) according to the manufacturers’ guidelines. In 
brief, a required volume of Nucleotide Detection Reagent was equilibrated to RT. 300µL UDP-
Glo™ working solution was prepared by mixing 4µL UDP-Glo™ Enzyme with 296µL Enzyme 
Dilution Buffer. 10µL of UDP-Glo™ working solution was added per 1mL Nucleotide Detection 
Reagent and mixed to homogeneity immediately before use. A standard curve of 0-25µM UDP 
was generated to estimate the amount of UDP produced in the glycosyltransferase reaction. 
To create the standard curve, 25µM UDP solution was prepared in 1x glycosyltransferase 
reaction buffer (50mM Tris pH 7.5, 5mM MnCl2) and serially diluted (1:2) with 25µL per well of 
a 96-well plate. A no-UDP served as a negative control. 25µL glycosyltransferase reactions 
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were assembled on ice accordingly: 
- 1.5µL 0.1M MnCl2  
- 1.25µL 1M Tris  
- 12.5µL UDP sugar substrate (serially diluted: 40mM-0.15625mM) 
- Purified enzyme (serially diluted: 28mg/mL-0.109375mg/mL) in lysis buffer (see 
section 2.2.3.6)  
- 8µL dH2O.  
To determine the kinetic parameters of the glycosyltransferase enzyme, multiple reactions 
with varying concentrations of either enzyme or substrate were carried out simultaneously in 
the presence of fixed volumes of all other components. Glycosyltransferase reactions were 
run at 37°C for 60 minutes and terminated through the addition 25µL nucleotide detection 
reagent to each well of the assay plate. Plates were mixed on a plate shaker for 30 seconds 
and incubated for 60 minutes in the dark at RT. Luminescence was recorded using a 
PHERAstar FS System (BMG Labtech). Statistical analysis was performed using GraphPad 
Prism (see section 2.2.6).       
 
2.2.3.8. Immunocytochemistry  
For Nikon Eclipse Ni-U fluorescence microscopy and SP5 confocal microscopy, cells were 
seeded at a density of 3x104 cells per well of a 24-well plate onto glass coverslips and cultured 
for 3 days prior to immunocytochemistry. For imaging using an Opera PhenixTM High Content 
Screening System (PerkinElmer), cells were seeded into black Greiner 96-well plates 
(ThermoFisher Scientific). The volumes of solutions used in this section were relative to the 
size of the well. Media was removed from cells in culture, and cells were washed 2x with PBS. 
Cells were fixed in 4% paraformaldehyde (PFA) at RT for 20 minutes, and then washed 
another 2x with PBS. Cells were blocked using 5% normal goat serum (NGS) (v/v) in PBS, 
and were incubated at RT for 45 minutes. Blocking buffer was removed and cells were 
incubated in 0.01% Triton™ X-100 (+ PBS) for 30 minutes at RT. Triton™ X-100 was removed 
and cells were incubated in primary antibody (see Table 2.2), diluted in 5% NGS (v/v), at RT 
for 1 hour or overnight at 4°C. Cells were washed 3x in PBS (5 minutes per wash), then 
incubated in an appropriate fluorescent secondary antibody (see Table 2.3), diluted in 5% 
NGS (v/v), in a dark environment at RT for 1 hour. The secondary antibody was removed and 
cells were incubated with a nuclear counterstain (Hoechst 33342) (1μg/mL in PBS) in the dark 
for 5 minutes at RT and washed 3x with PBS (5 minutes per wash). Cell-containing glass 
coverslips were mounted onto microscope slides using fluorescence mounting medium 
(DAKO) and stored in a dark environment at 4°C overnight to dry.   
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2.2.3.9. Multiphoton and confocal microscopy imaging and image analysis 
Cells were imaged using either a Nikon Eclipse Ni-U microscope and Nikon DS-Ri1 camera 
with Nikon NIS- Elements Viewer software, or an SP5 confocal microscope system (Leica) 
with an X63/1.4 oil immersion objective lens. For confocal imaging, a z-stack was made up of 
images at 0.13μm intervals through the entire nuclear volume of the cell under consideration.  
Pixel intensity spatial correlation analysis was performed using ImageJ (NIH). The JACoP 
plugin was used for co-localisation analysis. Colour channels were split to create separate 
images, thresholds were automatically determined, and the M1/M2 and Pearson’s coefficients 
were calculated (Manders et al., 1993). 
 
2.2.3.10. Live-cell imaging using fluorescent molecular probes   
 
Greiner 96-well culture plates were coated in sterile 0.5% (w/v) gelatin (100µL/well) overnight 
at 4°C prior to cell seeding. Cells were seeded at densities of 1x104 cells per well and cultured 
for 2 days prior to imaging. For live-cell imaging, fluorescent probe solutions of 1mg/mL 
(Molecular Probes®) were prepared by dissolving 5mg of lyophilized conjugate in 5mL of 
sterile PBS (Table 2.3). 1mg/mL conjugate stock solutions were diluted in Hanks Balanced 
Salt Solution (HBSS) to create a working concentration of 5µg/mL of labelling solution. Media 
was removed and 100µL of labelling solution was added to cell-containing wells and incubated 
for 45 minutes at 37°C, 5% CO2. The labelling solution was removed, and cells were incubated 
with a nuclear counterstain (Hoechst 33342) (1μg/mL in HBSS) for 5 minutes at 37°C, 5% 
CO2. Nuclear counterstain was removed and cells were washed 2x in PBS, then incubated in 
200µL pre-warmed HBSS for confocal imaging. Live imaging was performed via confocal 
microscopy using an Opera PhenixTM High-Content Screening System (PerkinElmer) at 37°C, 
5% CO2. Cells were visualised within a high-resolution z-stack consisting of images at 0.5µm 
intervals through the entire nuclear volume of the cell. Images were analysed using Harmony 
High-Content Imaging and Analysis Software (PerkinElmer).   
 
2.2.3.11. MTT cell viability assay  
HEK293 and N2A cells were seeded at a density of 3x104 cells per well of a 24-well culture 
plate. Cell viability was assessed 2 and 3 days post transfection in N2A and HEK293 cells, 
respectively (see section 2.2.1.16). 55µL of 5mg/mL MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide] reagent was added per well of the 24-well culture plate and 
incubated at 37°C, 5% CO2 for 1 hour. 550µL of un-precipitated SDS/DMF lysis buffer (20% 
(v/v) SDS [Melford]; 50% (v/v) di-methyl formamide (DMF); pH 4.7) was added per well and 
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mixed thoroughly to lyse the cells. Cells were incubated in a dark environment on an orbital 
shaker at RT for 1 hour. The colorimetric change was measured using a PHERAstar FS 
spectrophotometer (BMG Biotech), and absorbance readings taken at 590nm were 
normalised to media-only wells. Statistical analysis was performed using GraphPad Prism 
(GraphPad Software, Inc.) (see section 2.2.6).   
 
2.2.3.12. Lactate dehydrogenase assay   
A PierceTM Lactate Dehydrogenase (LDH) Cytotoxicity Assay Kit (ThermoFisher Scientific) 
was used according to the manufacturers’ instructions. Initially, HEK293 and N2A cells were 
seeded into white 96-well culture plates at a density of 2000 cells per well. Cytotoxicity was 
measured 2 and 3 days post transfection (see section 2.2.1.16) in N2A and HEK293 cells, 
respectively. Sterile, ultra-pure H2O was added to one set of triplicate cell-containing wells 
(10% v/v) as a measure of spontaneous LDH activity. 10x lysis buffer was added to another 
set of triplicate cell-containing wells (10% v/v) to determine the maximum LDH activity. Cells 
were incubated at 37°C in 5% CO2 for 45 minutes. 50µL of each sample medium was 
transferred to an optically clear 96-well plate in triplicate wells. 50µL of reaction mixture 
(lyophilizate, 11.4mL ultra-pure H2O, 0.6mL assay buffer) was added to each sample well and 
plates were incubated in a dark environment for 30 minutes at RT. 50µL of stop solution was 
added to each sample well and the absorbance was measured at 490nm and 680nm on a 
PHERAstar FS spectrophotometer (BMG Biotech). The 680nm absorbance value was 
subtracted from the 490nm absorbance value to determine LDH activity. Statistical analysis 





2.2.4. Modelling in zebrafish (Danio rerio)  
 
All zebrafish work was performed in collaboration with Dr Tennore Ramesh. Dr Ramesh is a 
registered project licence holder (70/8058) under the Animals (Scientific Procedures) Act, 
1986. I hold a Home Office approved personal licence (I5BBF6E32) to carry out regulated 
procedures on zebrafish, as specified on the project licence. However, all experimentation 
was performed using zebrafish larvae <5.2 days post-fertilisation, at a time when zebrafish 
are not protected by European law (EU Directive 2010/63/EU).   
2.2.4.1. RNA Synthesis for zebrafish embryo microinjection  
 
Capped RNA was synthesised using a mMESSAGE mMACHINE® SP6 Transcription Kit 
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(ThermoFisher Scientific), according to the manufacturers’ instructions, using DNA templates 
harbouring an SP6 promotor site downstream of the target sequence. Circular DNA fragments 
within PCS2+ vectors (Table 2.6) were linearized via a restriction digest (see section 2.2.2.11). 
20µL of transcription reactions were assembled at RT accordingly: 10µL 2X NTP/CAP (10mM 
ATP; 10mM CTP; 10mM UTP; 2mM GTP; 8mM cap analog); 2µL 10X reaction buffer; 0.5µg 
linearized template DNA; 2µL enzyme mix (buffered 50% glycerol containing RNA 
polymerase, RNase Inhibitor, and other components). Nuclease-free water was added to 
create total reaction volume of 20µL. The reaction mixture was mixed thoroughly and 
incubated at 37°C for 2 hours to account for slower SP6 reactions and achieve maximum 
possible yield of RNA. RNA was recovered via Lithium Chloride (LiCl) precipitation by adding 
30µL nuclease-free water and 30µL LiCl precipitation solution. Samples were mixed 
thoroughly, incubated at -20°C for 30 minutes and then centrifuged at 16,000xg for 15 minutes 
at 4°C. The supernatant was removed and the RNA pellet was washed with 1mL of 70% 
ETOH. Samples were re-centrifuged to maximise the removal of unincorporated nucleotides. 
The 70% ETOH was removed and the RNA pellet was air dried at RT for 10 minutes. RNA 
was diluted in 20µL of injection buffer (0.5% Fast Green, 200mM Tris–Cl pH 7.0, 20mM 
EDTA). RNA concentration was estimated using a NanoDropTM 1000 Spectrophotometer 
(ThermoFisher Scientific® Inc.), and diluted in RNAse-free water to achieve a final 
concentration of 200ng/µL. RNA stocks were stored in RNase-free Eppendorf tubes (3µL per 
tube to avoid repeated freeze-thaw cycles) at -80°C to prevent degradation. The quality of the 
transcription was assessed using a NanoDropTM 1000 spectrophotometer and agarose gel 
electrophoresis (see section 2.2.2.2). 
 
2.2.4.2. Generation of a morpholino for zebrafish embryo microinjection 
 
Splice-blocking morpholino antisense oligonucleotides were designed and provided by Gene 
Tools, LLC, for the targeted knockdown of endogenous glt8d1 in zebrafish embryos. The 
glt8d1 start codon lies within exon 2, therefore skipping this exon was considered likely to alter 
expression of the gene. The morpholino sequence complementary to the splice junction target 
from 5’ - 3’ is shown below; brackets have been inserted either side of the pre-mRNA (sense 
strand) target to illustrate its position in the sequence: 
 
5’-ACATCAGAGTCTGCATACCTGAAGT[ACGCAGAGgtaactatattttacac]gactttca-3’ 
Morpholino powder was reconstituted in sterile Milli-Q water and 1% phenol red to create a 




2.2.4.3. Zebrafish maintenance and breeding  
Zebrafish of the AB strain were raised in recirculating systems (Tecniplast) at a density of 1 
zebrafish per 0.25 litres of water. Water was maintained at pH 7.4, a temperature of 28°C, and 
electrolytic conductivity of 500µS/cm. Zebrafish were exposed to 14-hour light and 10-hour 
dark cycles. The night before breeding, adult male and female zebrafish were transferred to 
breeding tanks, separated by a clear plastic divider. At the start of the light cycle the following 
day, the dividers were removed and eggs were collected. Zebrafish embryos were transferred 
to petri dishes containing fresh E3 media (34.8g NaCl; 1.6g KCl; 5.8g CaCl2·2H2O; 9.78g 
MgCl2·6H2O) and incubated at 28°C.  
 
2.2.4.4. Zebrafish embryo microinjection 
Glass capillaries with an outside diameter of 1.0mm were pulled to form microinjection needles 
with an inner tip diameter of 10µm. Needles were back-loaded with 3µL of injection material 
using a micro loader pipette and inserted into the micro injector attached to a PV 820 
Pneumatic PicoPump (World Precision Instruments). Needle tips were broken using forceps 
to allow ejection of the splice-blocking morpholino or RNA, leaving the needle narrow enough 
to pierce the chorion but deliver a consistent bead size. In order to calibrate the volume of 
each injection, a drop of oil was added to a graticule and the morpholino or RNA was injected 
into it, where 0.125mm contained approximately 1nL of injection material; the injection time 
was adjusted as required to obtain a 0.5nL, 1.0nL or 2.0nL volume of liquid. Embryos were 
lined up alongside a microscope slide, E3 media was removed, and oocytes were injected into 
the yolk at the one-cell stage with either 0.5nL, 1.0nL or 2.0nL of injection material. Embryos 
were transferred to petri dishes containing E3 media. Any unfertilised embryos, or embryos 
damaged during the injection process, were discarded into bleach. To increase the reliability 
of the data, zebrafish embryos from 3 separate clutch mates underwent the same injection 
process for each biological repeat where possible.   
 
2.2.4.5. Behavioural analysis   
The Zebralab screening tool (ViewPoint) was used to record the activity of individual larva in 
an optically clear 96-well plate at 5 days post-fertilisation (dpf). Zebrafish embryos were 
washed in fresh E3 media (approximately 50 embryos per group) and transferred to a 96-well 
plate, one fish per well in 200µL E3 medium. 100µL of E3 media was removed from one 
column and replaced with 100µL of Tricaine (MS222) (400mg Tricaine powder; 97.9mL dH2O; 
2.1mL 1M Tris; pH 7) (Sigma-Aldrich) (164 mg/L) to create a non-motile control group. Fish 
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were left to acclimatise to the 96-well plate for 30 minutes. Zebrafish were then placed inside 
the Zebrabox observation chamber and were habituated at 10% light intensity for 30 minutes 
prior to behavioural testing. Zebrafish were exposed to a 10-minute light (10% intensity) cycle 
followed by a 10-minute dark (0% intensity) cycle. These cycles were then repeated to equal 
40 minutes of tracking. Motor function was analysed according to the mean distance travelled 
and the average velocity of the zebrafish embryos. Statistical analysis was performed using 
GraphPad Prism (see section 2.2.6). 
 
2.2.4.6. Zebrafish RT-PCR 
 
Twenty zebrafish embryos (2dpf) were transferred to Eppendorf tubes containing 1mL E3 
media, for each condition. Tricaine (164 mg/L) was added and the zebrafish were incubated 
at RT for 5 minutes. E3 media was removed and 500µL TRIzol reagent was added per tube. 
Samples were incubated at RT for 5 minutes. 100µL chloroform was added and the samples 
were mixed by inversion for 15 seconds. Samples were incubated for 10 minutes at RT, then 
centrifuged at 12,000xg for 15 minutes at 4°C. The top aqueous phase was transferred to a 
fresh Eppendorf tube and mixed with 250µL isopropanol to precipitate the RNA. Samples were 
incubated for 15 minutes at RT, then centrifuged at 12,000xg for 10 minutes at 4°C. The 
isopropanol was removed and the pellet was left to air dry for 10 minutes, then resuspended 
in 50µL RNAse-free H2O. RNA quality was assessed using a NanoDropTM 1000 
spectrophotometer (ThermoFisher Scientific). 2μg of total RNA was converted to cDNA as 
previously described (see section 2.2.2.12). PCR reactions were assembled accordingly:   
 
- 4µL of 5x FIREPol® (Solis Biodyne)  
- 1µM forward primer (see table 2.7) 
- 1µM reverse primer (see table 2.7) 
- 1µL template DNA  
- Nuclease-free H2O to create overall reaction volume of 20µL 
 








Table 2.13. PCR programme for zebrafish RT-PCR. 
Step Temperature (°C) Time  Cycles 
Initial denaturation 94 3 minutes - 
Denaturation 94 30 seconds 
35x Primer annealing 60 45 seconds 
Elongation 72 2 minutes 
Final elongation 72 7 minutes - 
Hold 10 Infinite - 
 
PCR products were evaluated via agarose gel electrophoresis (see section 2.2.2.2).  
 
 
2.2.4.7. Zebrafish immunoblotting 
Dechorionated zebrafish embryos (2dpf) were transferred to Eppendorf tubes (20 embryos 
per tube) containing 1mL E3 media. Tricaine (164 mg/L) was added and the zebrafish were 
incubated at RT for 5 minutes. E3 media was removed and replaced with 3µL/embryo 2x 
Laemmli buffer (65.8mM Tris HCl; 26.3% (w/v) glycerol; 2.1% SDS; 0.01% bromophenol blue; 
355mM 2-mercaptoethanol; pH 6.8). Zebrafish embryos were lysed by sonication (Soniprep 
150, MSE) for 10 seconds at 25% amplitude followed by a 30-second incubation on ice; this 
process was repeated 3 times for each group. Embryos were subsequently boiled at 95°C for 
10 minutes, then centrifuged at 10,000xg for 3 minutes at RT. 10µL of lysate was added per 
lane and fractionated on a 12% SDS-PAGE gel as previously described (see section 2.2.3.3).  
 
2.2.6. Statistical analysis 
Statistical analysis was conducted in GraphPad Prism 7 (La Jolla, CA). All bar graphs show 
the mean ± SD. Data comparing two variables was transformed to identify outliers and 
analysed to identify statistical differences between the treatment groups. The statistical test 
used for datasets with greater than two conditions was a non-parametric analysis of variance 
(ANOVA). Non-parametric tests were chosen when data was not normally distributed, and to 
account for smaller sample sizes. Paired t tests were used for all in vitro datasets comparing 
two conditions. Zebrafish data were analysed using either a Mann-Whitney test or, in the case 




Chapter 3. ALS-linked G78W and R92C variants in GLT8D1 are 




This chapter is an extended version of work published during my PhD (Cooper-Knock et al., 
2019). I was responsible for conducting all experimental work presented within this chapter, 
and any collaborations are clearly stated. My focus was to generate cell models to characterise 
pathological mechanisms associated with ALS-linked GLT8D1-G78W and GLT8D1-R92C 
variants. The R92C mutation was chosen, as this was the most common and clinically 
aggressive mutation identified in ALS patients, affecting 10 individuals with a mean survival of 
21 months. The GLT8D1-G78W mutation was also identified in our local patient population; 
GLT8D1-G78W was associated with a disease duration of 58 months, offering a slow disease 
progression compared to the aggressive GLT8D1-R92C (Cooper-Knock et al., 2019).  
 
GLT8D1 is structurally and functionally uncharacterised; therefore, I began by identifying 
structural homologues to aid future crystallisation strategies for determining possible targets 
of interaction. In this chapter, I also describe the generation of GLT8D1 plasmid constructs 
with either a 3xFLAG- or eGFP-tag. The use of epitope tags was necessary given a lack of 
validated GLT8D1 antibodies, and generating an antibody of my own was not feasible due to 
time constraints. All overexpression experiments included an un-tagged control plasmid 
containing the same backbone, which was important, as GFP-tags have previously been 
shown to induce apoptosis in vitro (Liu et al., 1999, Coumans et al., 2014). eGFP-tags were 
useful for evaluating transfection efficiency under ultraviolet (UV) light. 3xFLAG-tags enabled 
the immunoprecipitation of recombinant GLT8D1 protein for the assessment of 
glycosyltransferase activity, using methods previously developed by our lab. In order to 
confirm the validity of the signal following the immunoprecipitation of GLT8D1, miRNA 
constructs targeting overexpressed and endogenous GLT8D1 were generated.  
 
GLT8D1-3xFLAG constructs were also used to engineer stable isogenic Flp-InTM T-RExTM 
HEK293_GLT8D1WT/R92C-3xFLAG cell models. Hereafter, these cell models will be referred to 
as isogenic HEK293-WT and isogenic HEK293-R92C. These cell lines utilise the Flp-In™ 
system which allows genomic site specific insertion of WT and mutant GLT8D1 into HEK293 
cells; and the T-REx™ system, which allows for tetracycline-inducible expression of WT and 
mutant GLT8D1. The isogenic nature of HEK293-WT and HEK293-R92C cells was desirable 
to reduce variability not linked to the GLT8D1 mutation.         
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Given the difference in disease severity between patients with GLT8D1-G78W and GLT8D1-
R92C mutations, I tested the relative toxicity of these two mutations in vitro via a combination 
of MTT and lactate dehydrogenase (LDH) assays. The MTT assay is a widely used measure 
of cell proliferation (Mosmann, 1983, van Tonder et al., 2015) and provides a useful indication 
of mitochondrial dysfunction. LDH assays (Chan et al., 2013) were subsequently performed 
to determine whether observed differences in the MTT signal were a result of growth inhibition 
or cytotoxicity.  
 
 
3.2. Aims and objectives for characterising ALS-linked G78W and R92C 
mutations in GLT8D1  
 
1. Generate pEGFP-N1-eGFP and pcDNA5/FRT/TO_3xFLAG plasmid constructs 
expressing GLT8D1-WT, GLT8D1-G78W and GLT8D1-R92C. 
2. Integrate pcDNA5/FRT/TO_3xFLAG-GLT8D1-WT and pcDNA5/FRT/TO_3xFLAG-
GLT8D1-R92C plasmids into the commercially available Flp-InTM HEK293 T-RExTM cell 
line and characterise cells for tetracycline-inducible expression of GLT8D1-WT and 
GLT8D1-R92C.  
3. Generate microRNA plasmids for the targeted knockdown of endogenous and 
overexpressed GLT8D1 in HEK293 cells.  
4. Identify structural homologues of GLT8D1 to aid future crystallisation strategies.  
5. Assess the relative toxicity of GLT8D1-G78W and GLT8D1-R92C mutations in 
neuronal and non-neuronal cell lines via a combination of MTT and LDH assays. 
6. Investigate the effect of GLT8D1-G78W and GLT8D1-R92C mutations on the 





3.3. Results  
 
3.3.1. Generation and characterisation of pEGFP-N1_GLT8D1-eGFP and 
pcDNA5/FRT/TO_3xFLAG-GLT8D1 expression vectors 
 
Plasmids utilised in this section were generated in collaboration with Dr Guillaume 
Hautbergue. For GFP-tagged fusions to the C-terminus of GLT8D1, pEGFP-N1 expression 
vectors (Figure 3.1a) were digested using NheI and XhoI restriction enzymes and purified via 
agarose gel electrophoresis and gel extraction. The GLT8D1 open reading frame (I.M.A.G.E. 
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40116197) was amplified using oligonucleotides GLT8D1-1-Kozak-NheI5 and GLT8D1-371-
XhoI3 (see Table 2.7), and subsequently cloned as a PCR fragment into the NheI/XhoI 
restriction sites of pEGFP-N1 to create pEGFP-N1_GLT8D1-eGFP. The Kozak sequence in 
the forward primer was necessary due to the absence of an ATG codon for the initiation of 
translation (Kozak, 1990). GLT8D1-G78W and GLT8D1-R92C mutations were introduced via 
site-directed mutagenesis; PCR reactions were assembled using the following 
oligonucleotides: GLT8D1-G78W_QC_fwd and GLT8D1-G78W_QC_rev; or GLT8D1-
R92C_QC_fwd and GLT8D1-R92C_QC_rev (Table 2.7). pEGFP-N1_GLT8D1-eGFP 
plasmids were validated via restriction digest (Figure 3.1b) and Sanger sequencing (see 
appendix 6).   
 
For FLAG-tagged fusions, the GLT8D1 open reading frame (I.M.A.G.E. 40116197) was 
amplified using oligonucleotides GLT8D1-1-BclI5 and GLT8D1-371stp-XhoI3 (Table 2.7) and 
cloned as a BclI/XhoI PCR fragment into the BamHI/XhoI restriction sites of the 
pcDNA5/FRT/TO_3xFLAG vector to generate pcDNA5/FRT/TO_3xFLAG-GLT8D1 (see 
appendix 7). GLT8D1-G78W and GLT8D1-R92C mutations were introduced via site-directed 
mutagenesis; PCR reactions were assembled using the following oligonucleotides: GLT8D1-
G78W_QC_fwd and GLT8D1-G78W_QC_rev; or GLT8D1-R92C_QC_fwd and GLT8D1-
R92C_QC_rev (Table 2.7). pcDNA5/FRT/TO_3xFLAG-GLT8D1 plasmids were validated via 
restriction digest (Figure 3.1b) and Sanger sequencing (see appendix 8). 
 
3.3.2. Flp-InTM T-RExTM GLT8D1 isogenic HEK293 cell line generation 
 
Isogenic HEK293 cells stably expressing GLT8D1 were engineered for the production of 
recombinant enzyme for subsequent analysis of glycosyltransferase function. Therefore, it 
was important to generate a robust and highly proliferative cell model to achieve maximal 
biomass; hence, a neuronal line with stable expression of GLT8D1 was not deemed necessary 
at this stage of the project.  
 
Isogenic HEK293-WT and HEK293-R92C cell lines utilised in this project were generated in 
collaboration with Dr Adrian Higginbottom. pcDNA5/FRT/TO_3xFLAG-GLT8D1 and 
pcDNA5/FRT/TO_3xFLAG-GLT8D1-R92C (see section 3.3.1) were stably transfected into the 
Flp-InTM T-RExTM  (RRID: CVCL_U427) HEK293 cell line. pPGKFLPobpA (which expresses a 
codon optimised FLP DNA-recombinase) was co-transfected with each of the GLT8D1 
plasmids separately. The FLP DNA recombinase catalysed recombination between the FRT 
site on the pcDNA5/FRT/TO_3xFLAG-GLT8D1 plasmids and the genomic FRT site in the Flp-
In™ T-REx™ HEK293 cells, stably inserting the tetracycline-inducible GLT8D1 constructs 
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(Figure 3.2). Cells were screened for Zeocin™ sensitivity and Blasticidin-S/Hygromycin-B 
resistance to ensure isogenic, then expanded and cryopreserved. Zeocin™ resistance would 
suggest random integration of the pcDNA5/FRT/TO_GLT8D1 plasmid into the host cell 
genome, and not at the genomic FRT site. Blasticidin-S/Hygromycin-B selection antibiotics 
were added to the media to select for cells with pcDNA5/FRT/TO_3xFLAG-GLT8D1 stably 
integrated into the genomic FRT site. Tetracycline-inducible expression of GLT8D1-3xFLAG 
was confirmed via immunoblotting (Figure 3.6).  
3.3.3. Generation of microRNA plasmids targeting human GLT8D1 
 
MicroRNA (miRNA) knockdown of over-expressed and endogenous GLT8D1 was used to 
validate the specificity of GLT8D1 immunoblot bands. This was necessary because validated 
GLT8D1 antibodies were not available. miRNA sequences against human GLT8D1 (NCBI 
Reference Sequence: NM_152932.2, transcript variant 1) were designed using the ‘miR RNAi’ 
Block-IT RNAi designer tool (ThermoFisher). The target sequences are as follows: 
 
 GLT8D1_miR1 target: ATTGTAGGGCCTCAACCTATA starts at 241nt  
 GLT8D1_miR2 target: GAGCAGGAAACCAGTACAATT starts at 749nt  
 GLT8D1_miR3 target: TTTGTAAAGGCTGCCAAGTTA starts at 1075nt.  
 
Synthesized oligonucleotides (see Table 2.7) were annealed and ligated into pcDNA6.2-
GW/EmGFP vectors. HEK293 cells were co-transfected with pcDNA5/FRT/TO_3xFLAG 
vectors expressing GLT8D1-WT with and without pcDNA6.2-GW/EmGFP vectors expressing 
miRNA sequences (miR1-3 – see above). Knockdown was confirmed at two days post 







Figure 3.1. Construction and validation of pEGFP-N1_GLT8D1 and 
pcDNA5/FRT/TO_3xFLAG_GLT8D1 plasmids. (A) pEGFP-N1 plasmid map showing 
integration of WT GLT8D1 into the multiple cloning site under the control of a CMV promotor. 
GLT8D1 was cloned as a NheI / XhoI PCR fragment into the NheI and XhoI sites of pEGFP-
N1. GLT8D1-G78W and GLT8D1-R92C mutations were subsequently introduced via site-
directed mutagenesis and confirmed via Sanger sequencing (see appendix 6). See appendix 
7 for pcDNA5/FRT/TO_3xFLAG_GLT8D1 plasmid maps, or refer to Figure 3.2 for a structural 
overview. (B) Restriction digest of pEGFP-N1 and pcDNA5/FRT/TO_3xFLAG plasmids to size 
the GLT8D1 inserts; pEGFP-N1_GLT8D1 plasmids were cut using NheI and XhoI restriction 
enzymes. pcDNA5/FRT/TO_3xFLAG plasmids were cut using BamHI and XhoI restriction 
enzymes. Agarose gel electrophoresis was performed to size the 1.1kb GLT8D1 inserts. The 
empty peGFP-N1 and pcDNA5/FRT vectors show no insert present. Molecular weight markers 
































Figure 3.2. Flp-In™ and T-REx™ systems used to generate isogenic HEK293 cell lines 
with tetracycline-inducible expression of WT and mutated GLT8D1. 
pcDNA5/FRT/TO_3xFLAG vectors expressing WT GLT8D1 and GLT8D1-R92C were 
separately co-transfected with a FLP recombinase into the Flp-In™ T-REx™ mammalian cell 
line in a ratio of 6:4 using polyethylenimine. FLP recombinase catalyses homologous 
recombination between the genomic FRT site and the FRT site within the pcDNA5/FRT/TO 
vector. Successful integration of the pcDN5/FRT/TO_3XxFLAG-GLT8D1 plasmid is 
demonstrated through the Hygromycin-B resistant and Zeocin™ sensitive nature of the host 
cell line. GLT8D1 expression is repressed by the Tet repressor element (tetR). Expression of 
GLT8D1 is initiated through the addition of tetracycline, which de-represses the CMV/TetO2 
promoter. (G8 – GLT8D1; FRT – flippase recognition target; AmpR – ampicillin resistant 
promotor; pA – polyadenylated tail). This figure was adapted from Invitrogen™.  
79 
 
3.3.4. Structural-based sequence alignment identifies 5GVV (S. pneumonia 
glycosyltransferase glyE) as a structural homologue of GLT8D1  
 
Structural characterisation of GLT8D1 was performed in collaboration with Dr Sam Dix. The 
majority of proteins must fold to their active native state when they are released from 
ribosomes in order to perform their biological function. Proteins repeatedly unfold and refold 
during their lifetime (Englander and Mayne, 2014). The crystal structure for GLT8D1 is 
currently undefined. A well-established method of assigning protein fold, and therefore 
possibly function, is to identify a closely related homologue with a known structure. Sequence 
comparison tools such as BLAST (Altschul et al., 1990) are capable of assigning folds for up 
to 30% of genes in microbial genomes (Wang et al., 2000, Ginalski et al., 2005). To identify a 
structural homologue, the translated protein sequence of GLT8D1 was inputted into PDB-
BLAST and aligned against all members of the Protein Data Bank (available at: 
https://www.rcsb.org/), which is comprised of all known protein structures to date. This 
identified 5GVV (S. pneumoniae glycosyltranferase glyE) as a potentially related homologue. 
Using Clustal Omega Multiple Sequence Alignment (available at: 
https://www.ebi.ac.uk/Tools/msa/clustalo/), the sequence identity between GLT8D1 and 
5GVV was calculated to be only ~27% across the entire protein, which coincides with the N-
terminal domain of 5GVV. The N-terminal domain contains core secondary structure features 
as well as the proposed GLT8D1 ligand-binding pocket (Bourne and Henrissat, 2001); 
therefore, the fold will likely be conserved (Figure 3.3). Of note, sequence similarity is not 
necessary for structural similarity. Therefore, seemingly unrelated proteins based on protein 
sequence alone are capable of adopting the same fold (Ginalski et al., 2005). Due to this 
predicted structural conservation, it is likely that GLT8D1 will adopt a similar fold to that of the 
N-terminal domain in 5GVV. The implication of the conserved fold for future experimentation 
is discussed in section 3.4.3. 
 
The protein sequence encoding the C-terminal domain of 5GVV does not align closely with 
GLT8D1. Due to this breakdown in alignment, I propose truncation of the linker region 
connecting the two domains at protein position 266 leading to loss of the C-terminal domain. 
Finally, the lack of sequence complementarity at the beginning of the trace (Figure 3.3a) may 
represent a GLT8D1 Golgi-localisation signal, which is not present in prokaryotic cells; 
however, this is purely speculative and warrants functional characterisation. GLT8D1-Golgi 








Figure 3.3. Structural-based sequence alignment identifies 5GVV (S. pneumoniae 
glycosyltranferase glyE) as a related homologue of GLT8D1. (A) Protein sequence 
alignment showing degree of conservation between 5GVV and GLT8D1. The residue-
enriched N-terminal domain is highly conserved between 5GVV and GLT8D1, suggesting 
GLT8D1 will adopt a similar fold to 5GVV. (B) Structural representation of aligned sequences 
showing two distinct protein domains separated by a linker sequence (yellow). The highly-
conserved N-terminal domain contains the binding pocket and is enriched with amino acid 
residues that determine protein folding. The less conserved C-terminal domain is also shown. 
(C) Structure of the highly-conserved N-terminal domain with a truncated linker region to more 
closely resemble of the structure of GLT8D1. Structures were generated using PyMOL.  
(Figure kindly provided by Dr Sam Dix).   
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3.3.5. A GLT8D1-R92C mutation reduces viability and increases cytotoxicity of 
HEK293 and N2A cells 
 
My next aim was to characterise the relative toxicity of GLT8D1-G78W and GLT8D1-R92C 
mutations via a combination of MTT proliferation and LDH cytotoxicity assays. MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is a yellow tetrazolium dye which is 
metabolised in the mitochondria by mitochondrial succinate dehydrogenase into an insoluble 
purple-coloured formazan product, measurable via spectrophotometry. Viable cells with an 
active metabolism exhibit high levels of MTT reduction to produce an absorbance maximum 
close to 570nm (Riss et al., 2004). WT and mutant GLT8D1 were transiently overexpressed 
in HEK293 and N2A cells via liposome-mediated transfection with pEGFP-N1_GLT8D1-eGFP 
plasmids (see section 3.3.1). MTT assays were used to indirectly assess the viability of 
HEK293 and N2A cells at two and three days post transfection, respectively. Mutation-specific 
reductions in absorbance were observed across six biological repeats of the MTT assay in 
HEK293 cells, relative to over-expression of GLT8D1-WT (n=6, ANOVA p=0.0281) (Figure 
3.4a). A similar reduction was seen in N2A cells, with GLT8D1-R92C producing a greater 
effect than GLT8D1-G78W (n=6, ANOVA p=0.0281) (Figure 3.4b).  
 
To validate the observed MTT signal, LDH assays were performed to measure LDH in 
HEK293 and N2A extracellular growth medium, following transient overexpression of 
GLT8D1-WT-eGFP, GLT8D1-G78W-eGFP and GLT8D1-R92C-eGFP. This colorimetric 
assay quantitatively measures the release of the cytoplasmic enzyme, LDH, from necrotic 
cells with reduced plasma membrane integrity. LDH is a stable cytoplasmic enzyme present 
in all cells (Kumar et al., 2018) and is released into the extracellular space when the plasma 
membrane is damaged. The assay is based on the principle that LDH reduces nicotinamide 
adenine dinucleotide to its reduced form through the oxidation of lactate to pyruvate. The 
reaction products then interact with a tetrazolium salt to form a red formazan dye, which is 
quantifiable through measuring absorbance at 490nm and 680nm. The absorbance reading is 
proportional to the number of damaged cells (i.e.  apoptotic or necrotic) within the culture. This 
assay was chosen based on its reliability, speed, and ease of evaluation (Chan et al., 2013, 
Fotakis and Timbrell, 2006). Expression of GLT8D1-R92C correlated with an increase in 
cytotoxicity across six biological repeats in HEK293 (n=6, ANOVA p=0.0117, Figure 3.4c) and 
N2A (n=6, ANOVA p=0.0117, Figure 3.4d) cells, compared to over-expression of GLT8D1-
WT. GLT8D1-G78W produced a similar trend but this did not reach statistical significance 
(n=6, p=0.4467). R92C was the more cytotoxic of the two substitution mutations in both cell 
lines, which is in line with the observed clinical severity. Indeed, overexpressing any WT gene 
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in a model system can cause mutant phenotypes (Prelich, 2012), therefore it was important to 
include a WT transfection alongside a negative control in order to observe a defined mutation-








Figure 3.4. Overexpression of mutated GLT8D1 causes cytotoxicity and reduces 
viability in HEK293 and N2A cells compared to overexpression of the WT protein. Cell 
viability was indirectly measured using MTT assays (A, B) and cytotoxicity was measured 
using LDH assays (C, D). All experiments included six biological replicates and either two 
(MTT assays) or four (LDH assays) technical replicates were included per biological replicate. 
*p < 0.05; one-way ANOVA. Each data point is expressed as a percentage of a control 
transfection with an empty peGFP-N1 vector. Error bars represent mean and SD. Figure taken 
from (Cooper-Knock et al., 2019).  
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To confirm that observed differences in cell viability and cytotoxicity (Figure 3.4) were 
mutation-specific and not due to increased expression of the mutant protein, immunoblotting 
was used to quantify the relative expression level of GLT8D1-WT, GLT8D1-G78W and 
GLT8D1-R92C in HEK293 and N2A cells for each biological repeat of the MTT and LDH 
assays. No significant differences were observed in the level of protein expression in between 
the transfection groups in either cell line (n=6, ANOVA p>0.05, Figure 3.5). The band at 
~70kDa is indicative of the GLT8D1-eGFP fusion protein (Figure 3.5a, 3.5b). Densitometry 












Figure 3.5. Immunoblotting shows similar expression levels of WT and mutant GLT8D1 
in HEK293 and N2A cells. (A) Representative images showing overexpression of GFP-
tagged WT and mutant GLT8D1 in HEK293 cells (left panel) and (B) N2A cells (right panel). 
Densitometry demonstrates non-significant differences between WT and mutant GLT8D1 
expression in (C) HEK293 and (D) N2A cells (n=6, one-way ANOVA p>0.05). Error bars 
represent SD. Immunoblotting suggests that observed phenotypes were not a result of relative 
overexpression of mutated protein. Molecular weight markers are indicated (kDa). (CTRL - 
control; WT – wild-type; UT - un-transfected; G8 – GLT8D1). Figure adapted from (Cooper-




3.3.6. An ALS-linked R92C mutation impairs the glycosyltransferase activity of 
GLT8D1 
 
Based on sequence homology, GLT8D1 is a member of glycosyltransferase family 8, and 
exon 4 contains ALS-associated mutations and encodes the substrate-binding site within the 
glycosyltransferase domain (Figure 1.4). To assess the impact of discovered mutations on 
glycosyltransferase activity, a uridine diphosphate (UDP)-GloTM glycosyltransferase assay kit 
(Promega) with five commercially available UDP-sugar substrates was used.  
 
GLT8D1-WT clone 2B1 and GLT8D1-R92C clone 2B1 were selected from my isogenic screen 
as they demonstrated a similar expression level after normalising for total protein 
concentration (Figure 3.6). 3xFLAG-tagged GLT8D1-WT and GLT8D1-R92C proteins were 
immunopurified from isogenic HEK293 cells in stringent conditions prior to competitive elution 
under a native form with a 3xFLAG peptide to preserve enzyme activity. Coomassie blue 
staining and immunoblotting were used to confirm that both proteins were purified in equivalent 








Figure 3.6. Immunoblotting confirms tetracycline-inducible expression of GLT8D1-WT 
and GLT8D1-R92C in isogenic HEK293 cells. Representative isogenic screen of selected 
(A) GLT8D1-WT and (B) GLT8D1-R92C clones showing tetracycline-induced expression of 
3xFLAG-tagged GLT8D1. GLT8D1-WT clone 2B1 and GLT8D1-R92C clone 2B1 were 
selected for GLT8D1 immunoprecipitation (red arrows) as they demonstrated a similar level 
of expression between the WT and mutant form after normalising for total protein 
concentration. (C) Representative blot showing tetracycline-induced expression of GLT8D1-
WT and GLT8D1-R92C in isogenic HEK293 cells. Relative GLT8D1 expression was detected 
using an anti-FLAG antibody; ɑ-Tubulin served as a loading control. Molecular weight markers 
are indicated (kDa). (TET – tetracycline; CTRL – control (Sham)-transfected; WT – wild-type; 







Figure 3.7. Immunopurification of GLT8D1-WT and GLT8D1-R92C from tetracycline-
induced isogenic HEK293 cells. (A) Coomassie blue gel and (B) immunoblot showing 
purified GLT8D1-WT and GLT8D1-R92C in equivalent amounts (red arrows). Input represents 
~0.1% of whole-cell protein extracts loaded onto anti-FLAG® M2 coated magnetic beads. FT 
indicates total remaining protein following incubation with a 3xFLAG peptide. Purified indicates 
3xFLAG-GLT8D1 proteins. Molecular weight markers are indicated (kDa). (WT – wild-type; 
FT – flow-through). 
 
 
The linear range for determination of accurate UDP concentration measurements was 
validated for the UDP-GloTM glycosyltransferase assay (Figure 3.8). Initial reaction velocity 
was measured at fixed enzyme concentration with increasing substrate concentrations. Initial 
reaction velocity is defined as the amount of product produced per unit time at the start of the 
reaction when the product concentration increases in a linear fashion. This is important for 
determining the rate of reaction before substrate levels are depleted (Choi et al., 2017). Data 
were fitted to a standard Michaelis-Menten equation by nonlinear regression to enable 
determination of maximal enzyme velocity (Vmax) and the Michaelis constant (Km). Purified 
GLT8D1 proteins behaved as expected for enzymes of this class (Sethi et al., 2010), and were 








Figure 3.8. Validating the linear range for determination of accurate UDP concentration 
measurements for the UDP-GloTM glycosyltransferase assay. Standard curve for the UDP-
Glo assay illustrates linear correlation for <500 mmol/min UDP (RFU – relative fluorescence 
units; UDP – uridine diphosphate). Figure adapted from (Cooper-Knock et al., 2019). 
 
 
Five commercially available UDP sugar substrates were tested: GalNAc, GlcNAc, Glucose, 
Galactose and Glucuronic acid. GLT8D1 only demonstrated sufficient affinity for UDP-
Galactose. With UDP-Galactose as the target substrate, Vmax was reduced ~25% (GLT8D1-
WT: 37.79 mmol/min; GLT8D1-R92C: 30.65 mmol/min) and Km was reduced ~40% (GLT8D1-
WT: 1.226 mmol/l; GLT8D1-R92C: 0.7492 mmol/l) in the GLT8D1-R92C protein compared to 
GLT8D1-WT (Figure 3.9a). Next, I fixed substrate concentration to >10-fold higher than Km 
in order to measure enzymatic activity at maximal enzyme velocity. I plotted the activities of 
enzymes as a function of enzyme concentration. At any enzyme concentration, the GLT8D1-
R92C enzyme activity was reduced compared to GLT8D1-WT (Figure 3.9b). Enzyme 
activities measured in the linear range of the UDP-GloTM glycosyltransferase assay indicated 
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an approximately 2-fold reduction for GLT8D1-R92C compared to GLT8D1-WT. These results 








Figure 3.9. ALS-linked GLT8D1-R92C mutation impairs glycosyltransferase activity. (A) 
3xFLAG-tagged GLT8D1-WT and GLT8D1-R92C proteins were immunopurified from 
tetracycline-induced isogenic HEK293 cells. Initial reaction velocity was measured at fixed 
enzyme concentration (3mg/25μL reaction) with variable substrate concentrations. Michaelis-
Menten curves were fitted with nonlinear regression. (B) Enzyme concentration was varied in 
the presence of fixed substrate concentration (20mM) (15mol/l corresponding to >10xKm). 
The curve for GLT8D1-R92C enzyme velocity is right-shifted compared to GLT8D1-WT 
indicating lower enzyme activity at any given enzyme concentration. (WT – wild-type; UDP – 
uridine diphosphate).   
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3.3.7. ALS-linked G78W and R92C mutations impair the glycosyltransferase activity 
of GLT8D1 
 
I validated my previous findings regarding glycosyltransferase function (see section 3.3.6) by 
transiently overexpressing GLT8D1 in HEK293 cells using pcDNA/FRT/TO-3xFLAG plasmids 
containing GLT8D1-WT, GLT8D1-G78W, and GLT8D1-R92C open reading frames. This also 
enabled me to investigate the effect of the GLT8D1-G78W variant on glycosyltransferase 
function, as a stable cell line expressing this mutation had not previously been engineered. 
3xFLAG-tagged GLT8D1-WT, GLT8D1-G78W and GLT8D1-R92C proteins were transiently 
overexpressed in HEK293 cells via liposome-mediated transfection. Proteins were 
immunopurified as previously described (see section 3.3.6). Coomassie blue staining and 
immunoblotting were used to confirm that all three proteins were purified in equivalent 
amounts (Figures 3.10c, 3.10d). MicroRNA knockdown of GLT8D1 in HEK293 cells was used 
to validate the specificity of the signal following immunoprecipitation. For knockdown, HEK293 
cells were co-transfected with pcDNA5/FRT/TO_3xFLAG vectors expressing GLT8D1-WT 
with and without pcDNA6.2-GW/EmGFP vectors expressing miRNA sequences targeting 
GLT8D1. All three miRNAs significantly reduced GLT8D1-3xFLAG levels (n=3, ANOVA 
p=0.0398) (Figures 3.10a, 3.10b). These results suggest that the purification signal observed 








Figure 3.10. Immunopurification of GLT8D1-WT, GLT8D1-G78W and GLT8D1-R92C 
recombinant proteins from HEK293 cells. (A, B) Representative blot and densitometric 
analysis showing microRNA knockdown of GLT8D1 in HEK293 cells to validate the specificity 
of the signal following immunoprecipitation (n=3, ANOVA *p<0.05). (C, D) FLAG-tagged 
GLT8D1-WT, GLT8D1-G78W, and GLT8D1-R92C proteins were immunopurified in 1M NaCl-
containing buffer to maximize dissociation of interacting partners, and were eluted in native 
conditions prior to analysis by SDS-PAGE, Coomassie staining and immunoblotting. Input 
represents ~0.1% of whole-cell protein extracts loaded onto anti-FLAG coated beads. FT 
indicates total remaining protein following incubation with a 3xFLAG peptide. Purified indicates 
FLAG-GLT8D1 proteins. Molecular weight markers are indicated (kDa). (UT – un-transfected; 




In order to measure glycosyltransferase activity, the linear range was determined for the 
measurement of UDP concentration by the UDP-GloTM assay (refer to figure 3.8). Initial 
reaction velocity was measured at a fixed enzyme concentration with increasing substrate 
concentrations. A similar reduction in glycosyltransferase activity was observed with UDP-
Galactose as the target substrate. Vmax was reduced ~30%–40% (GLT8D1-WT: 67.5 
mmol/min; GLT8D1-G78W: 58.6 mmol/min; GLT8D1-R92C: 51.4 mmol/min), and Km was 
reduced ~50% (GLT8D1-WT: 3.5 mmol/l; GLT8D1-G78W: 2.3 mmol/l; GLT8D1-R92C: 2.5 
mmol/l) in GLT8D1-R92C and GLT8D1-G78W compared to GLT8D1-WT (Figure 3.11a). 
Consistent with the cell-based assays (see section 3.3.5), the relative effect of the two tested 
mutations mirrored the observed clinical severity, with GLT8D1-R92C producing a more 
severe phenotype. Next, UDP-Galactose substrate concentration was fixed to ~5-fold higher 
than Km in order to measure near maximal enzymatic velocity. Enzyme activity was plotted 
as a function of enzyme concentration. At all enzyme concentrations, the activity of GLT8D1-









Figure 3.11. ALS-linked GLT8D1-G78W and GLT8D1-R92C mutations impair 
glycosyltransferase activity. (A) Initial reaction velocity at fixed enzyme concentration 
(3mg/25μL reaction) with variable substrate concentration. (B) Enzyme activity at fixed 
substrate concentration (15mM) with variable enzyme concentration; Michaelis-Menten 
curves were fitted with nonlinear regression. The curves for GLT8D1-G78W and GLT8D1-
R92C enzyme velocity are right-shifted compared to GLT8D1-WT indicating lower enzyme 
activity at any given enzyme concentration. (WT – wild-type; UDP – uridine diphosphate). 





Within this chapter, I describe the generation of plasmid constructs expressing GLT8D1-WT, 
GLT8D1-G78W and GLT8D1-R92C. These plasmids were essential components for all 
subsequent experimentation linked to GLT8D1-ALS. In the current chapter, these plasmids 
were used to investigate the relative toxicity of ALS-linked GLT8D1 mutations in neuronal and 
non-neuronal cell lines. They were also used for the production of recombinant GLT8D1 
protein to investigate the effect of ALS-linked mutations on glycosyltransferase function. 
Finally, these plasmids were used in the generation of an isogenic HEK293 cell model for 
studying the early biochemical effects of GLT8D1-ALS linked to an R92C mutation (see 
Chapter 5). In addition to the above, I briefly discuss the identification of a structural 
homologue for GLT8D1, which will aid future work on GLT8D1 crystallisation, which in turn 
will aid in identifying possible targets of interaction.   
 
3.4.1. Generation of pEGFP-N1_GLT8D1-eGFP and pcDNA5/FRT/TO_3xFLAG-
GLT8D1 plasmid constructs  
  
GLT8D1 DNA exhibited stable growth in E.coli, and Sanger sequencing confirmed the 
sequence integrity of the cloned fragment (see appendices 6 and 8). The generation of 
tagged constructs expressing the gene of interest are useful tools for investigating the 
expression and localisation of the protein of interest. In addition, they provide specific means 
of purifying the recombinant protein (Jarvik and Telmer, 1998); however, there are caveats to 
their use (Liu et al., 1999, Coumans et al., 2014). For example, the epitope tag may interfere 
with protein structure or function (Jarvik and Telmer, 1998), and both N- and C-terminal GFP 
tagging have been demonstrated to adversely affect protein localisation (Palmer and 
Freeman, 2004, Hanson and Ziegler, 2004). In some instances, the C-terminus can fold inside 
the protein, which would prevent detection of a fluorescent signal. This is unlikely to be the 
case for GLT8D1-eGFP, as GFP-positive cells were clearly visible under UV light for all 
conditions. Despite these limitations, epitope tagging of GLT8D1 was necessary due to a lack 
of validated GLT8D1 antibodies. Indeed, I tested various anti-GLT8D1 antibodies, but their 
specificity was masked by the presence of multiple bands through immunoblotting (see 
appendix 9). I now have a system to test the specificity of commercially available anti-GLT8D1 
antibodies through overexpression of GLT8D1-eGFP and GLT8D1-3xFLAG, followed by 
subsequent knockdown using miRNAs (Figure 3.9a). It is noteworthy that overexpression 
techniques may influence levels of the endogenous protein, which I was unable to measure. 
However, fluorescent tagging of endogenous protein is now possible using CRISPR/Cas9 
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genome editing (Ratz et al., 2015). Plasmid constructs are useful tools for studying short-term 
gene expression; however, transiently transfected cells do not integrate the plasmid into the 
genome and therefore express the gene of interest for a finite period of time, which can vary 
depending on the cell type. Gene expression is subsequently lost through factors such as cell 
division (Kim and Eberwine, 2010).  
  
 
3.4.2. Generation of the Flp-In T-RExTM GLT8D1 host cell lines 
 
Isogenic HEK293 cells with tetracycline-inducible expression of GLT8D1-WT and GLT8D1-
R92C (Figure 3.2) were initially engineered to produce recombinant protein for the 
assessment of enzymatic function. Compared to transient transfection, the amount of 
recombinant protein expressed via tetracycline induction is much lower. Therefore, in order to 
generate a sufficient yield for the assessment of enzymatic function, a larger cell biomass was 
required. The isogenic nature of these lines was desirable to reduce variability not linked to 
the GLT8D1-R92C mutation. Furthermore, overexpression of WT and mutant GLT8D1 upon 
induction would enable subsequent investigations into the early biochemical effects of an ALS-
linked R92C mutation. The inducible nature of these cell lines prevents them adapting to the 
effects of the mutation, assuming selection pressure was maintained at a sufficient level to 
minimise unintended gene expression.  
 
Isogenic HEK293 cells were characterised for tetracycline-inducible expression of GLT8D1-
WT and GLT8D1-R92C at the protein level from the FRT site (Figure 3.6). A concentration of 
10mg/mL tetracycline was sufficient to maintain induction for at least 48 hours without inducing 
cell toxicity. Basal levels of GLT8D1-WT and GLT8D1-R92C were undetectable through 
immunoblotting, even following overexposure of the image. This cell model is advantageous 
over transiently transfected models due to its isogenic nature and ability to switch on GLT8D1 
expression.  
 
The isogenic screen in HEK293-WT and HEK293-R92C cell lines suggests that an R92C 
mutation in GLT8D1 causes post-translational modification of the protein, represented by a 
double band in all blots targeting the mutant form. It is possible that the R92C mutation is 
causing GLT8D1 to misfold, which would suggest disruption of the ligand-binding pocket and 
explain why enzymatic activity in GLT8D1-R92C is reduced (Figures 3.9 and 3.11). Indeed, 
post-translational modifications such as phosphorylation are fundamental to proper enzymatic 
function. However, if these processes are not tightly regulated, they can lead to adverse 
effects such as hyper-phosphorylation, which is well described in many neurodegenerative 
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disorders. By example, hyper-phosphorylation of tau protein is implicated in Alzheimer’s (Iqbal 
et al., 2010), Parkinson’s (Zhang et al., 2018) and ALS (Strong et al., 2006). 
 
 
3.4.3. Structural-based sequence alignment identifies 5GVV as a homologue of 
GLT8D1 
 
The structure of a protein is fundamental to its function, and understanding protein fold is 
essential for curing disease (Pandey et al., 2016). Determining the crystal structure of proteins 
such as GLT8D1 is essential to understanding its enzymatic function. The Research 
Collaboratory for Structural Bioinformatics Protein Data Bank is an online resource for 
understanding the relationship between sequence, structure and function of biological 
macromolecules (available at: https://www.rcsb.org/). Using this resource, I identified 
glycosyltranferase glyE in Streptococcus pneumonia TIGR4 (Jiang et al., 2017) as a structural 
homologue of GLT8D1 (Figure 3.3). Further efforts to define the crystal structure of GLT8D1 
were not pursued due to time constraints; however, I have identified a conserved fold that 
provides useful information for future crystallisation strategies. For example, the flexibility of 
the identified linker region can interfere with crystallization (Reddy Chichili et al., 2013, Pandey 
et al., 2016); therefore, it would be important to truncate this region prior to any structural work.   
 
With more time, I would look to grow the GLT8D1 plasmids in E. coli, which is the most widely 
used expression system amongst structural biologists due to its rapid growth rate, high protein 
production, and relatively low cost (Pandey et al., 2016). The rationale for growth in E. coli is 
that mammalian cell systems do not typically yield sufficient protein for subsequent 
crystallisation, even under conditions of induced overexpression. Therefore, it is expensive to 
generate sufficient protein for structural studies (Andrell and Tate, 2013). I would then attempt 
to purify the recombinant GLT8D1 protein using techniques such as affinity chromatography 
(Vassylyeva et al., 2017), and then use macromolecular X-ray crystallography (Dessau and 
Modis, 2011) to determine its structure. Structural characterisation would aid future work in 
identifying possible targets of interaction.  
 
 
3.4.4. ALS-linked GLT8D1 mutations are toxic to HEK293 and N2A cells 
 
The next stage of this project was to examine the effects of GLT8D1-G78W and GLT8D1-
R92C mutations on the viability of HEK293 and N2A cells. HEK293 cells were chosen based 
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on their high transfection efficiency (Thomas and Smart, 2005), suggesting observed effects 
would likely be representative of the entire cell population. N2A cells were necessary to 
investigate a neuronal phenotype, which is important when modelling neurodegenerative 
diseases such as ALS. Functional characterisation of ALS-linked GLT8D1 mutations was 
addressed through a combination of MTT and LDH assays. The MTT assay was used as an 
indirect measure of growth rate. This assay does not distinguish between growth inhibition 
and cytotoxicity; therefore, LDH assays were subsequently performed to determine whether 
the reduction observed in the MTT signal was due to cytotoxicity. A mutation-specific decrease 
in cell viability and an increase in cytotoxicity was observed across six biological repeats of 
the MTT and LDH assays, respectively (Figure 3.4). In accordance with the clinical phenotype, 
GLT8D1-R92C was notably the more toxic of the mutations in both assays, despite it 
demonstrating a lower expression level than the GLT8D1-G78W protein (Figure 3.5). This is 
consistent with the phenotypic data, as ALS patients with GLT8D1-R92C mutations 
experienced a more aggressive form of the disease, with a mean survival of 21 months, 
compared to the 58-month survival observed in the single patient with a GLT8D1-G78W 
mutation (Table 1.3) (Cooper-Knock et al., 2019). In contrast, the higher expression level of 
the GLT8D1-G78W protein may suggest that observed toxicity is due to level of expression 
rather than mutation-specific. However, GLT8D1-G78W toxicity is supported by its effect on 
glycosyltransferase function (Figure 3.11). To obtain a more defined mutation-specific effect, 
RNAi technology could be used to knockdown endogenous GLT8D1. In these circumstances, 
RNAi-resistant GLT8D1 plasmids would be required to maintain a high expression level of the 
transfected gene of interest. As such, the miRNA would be designed to target a section of the 
GLT8D1 sequence that is not present in the expression vector. 
 
Two distinct protein bands were observed in all blots used to compare the relative expression 
of transiently expressed GLT8D1-eGFP protein (Figure 3.5). These bands are products of 
overexpression. The band at ~70kDa is representative of the GLT8D1-eGFP fusion product, 
but the lower band at ~27kDa may be present for various reasons. It is possible that there is 
a protease site proximal to the C-terminus that has been cleaved. Alternatively, it may be due 
to an unstable fusion. It may also suggest that the transfected plasmid contained traces of 
pEGFP-N1 minus the GLT8D1 sequence; however, this is unlikely given that single bacterial 
clones were carefully analysed via Miniprep prior to amplification using a Midiprep. Observed 
variability in the overexpression of GLT8D1 between biological repeats of the immunoblotting 
was unlikely due to inconsistent transfection efficiencies. Transfection efficiency, determined 
by the number of GFP-positive cells, was consistent at ~70-80% for HEK293 and ~30-40% for 
N2A across all three biological repeats. Rather, the variability is likely due to inconsistent 
signal intensities of the immunoblot bands between biological repeats. Indeed, it is important 
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to control for this variability to improve the accuracy and reliability of the data. However, in 
each biological repeat, the fluorescence intensity of the GLT8D1-R92C band was markedly 
lower, yet overexpression of this protein produced the more toxic phenotype in all subsequent 
experimentation, highlighting its relative pathogenicity.   
 
When performing the MTT and LDH assays, it was important to control for cellular growth rate. 
For example, the growth rate of HEK293 cells is higher compared to N2A cells; therefore, it 
was important to seed the cells at different densities (see Table 2.8). When adherent cells 
reach confluence and growth becomes contact inhibited, the amount of MTT reduction per cell 
may decrease due to attenuated cellular metabolism. Furthermore, at ~30-40%, the 
transfection efficiency of N2A cells was significantly lower than HEK293 cells (~70-80%), 
suggesting that the effects of the GLT8D1-G78W and GLT8D1-R92C mutations were masked 
by a larger population of healthy N2A cells. Transfection efficiency was determined by the 
number of GFP-positive cells. Cell passage number is likely to influence transfection efficiency 
(de Los Milagros Bassani Molinas et al., 2014); therefore, all cell lines were maintained within 
the range of 7-32 passages to overcome this potential limitation. 
 
It has been suggested that certain transfection reagents, including PEI, can cause 
fluorescence false positives, particularly when the GFP expression levels are low (Guo et al., 
2001). Therefore, my experiments included a no-GFP control transfection as a comparison; I 
did not observe any false positive signals. Given the lower transfection efficiency of N2A cells, 
the correlation between GLT8D1-R92C and cytotoxicity is encouraging, particularly as it is in 
line with the observed clinical phenotype. PEI can be toxic to certain cell types if used in 
excess, but its use is warranted, as it demonstrates high transfection efficacy (Longo et al., 
2013). The observed survival rate of N2A cells was markedly lower than HEK293 cells, 
possibly due to PEI; hence, the MTT and LDH assays were conducted in N2A cells 48 hours 
post transfection, compared to 72 hours in HEK293 cells. The shorter time scale in N2A cells 
enabled measurements of viability and toxicity to be performed before viable cells were 
reduced to a level that decreased the sensitivity of the assays. The generation of a stable 
neuronal cell line would overcome the limitation of PEI-mediated toxicity. Such lines have 
previously been generated using human neuroblastoma SH-SY5Y cells to model the 
neurodegenerative disorder, Niemann-Pick Disease Type C (Rodriguez-Pascau et al., 2012).  
 
These results support my hypothesis, indicating that ALS-linked mutations in GLT8D1 lead to 
a dominant phenotype with neurotoxicity. Whilst my results provide novel insights into the 
transient effects of GLT8D1 mutations on cellular function, I may not recognise the longitudinal 
impact, which is important given that ALS is an age-related disorder (Hardiman et al., 2017). 
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The isogenic lines would be useful for longitudinal studies through maintaining induction over 
a defined period. The toxicity data presented here are consistent with an age-of-onset 
disorder. A sudden burst in the expression of ALS-linked GLT8D1 mutations is sufficient to 
cause a toxic phenotype. However, this does not mimic the physiological expression of the 
mutations in the patients, which are expressed at a lower level, hence the development of 
symptoms after many decades.  
 
3.4.5. ALS-linked GLT8D1 mutations impair glycosyltransferase activity  
 
Glycosyltransferase assays were performed using recombinant GLT8D1-WT and GLT8D1-
R92C protein immunopurified from isogenic HEK293 cells, as well as following transient 
transfection with pcDNA5/FRT/TO_3xFLAG plasmids expressing GLT8D1-WT, GLT8D1-
G78W and GLT8D1-R92C. Protein purification was assessed via Coomassie blue staining 
and immunoblotting (Figures 3.7 and 3.10); however, these techniques are not sensitive for 
the detection of low-level impurities (<100ng) (Raynal et al., 2014). Therefore, degradation 
products can easily go unnoticed, particularly in low concentration samples. More highly 
sensitive colorimetric staining methods can be used directly after agarose gel electrophoresis. 
Such techniques include zinc-reverse staining (Fernandez-Patron et al., 1998) and silver 
staining (Chevallet et al., 2006), both of which can detect protein bands as low as 10ng and 
1ng, respectively. 
 
Based on sequence homology, GLT8D1 is a member of glycosyltransferase family 8 and is 
expected to catalyse the transfer of a glycosyl group from a donor to an acceptor via a 
“retaining” mechanism involving a glycosyl-enzyme intermediate. Although the crystal 
structure of GLT8D1 is unknown, it contains a conserved “DXD” metal ion binding site that 
indicates that it is a Leloir glycosyltransferase where donor and acceptor binding sites are 
divided by a single “GT-A” fold (Bourne and Henrissat, 2001). Discovered ALS-associated 
mutations in GLT8D1 cluster together in a short sequence of ∼20 amino acids in close 
proximity to the substrate-binding site, suggesting a common effect on this function. 
Consistent with this, I observed a significant reduction in enzyme activity in mutated GLT8D1-
R92C and GLT8D1-G78W compared to the WT protein. Measured Km was reduced in the 
mutated proteins, commensurate with an increase in substrate affinity, which could impair 
cycling of substrate through the enzyme and, thus, reduce overall velocity (Figure 3.11). This 
could also resolve an apparent paradox between the observations that discovered GLT8D1 
mutations are autosomal dominant but reduce enzyme activity suggesting a loss-of-function 
mechanism, which is often present in the case of autosomal recessive inheritance. I propose 
100 
 
that higher substrate affinity could result in a dominant-negative effect with a competitive 
antagonism of WT enzyme function. Classically, enzyme mutations are thought to be 
recessive but it is estimated that as many as 25% of enzyme mutations are autosomal 
dominant (Veitia, 2002), as in our patients. For example, dominant-negative mutations in the 
GTPase Ras increase its substrate affinity and, thus, allow it to act as a competitive antagonist 
of the WT protein (Nassar et al., 2010). I cautiously note the example of SOD1 mutations that 
were originally thought to cause ALS through loss-of-function, but were subsequently shown 
to cause gain-of-function toxicity (Boillee et al., 2006). My work awaits validation in a higher 
organism.  
 
It is noteworthy that measured Km values were relatively high compared to reports of other 
members of the glycosyltransferase 8 family (Persson et al., 2001), suggesting low substrate 
affinity. It is possible that absolute substrate affinity would be higher under physiological 
conditions, particularly as the identities of the normal donor and acceptor for GLT8D1 are 
unknown, and glycosyltransferase enzymes with a GT-A fold structure have been observed to 
show cooperation between donor and acceptor binding (Shoemaker et al., 2008). My reaction 
conditions utilized UDP-galactose and occurred without an acceptor.  
 
 
3.4.6. Clinicopathological characterisation of patients with ALS-linked GLT8D1 
mutations 
 
Clinically, patients carrying mutations in GLT8D1 are within the spectrum of sporadic ALS, 
suggesting that they may share a common disease mechanism. DNA samples (n=200, of 
which 21 have a positive family history of ALS) from the Sheffield Brain Tissue Bank were 
screened for mutations in GLT8D1 by Sanger sequencing. Unfortunately, pathological 
material was not available from any cases with identified GLT8D1 mutations and so I was not 
able to confirm the presence of TDP-43-positive neuronal inclusions, which are the hallmark 
of 97% of ALS cases (Neumann et al., 2006). GLT8D1-R92C patients all suffered limb onset 
disease which was unusually aggressive. In contrast the individual with a GLT8D1-G78W 
mutation suffered less aggressive bulbar onset disease. All patients suffered relatively young 
onset disease, which is consistent with a monogenic disorder, and all patients were within the 
spectrum of recognised ALS (Cooper-Knock et al., 2019) (Tables 1.2, 1.3). Clinical data were 





3.4.7. Ganglioside signalling as a GLT8D1-ALS pathological mechanism 
 
Gangliosides are sialic acid-containing glycosphingolipids which are particularly abundant 
within the CNS (Vajn et al., 2013). Gangliosides within the CNS are typically synthesised in 
the endoplasmic reticulum (ER) from a lactosylceramide precursor, and are remodelled during 
transit from the cis-Golgi to the trans-Golgi network by a series of glycosyltransferase enzymes 
which incorporate galactose and GalNAc groups. Consistent with a role in this process, I have 
shown that GLT8D1 is able to accept UDP-galactose as a substrate. Mature gangliosides are 
carried to the cell surface where they function prominently in cell signalling (Yu et al., 2012). 
Interestingly, autoantibodies against specific gangliosides produce an inflammatory disease 
of spinal motor neurons known as multifocal motor neuropathy with conduction block 
(Harschnitz et al., 2014), which is an important differential diagnosis for ALS. Altered levels of 
gangliosides have been reported in animal models of ALS and in post-mortem CNS tissue 
from ALS patients (Dodge et al., 2015, Ariga, 2014). I have shown that ALS-linked mutations 
in GLT8D1 impair its glycosyltransferase activity, which I predict will negatively impact on 
ganglioside signalling. I subsequently investigated ganglioside signalling as a possible 





In summary, I have successfully generated plasmid constructs to investigate the functional 
implications of ALS-linked GLT8D1 mutations. These constructs were used to engineer 
isogenic HEK293-WT and HEK293-R92C cells, which will enable studies into the early 
biochemical effects of a GLT8D1-R92C mutation. I have shown that GLT8D1-G78W and 
GLT8D1-R92C mutations are toxic to neuronal and non-neuronal cells, and the relative toxicity 
of the mutations mirrors the clinical severity. Observed mutation-specific effects on cell toxicity 
are consistent with an age-of-onset disease, as overexpression in my model does not reflect 
the physiological expression of mutant GLT8D1 in the patients. It is difficult to rationalise this 
dramatic toxicity with a disease in which people do not present with symptoms for several 
decades. However, patients will express relatively lower levels of the mutant protein, and 
homeostatic mechanisms will likely curtail the effects of the mutations for a period of time.  
 
I was the first to publish information regarding the substrate specificity of GLT8D1. I have 
shown that GLT8D1-G78W and GLT8D1-R92C mutations impair the glycosyltransferase 
activity of the enzyme with UDP-Galactose as the target substrate. The observed reduction in 
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reaction velocity is likely due to increased substrate affinity, which could impair cycling of the 
substrate through the enzyme. ALS-associated GLT8D1 mutations are autosomal dominant 
but the reduction in enzyme activity suggests a loss-of-function mechanism, which is often 
coincident with autosomal recessive inheritance. Indeed, misfolded SOD1 was initially 
proposed to cause ALS via a loss-of-function mechanism; however, a gain-of-function toxicity 
is now the accepted mechanism thought to arise from misfolding of the protein. It is possible 
that the R92C mutation is causing GLT8D1 to misfold. I propose that higher substrate affinity 
could result in a dominant-negative effect with a competitive antagonism of the WT enzyme 
function. The data presented here are consistent with the association of mutations in GLT8D1 
with ALS. Confirmation of the pathogenic mechanism(s) will require validation in a higher 
organism but my discovery places this pathway upstream in the pathogenesis of ALS, making 




Chapter 4. Knockdown of endogenous glt8d1 and 
overexpression of mutant GLT8D1 produces motor impairment 




This chapter is an extended version of work published during my PhD (Cooper-Knock et al., 
2019). Unless stated otherwise, I was responsible for conducting all experimental work 
presented within this chapter, and any collaborations are acknowledged. Zebrafish (Danio 
rerio) have become increasingly popular as a model organism for the investigation of 
neurodegenerative disorders (Beattie et al., 2007) due to their ease of genetic manipulation, 
robust behavioural phenotypes, rapid development, and low maintenance cost (Grunwald and 
Eisen, 2002). The use of zebrafish embryos is particularly attractive, as their optical 
transparency enables the detection of morphological abnormalities and the visualisation of 
neuronal activity using non-invasive imaging techniques. This is useful when modelling 
neurodegeneration in a multicellular and complex system (Kalueff et al., 2014). In addition, a 
major advantage of zebrafish is the high homology in relation to human genes (Howe et al., 
2013), which is important for modelling human genetic disorders such as ALS. Zebrafish have 
a fully sequenced genome, allowing for the straightforward comparison of zebrafish genes to 
human genes (Grunwald and Eisen, 2002). Zebrafish glt8d1 shares 79% homology with its 
human GLT8D1 orthologue, and the G78W and R92C mutation sites are highly conserved 
(Ensembl, 2020). These advantages influenced my decision to model GLT8D1-linked ALS in 
zebrafish.  
 
My glycosyltransferase assay data suggest that ALS-linked GLT8D1 mutations cause a loss-
of-function mechanism and a possible dominant negative effect (see sections 3.3.6 and 3.3.7). 
To investigate loss-of-function in the context of a whole organism, I assessed whether 
transient knockdown of endogenous glt8d1 in zebrafish embryos via microinjection of 
antisense morpholino oligonucleotides (AMOs) led to the onset of a motor phenotype. I 
cautiously use the term “loss-of-function”, which more accurately describes genetic mutant 
models with verified loss-of-function mutations (Schmid and Haass, 2013). AMOs are a widely 
used tool in zebrafish research for the efficient and specific knockdown of gene function (Eisen 
and Smith, 2008, Bill et al., 2009); however, there are caveats to their use, which I will discuss 
in section 4.4.2. AMOs hybridise to mRNA target sequences to either block translation or pre-
mRNA splicing. Translation blocking occurs when the AMO targets mRNA sequences 
proximal to the initiation codon. Splice blocking occurs when the AMO targets mRNA 
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sequences that span exon-intron boundaries, thus blocking the binding of splicing factors to 
the pre-mRNA (Xi et al., 2011). AMOs utilised in this project were designed to block pre-mRNA 
splicing of glt8d1, thus reducing expression of the protein.  
 
In single cell-type culture models, GLT8D1-G78W and GLT8D1-R92C mutations are 
associated with gain-of-function toxicity (see section 3.3.5). Therefore, I decided to investigate 
the effects of transiently overexpressing mutant human GLT8D1 mRNA in zebrafish to place 
these mutations in the context of motor system function. Observed reductions in motor activity 
would be consistent with a gain-of-function mechanism. Importantly, characterising a toxic 
gain-of-function usually requires a heterozygous model that is generated using a genome 
editing method (Schmid and Haass, 2013). Human mRNA encoding GLT8D1-WT, GLT8D1-
G78W, or GLT8D1-R92C was microinjected into zebrafish embryos at the one-cell stage and 
survival rates were recorded. A similar motor phenotype in both knockdown and 




4.2. Aims and objectives to investigate whether knockdown of endogenous 
glt8d1, or overexpression of mutant GLT8D1 mRNA, cause motor impairment 
in zebrafish larvae 
 
1. Transiently knockdown endogenous glt8d1 in zebrafish embryos using AMOs, and 
assess knockdown via RT-PCR.  
2. Transiently overexpress synthesised GLT8D1-WT, GLT8D1-G78W and GLT8D1-
R92C human mRNA in zebrafish embryos, and assess overexpression via 
immunoblotting. 
3. Evaluate the effect of overexpressing mutant GLT8D1 on zebrafish embryo survival. 
4. Assess the effect of endogenous glt8d1 knockdown on motor function in zebrafish 
larvae. 
5. Analyse the effect of overexpressing GLT8D1-G78W and GLT8D1-R92C human 
mRNA on motor function in zebrafish larvae, compared to overexpression of GLT8D1-
WT human mRNA. 
6. Validate the sensitivity of two automated tracking platforms (Viewpoint and EthoVision 






4.3.1. Knockdown of endogenous glt8d1 impairs motor function in zebrafish larvae 
 
All experimentation within this chapter was performed in collaboration with Dr Tennore 
Ramesh. Zebrafish embryos were microinjected at the one-cell stage with splice-blocking 
AMOs to transiently knockdown endogenous glt8d1. A commercially available anti-GLT8D1 
antibody did not detect endogenous glt8d1 in zebrafish embryos at 2dpf; therefore, I was 
unable to confirm knockdown via immunoblotting. However, knockdown of endogenous 
GLT8D1 RNA was confirmed at 2dpf via RT-PCR (n=1; no statistical analysis was performed) 
(Figure 4.1). Knockdown of GLT8D1 RNA was no longer present at the time of behavioural 





Figure 4.1. Agarose gel electrophoresis showing a reduction in the expression of 
zebrafish GLT8D1 RNA following microinjection of ~1.5ng splice blocking AMO. RNA 
was extracted from twenty zebrafish embryos at 2dpf per cohort, and knockdown was 
evaluated via RT-PCR following 1.0ng and 1.5ng doses of AMO. A 1.0ng dose of AMO did 
not lead to an observable reduction in GLT8D1 RNA levels compared to un-injected. A 1.5ng 
dose was sufficient to reduce GLT8D1 RNA, represented by the weaker band at the expected 
height of ~149bp. Molecular weight markers are indicated (bp/kb) (RT-PCR was performed by 
Dr Johnathan Cooper-Knock).  
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All zebrafish larvae appeared morphologically normal prior to behavioural testing. Zebrafish 
larvae behaviour was analysed at 5dpf to determine whether knockdown of endogenous 
glt8d1 correlated with the onset of a motor phenotype. The distance moved by 96 zebrafish 
embryos for each condition from three separate clutch mates (~32 zebrafish per clutch) was 
evaluated via infrared tracking using a ZebraBox® apparatus with Zebralab software 
(ViewPoint) (Scott et al., 2016). This equipment is commonly used in the University of Sheffield 
CDBG aquarium. Knockdown of endogenous glt8d1 correlated with a significant reduction in 
the distance moved by zebrafish larvae at 5dpf, compared to injection with a control AMO 
(n=96, t test, p=0.0073) (Figure 4.2a).  
 
ViewPoint infrared tracking was compared to manual video observation. Observed 
inconsistencies in the automated tracking included automatically detected movements in the 
absence of observed movement, and failure to detect certain larvae. Due to these anomalies, 
I decided to validate the accuracy of the ViewPoint tracking software by trialling a commercially 
available alternative platform called EthoVision XT. EthoVision XT was chosen based on its 
precision in distinguishing between test subject and background (Noldus et al., 2001). I 
reanalysed the same videos and observed a similar reduction in the distance moved by 
zebrafish larvae injected with a GLT8D1 splice-blocking AMO compared to zebrafish injected 
with a control AMO (n=96, unpaired t test, p=0.0017) (Figure 4.2b). Using this software, I also 
measured the velocity of zebrafish larvae. Consistent with the distance moved, velocity was 
also reduced in zebrafish larvae injected with a GLT8D1 splice-blocking AMO, compared to 
larvae injected with a control AMO (n=96, unpaired t test, p=0.0016) (Figure 4.2c). This result 
gave me confidence in the accuracy of the ViewPoint software; therefore, subsequent 







Figure 4.2. Knockdown of endogenous glt8d1 correlates with a reduction in the velocity 
and distance moved by zebrafish larvae at 5dpf. Distance moved (mm) by 96 zebrafish 
larvae for each condition (5dpf) (~32 per clutch) during 40 minutes of automated tracking using 
(A) ViewPoint and (B) EthoVision XT. Injection with 1.5ng GLT8D1 splice blocking AMO 
correlates with a significant reduction in the distance moved by zebrafish larvae, compared to 
injection with 1.5ng control AMO (n=96, unpaired t test, **p<0.001). (C) EthoVision XT shows 
that the mean velocity (mm/s) is reduced in zebrafish larvae injected with a GLT8D1 splice-
blocking AMO, compared to zebrafish injected with a control AMO (n=96, unpaired t test, 
**p<0.01). Each data point represents a single zebrafish larva (SB – splice blocking; MO - 







4.3.2. Overexpression of GLT8D1-G78W and GLT8D1-R92C mRNA impairs motor 
function in zebrafish larvae, compared to overexpression of GLT8D1-WT mRNA 
 
The observed behavioural phenotype following transient knockdown of endogenous glt8d1 in 
zebrafish larvae is consistent with a role for GLT8D1 in motor function. I then tested whether 
overexpression of GLT8D1-G78W and GLT8D1-R92C mRNA had a similar effect on motor 
activity, compared to overexpression of GLT8D1-WT mRNA. For RNA synthesis, full-length 
GLT8D1 nucleotide sequences were linearised from pEGFP-N1_GLT8D1-eGFP vectors (see 
section 3.3.1) using NheI and XhoI restriction enzymes. Cleaved sequences were cloned into 
PCS2+ vectors. PCS2+ vectors contain an SP6 promotor required for the transcription of 
capped RNA in vitro (Wang et al., 2016). Restriction digests were used to confirm successful 
integration of GLT8D1 nucleotide sequences into PCS2+ vectors (Figure 4.3a). PCS2+ 
vectors were also validated via Sanger sequencing (see appendix 10). mRNA encoding 
human GLT8D1-WT, GLT8D1-G78W and GLT8D1-R92C was synthesised from PCS2+ 
vectors using the mMESSAGE mMACHINE® SP6 Transcription Kit. The quality of the RNA 










Figure 4.3. Generation of GLT8D1-WT, GLT8D1-G78W and GLT8D1-R92C mRNA for 
zebrafish embryo microinjection. (A) GLT8D1 sequences were cleaved from pEGFP-N1 
expression vectors (see section 3.3.1) using NheI and XhoI restriction endonucleases and 
cloned into PCS2+ vectors. Restriction digests using BcII and XbaI restriction enzymes were 
performed to confirm the size of GLT8D1 inserts. PCS2+ plasmids were also validated via 
Sanger sequencing (see appendix 10). (B) PCS2+ vectors were linearized for SP6 RNA 
transcription in vitro. RNA quality was assessed using agarose gel electrophoresis and 




Synthesised mRNA did not contain an eGFP-tag; therefore, I aimed to confirm overexpression 
of GLT8D1 in zebrafish embryos using a commercially available anti-GLT8D1 antibody. To 
validate the anti-GLT8D1 antibody, I compared the relative expression level of GLT8D1 in 
embryos injected with 350pg and 700pg doses of mRNA encoding both GLT8D1-WT and 
GLT8D1-R92C. I observed stronger bands at the expected height of ~42kDa in zebrafish 
injected with 700pg mRNA, compared to those injected with 350pg mRNA, for both GLT8D1-
WT and GLT8D1-R92C cohorts. I did not observe a protein band in the un-injected cohort 
(n=2, no statistical analysis was performed) (Figure 4.4). This suggests that endogenous 
levels of glt8d1 are not detectable using this anti-GLT8D1 antibody. The molecular weight of 






Figure 4.4. Overexpression of GLT8D1-WT and GLT8D1-R92C in zebrafish embryos is 
confirmed via immunoblotting at 2dpf. Representative blot used to validate the anti-
GLT8D1 antibody, showing the relative expression level of GLT8D1 following injection with 
350pg and 700pg doses of synthesised GLT8D1-WT and GLT8D1-R92C human mRNA (red 
arrows). Stronger bands are present at the high dose (700pg). The molecular weight of the 
GLT8D1 bands was sized at 41.46kDa using GeneTools (Syngene). The entire lysate of 










High quality human mRNA encoding GLT8D1-WT, GLT8D1-G78W or GLT8D1-R92C was 
microinjected into a fresh batch of zebrafish embryos at the one-cell stage to characterise the 
effect of overexpressing mutant GLT8D1 mRNA on survival. Two doses of mRNA were 
administered for each condition: 350pg and 700pg. Percentage embryo survival was recorded 
at 8-, 24-, and 48-hour time intervals post injection to compare the toxicity of GLT8D1-WT, 
GLT8D1-G78W and GLT8D1-R92C. Zebrafish from three separate clutch mates were injected 
for each condition.  
   
I did not observe significant reductions in the survival rate between GLT8D1-WT and GLT8D1-
G78W at doses of 350pg mRNA (24 hours: n=3, paired t test, p= 0.501776; 48 hours: n=3, 
paired t test, p=0.694731) or 700pg mRNA (24 hours: n=3; paired t test, p=0.678639; 48 hours: 
n=3, paired t test, p= 0.850333). Neither did I observe a significant reduction in the survival 
rate between GLT8D1-WT and GLT8D1-R92C at doses of 350pg mRNA (24 hours: n=3, 
paired t test, p= 0.727215; 48 hours: n=3, paired t test, p= 0.292042) or 700pg mRNA (24 
hours: n=3, paired t test, p= 0.146395; 48 hours: n=3, paired t test, p=0.0652) (Figure 4.5). 







Figure 4.5. Survival of zebrafish embryos following microinjection of human mRNA 
encoding GLT8D1-WT, GLT8D1-G78W and GLT8D1-R92C. Injection of (A) ~350pg and (B) 
~700pg mature mRNA encoding human GLT8D1-G78W or GLT8D1-R92C does not 
significantly reduce the survival of zebrafish embryos at 24- and 48-hours compared to mature 
mRNA encoding human GLT8D1-WT (n=3; paired t-test, p>0.05 for 350pg and 700pg doses). 
Turquoise line = un-injected; blue line = GLT8D1-WT mRNA; purple line = GLT8D1-G78W 





Twenty zebrafish embryos from each cohort were selected at 2dpf to evaluate the 
overexpression of GLT8D1-WT, GLT8D1-G78W and GLT8D1-R92C via immunoblotting. All 
twenty selected embryos from each cohort were fractionated per lane. The molecular weight 
of the GLT8D1 bands were sized at 41.98kDa using GeneTools (Syngene). Protein bands 
appeared stronger in the GLT8D1-WT, GLT8D1-G78W and GLT8D1-R92C cohorts compared 
to the un-injected group, suggesting overexpression of GLT8D1 (n=2, no statistical analysis 
was performed) (Figure 4.6a). I performed only two biological repeats of the immunoblotting 
in order to maximise the number of zebrafish embryos for behavioural testing.   
 
All zebrafish appeared morphologically normal prior to behavioural testing. Behavioural 
analysis was conducted in zebrafish larvae at 5dpf to assess the effects of overexpressing 
GLT8D1-WT, GLT8D1-G78W and GLT8D1-R92C human mRNA on zebrafish locomotion. I 
observed mutation-specific reductions in the distanced moved by zebrafish injected with 
GLT8D1-G78W (23 embryos from 1 clutch; t test, p=0.0044) and GLT8D1-R92C (49 embryos 
from 2 clutches; t test, p=0.0315) mRNA, following 40 minutes of behavioural tracking using 




















Figure 4.6. Overexpression of GLT8D1-G78W and GLT8D1-R92C mRNA produces motor 
impairment in zebrafish larvae, compared to overexpression of GLT8D1-WT. (A) 
Representative blot showing the relative expression of GLT8D1-WT, GLT8D1-G78W and 
GLT8D1-R92C protein (red arrows) in zebrafish larvae at 2dpf. Twenty embryos were 
fractionated per lane (n=2, no statistical analysis was performed). Molecular weight markers 
are indicated (kDa). Distance moved (mm/40 min) during two light-dark cycles (10 minutes per 
cycle) at 5dpf is reduced following injection with ~700pg mRNA encoding human (B) GLT8D1-
G78W (23 embryos from 1 clutch) or (C) GLT8D1-R92C (49 embryos from 2 clutches) 
compared to ~700pg mRNA encoding human GLT8D1-WT. Each data point represents a 
single zebrafish larva. Un-paired t-test to compare the two injection groups * p<0.05; ** p<0.01. 






4.4.1. Zebrafish as a neurodegenerative disease model 
 
I chose zebrafish (Danio rerio) as the organism to initially model ALS-linked GLT8D1 
mutations in vivo due to their fecundity, rapid development, and ease of genetic manipulation 
(Bradford et al., 2017). The zebrafish genome has been fully sequenced, and approximately 
71% of the 20,479 human protein-coding genes have orthologues within the zebrafish 
genome. Moreover, 69% of the 26,206 protein-coding zebrafish genes have orthologues 
within the human genome (Howe et al., 2013). This makes zebrafish a useful model for the 
study of human genetic diseases. GLT8D1 shares 79% homology between zebrafish and 
humans, and the mutation sites are highly conserved (Ensembl, 2020). Zebrafish exhibit a 
wide range of complex behaviours such as social, anxiety, learning, and memory, which are 
useful for modelling neurological diseases (Basnet et al., 2019). Furthermore, high-throughput 
tracking of zebrafish embryos and larvae has greatly enhanced behavioural research in the 
zebrafish field (Kalueff et al., 2013). The development of software for tracking larval 
movements at high resolution enables experimenter-independent, high-throughput screening 
for motor activity deficits (Fontaine et al., 2008, Mirat et al., 2013). Finally, in contrast with 
mammals, the development of zebrafish larvae occurs externally, which makes them 
accessible for experimental manipulation (Schmidt et al., 2013). 
 
There are limitations to the use of zebrafish as a model for ALS. ALS is characterised by the 
degeneration of upper and lower motor neurons; however, the relevance of zebrafish in 
modelling upper motor neuron disorders is limited due to the absence of corticospinal and 
rubrospinal tracts in their CNS (Babin et al., 2014). In contrast to mammals, zebrafish have a 
remarkable ability to regenerate damaged neurons leading to functional recovery. Indeed, 
most studies focus on axonal regeneration in adult zebrafish, which usually takes weeks to 
occur; however, there is also evidence of motor neuron regeneration in zebrafish at the larval 
stage, which is detectable within 48 hours (Ohnmacht et al., 2016). Whilst the regenerative 
capacity of adult and larval zebrafish neurons is apparent, it is usually studied in response to 
mechanical lesions or motor neuron ablation, which is inconsistent with my models. 
Furthermore, many studies take advantage of the optical transparency by analysing zebrafish 
at embryonic or early developmental stages, which is inconsistent with an age-related disorder 
such as ALS (Kabashi et al., 2010, Sukardi et al., 2011, Ciura et al., 2013, Schmid et al., 2013, 
Morrice et al., 2018, Svahn et al., 2018).  
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Reproducibility is a major concern with transient zebrafish models, or any transient model for 
that matter. Multiple studies in the ALS field have highlighted this. For example, AMO-
mediated knockdown of zebrafish C9orf72 resulted in behavioural deficits concurrent with 
reduced axonal length (Ciura et al., 2013). However, depletion of C9orf72 transcripts in iPSC-
derived neurons and the mouse CNS did not lead to any adverse effects (Donnelly et al., 2013, 
Sareen et al., 2013, Lagier-Tourenne et al., 2013). Therefore, stable mutants are critical to 
ensure that observed phenotypes in transient models are reliable. Stable, transgenic mutant 
zebrafish lines can be generated using CRISPR/Cas9 genome editing (Burket et al., 2008). 
However, when I was performing the zebrafish work, CRISPR/Cas9 genome editing was 
reported to cause numerous off-target mutations in vivo due to poor specificity of the single 
guide RNAs (Schaefer et al., 2017). The specificity of this technology has since improved 
dramatically (Anzalone et al., 2019, Kocak et al., 2019). 
Various studies have used zebrafish as an in vivo model for investigating ALS pathogenesis; 
however, these models vary pathologically and phenotypically depending on the method of 
genetic manipulation (Table 4.1). Both of my models demonstrate an early-onset and dramatic 
effect compared to the human phenotype. This is similar to the early-onset phenotype seen in 
the SODG93A ALS mouse model (Gurney et al., 1994). Much like the SOD1G93A model, this 
observed embryonic phenotype is not representative of the human disease. However, my 
models are transient, and do not reflect the physiological expression of GLT8D1 in the 
patients. Despite this, my models are useful as they provide evidence for motor system 
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Table 4.1. Zebrafish ALS models recapitulate pathological and phenotypic disease 
traits. Common ALS genes, genetic alterations, observed pathological and phenotypic traits, 
and references are shown.     
 
4.4.2. Advantages and limitations concerning the use of AMOs   
 
AMOs are useful tools for the functional characterisation of gene activity in vivo. The use of 
AMOs in zebrafish have been shown to be sequence specific and extremely potent in cells 
during the initial fifty hours of development; therefore, resulting phenotypes can be rapidly 
observed using a relatively inexpensive method (Corey and Abrams, 2001). Moreover, AMOs 
are water soluble and immune to nucleases (Summerton and Weller, 1997). Indeed, there are 
caveats to the use of AMOs, such as off-target effects not associated with loss-of-function of 
the target locus. Underlying off-target mechanisms are not fully understood, although p53-
dependent neural toxicity is a well-described and consistent phenotype. Therefore, it may be 
justifiable to co-inject with an AMO targeting p53, although this approach should mask the 
effects of gene-specific p53-dependent phenotypes (Xi et al., 2011, Bedell et al., 2011).  
 
Dose curves are often generated to overcome AMO-induced off-target toxicity. Increasing the 
AMO dosage will enhance phenotypic penetrance and subsequently increase phenotypic 
severity (Nasevicius and Ekker, 2000), but it may also increase the likelihood of off-target 
toxicity (Robu et al., 2007). A dose curve would provide information as to the upper limit for 
subsequent testing, as well as determine the lethal dose 50 (the dose at which ≥50% of 
injected embryos die) for each tested AMO (Bedell et al., 2011). In the present study, I tested 
AMOs at doses of 1.0ng, 1.5ng and 2.0ng. 1.0ng and 1.5ng doses were well tolerated and 
larvae appeared morphologically normal; however, 2.0ng doses caused morphological 
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abnormalities and led to a higher rate of premature death. Therefore, in order to obtain 
maximal phenotypic penetrance without inducing high rates of morphological abnormality or 
fatality, 1.5ng AMO doses were administered to zebrafish embryos for subsequent 
behavioural testing. As a result, observed phenotypes were more likely to be knockdown 
specific.  
 
Numerous other groups have performed AMO-mediated knockdown in zebrafish to model 
ALS-causing mutations. Knockdown of C9orf72 (Ciura et al., 2013), tardbp (Kabashi et al., 
2010) and fus (Armstrong and Drapeau, 2013) using AMOs have all been shown to correlate 
with the onset of a motor phenotype. However, it is noteworthy that the study by Kabashi and 
colleagues only reported knockdown of one tardbp orthologue, whereas a more recent study 
reported that two tardbp orthologues are present in zebrafish (Schmid et al., 2013). Much of 
the published work concerning transient knockdown of target genes in zebrafish using AMOs 
has been performed during the early developmental stages. Therefore, it is difficult to detect 
potential direct or indirect interactions between developmental and neurodegeneration 
processes, particularly in the context of late-onset diseases such as ALS (Schmid and Haass, 
2013).  
 
Due to controversies in the field pertaining to the non-specific effects of AMOs, future work 
should consider CRISPR/Cas9 genome editing to create a knockout zebrafish model to study 
GLT8D1 loss-of-function. This approach has already been applied in zebrafish to investigate 
other ALS-associated genes. For example, CRISPR-mediated knockout of FUS was not 
shown to cause an ALS-like phenotype (Lebedeva et al., 2017), contrary to previous reports 
using AMOs (Armstrong and Drapeau, 2013) (Table 4.1). Despite the aforementioned 
limitations, the use of AMOs in vivo is advantageous over knockdown using miRNAs, which 
may undergo nuclease-mediated degradation before obtaining modulation of the target gene 
(Rupaimoole et al., 2011). RNAi technology has been reported to work in zebrafish but with 




4.4.3. Transient knockdown of endogenous glt8d1 causes motor impairment in 
zebrafish larvae 
 
Transient knockdown of endogenous glt8d1 using splice-blocking AMOs was performed to 
test for a potential loss-of-function mechanism, and to indirectly assess whether GLT8D1 is 
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involved in motor system function. This is a transient model and therefore most resulting 
phenotypes are identified within the first 3 days of embryonic development, but sometimes 
persist to 5dpf. Observed effects rarely continue beyond 5dpf, possibly due to high rates of 
protein turnover (Bill et al., 2009). This is advantageous from an ethical standpoint as 
modelling can be performed at a stage in embryonic development when zebrafish are not 
protected by UK and EU legislation (ASPA, 1986).  
 
Evaluation of glt8d1 knockdown at 2dpf was not possible via immunoblotting because the anti-
GLT8D1 antibody was only able to detect GLT8D1 when overexpressed (Figure 4.4). 
However, my AMO was designed to remove exon 2, which would lead to a frameshift allowing 
for easy assessment via RT-PCR (Bill et al., 2009). Therefore, knockdown was evaluated at 
the RNA level via RT-PCR at 2dpf, following 1.0ng and 1.5ng doses of AMO. I observed 
knockdown at the higher dose of 1.5ng, which was the same dose zebrafish received prior to 
behavioural testing. I performed behavioural analysis at 5dpf because zebrafish larvae are at 
a stage in their development when they exhibit robust locomotor activity. Moreover, they show 
responsiveness to light, and they are sufficiently developed to enable tracking technology to 
distinguish between zebrafish and background with higher precision (Colwill and Creton, 
2011). Therefore, behavioural testing at an earlier time point may have reduced the accuracy 
of the tracking software. A recent study investigated the effects of C9ORF72-related dipeptide 
expression on zebrafish locomotion at 2dpf using a touch-evoked escape response. In this 
assay, the tail of the embryo is lightly touched with forceps. Healthy embryos responded by 
swimming away, whilst embryos with motor neuron impairment swam a shorter distance 
(Swaminathan et al., 2018). Whilst this technique can provide detailed measurements of force 
in the zebrafish embryos, I did not consider it to be suitable for higher throughput experiments 
such as my own.  
 
The reduction in motor activity that I observed at 5dpf following knockdown of GLT8D1 RNA 
(Figure 4.1) may suggest a loss-of-function mechanism. Initially, behavioural analysis was 
performed using ViewPoint software (Scott et al., 2016). Observed anomalies during manual 
video observation led me to evaluate motor activity using an alternative tracking platform 
called EthoVision XT (Noldus et al., 2001). Both platforms showed similar trends and degrees 
of significance (ViewPoint: p=0.0073; EthoVision XT: p=0.0017) (Figure 4.2). This result gave 
me confidence in the ViewPoint software, which I subsequently used for the behavioural 





4.4.4. Overexpression of mutant human GLT8D1 mRNA produces motor impairment 
in zebrafish larvae  
 
ALS-linked GLT8D1 mutations are toxic to cells in vitro (see section 3.3.5); therefore, I decided 
to investigate the effects of mutant GLT8D1 in a zebrafish model to place these mutations in 
the context of motor system function. Microinjection of synthetic capped mRNA leads to global 
expression throughout the early zebrafish embryo, unlike injection of a zebrafish-compatible 
expression plasmid, which distributes in a mosaic manner. The use of such plasmids would 
suggest a limited number of cells in the multicellular embryo would express the protein of 
interest (Koster and Fraser, 2001). 
 
Overexpression of GLT8D1-G78W and GLT8D1-R92C mRNA in zebrafish larvae did not 
significantly affect survival, compared to overexpression of GLT8D1-WT mRNA during the first 
48 hours of embryogenesis (Figure 4.5). To determine overexpression, I evaluated the 
specificity of a commercially available anti-GLT8D1 antibody following injection with 350pg 
and 700pg doses of human mRNA encoding GLT8D1-WT and GLT8D1-R92C. I observed 
stronger protein bands at the expected height of ~42kDa following the higher dose of 700pg 
mRNA (Figure 4.4). Therefore, my immunoblotting is consistent with overexpression of 
GLT8D1-WT, GLT8D1-G78W, and GLT8D1-R92C at 2dpf (Figure 4.6a). The same antibody 
was unable to detect endogenous GLT8D1 in HEK293 and N2A cells; however, in the context 
of zebrafish, I have tentatively shown it is able to detect GLT8D1 when overexpressed.  
 
Behavioural tests were conducted at 5dpf, a stage in development when zebrafish larvae use 
light to independently hunt for food (Clift et al., 2014). My data show that overexpression of 
GLT8D1-G78W and GLT8D1-R92C correlates with a reduction in the motor activity of 
zebrafish larvae, compared to overexpression of GLT8D1-WT (GLT8D1-G78W: 23 embryos 
from one clutch, t test, p=0.0044; GLT8D1-R92C: 49 embryos from two clutches, t test, 
p=0.0315) (Figure 4.6b, 4.6c). My focus was to utilise high-throughput behavioural testing to 
evaluate motor impairment in the zebrafish models; therefore, I did not perform 
neuropathological analysis. However, the optical transparency of zebrafish larvae makes it 
possible to visualize the soma and axons of the Mauthner cells, which are a large pair of easily 
identifiable neurons located in the brainstem of zebrafish. Mauthner cells are activated during 
escape behaviour (Korn and Faber, 2005), making them a useful tool for measuring neuronal 
activity during the aforementioned touch-evoked escape response (Swaminathan et al., 2018). 
These cells can be visualised through confocal imaging of calcium using fluorescent dyes 





To investigate whether GLT8D1 mutations are toxic within a whole organism, I overexpressed 
human mutated and WT GLT8D1 mRNA in zebrafish embryos. At the high dose (700pg), 
motor function was specifically impaired in zebrafish injected with either the GLT8D1-R92C or 
GLT8D1-G78W mRNA, compared to injection with GLT8D1-WT mRNA. This is consistent with 
a specific effect on the motor system. Further supporting a role for GLT8D1 in motor function, 
knockdown of endogenous glt8d1 in zebrafish embryos produced a specific deficit of motor 
function without observable morphological abnormalities. Overlap between the effects of 
glt8d1 knockdown and overexpression of mutated GLT8D1 is consistent with a dominant-
negative mechanism.  
 
Precedence exists for dominant-negative mutations in other ALS-associated genes, notably 
TARDBP and OPTN. Mutant cytoplasmic TDP-43 has been shown to reduce DNA repair 
through preventing the nuclear translocation of XRCC4-DNA ligase 4. This finding was 
concurrent with elevated levels of reactive oxygen species, suggesting both dominant-
negative and loss-of-function effects of the mutation (Guerrero et al., 2019). Moreover, OPTN 
mutations are inherited in an autosomal recessive manner, and OPTN has been demonstrated 
to cause neurotoxicity through a loss-of-function mechanism. However, in heterozygous 
mutations with autosomal dominant inheritance, a dominant negative effect may play a role 
(Maruyama et al., 2010, Sakaguchi et al., 2011, Turner et al., 2013).  OPTN has been shown 
to co-localise with inclusion bodies formed through the truncation of TDP-43. This co-
localisation was dependent on the ubiquitin-binding domain of OPTN. Ubiquitin-binding 
domain mutants were shown to act as dominant-negative traps through the formation of WT-
mutant hybrid complexes, which compromised the maturation of autophagosomes. This 
subsequently interfered with OPTN-mediated autophagy and the clearance of inclusion bodies 
(Shen et al., 2015).  
 
In summary, my data suggest both GLT8D1 haploinsufficiency and gain-of-function toxicity 
may contribute to a behavioural phenotype in zebrafish larvae, which is consistent with 
previous reports on ALS genes TARDBP, C9ORF72, and OPTN. To fully characterise the 
effect of mutant GLT8D1 in the context of ALS, neuropathological analysis should be 
performed to assess hallmarks of the disease including degeneration of motor neurons, 
breakdown of neuromuscular junctions, and muscle atrophy. Finally, future work should aim 
to generate a stable transgenic zebrafish model using CRISPR/Cas9 genome editing to 




Chapter 5. Membrane ganglioside concentration is dependent 




Glycosyltransferases function prominently in the biosynthesis of gangliosides, which are sialic 
acid-containing glycosphingolipids that are expressed ubiquitously, but most prominently on 
the surface of neuronal cells (Vajn et al., 2013). Therefore, the next stage of this project was 
to investigate whether an R92C mutation in GLT8D1 affects the expression of gangliosides. I 
imaged ganglioside expression in isogenic GLT8D1-WT and GLT8D1-R92C cell models using 
the same isogenic clones described previously (2B1) (see section 3.3.6). Ganglioside 
expression was assessed in two separate live imaging assays. Initial investigations utilised a 
Wheat Germ Agglutinin (WGA) Alexa-conjugated molecular probe, which selectively binds to 
sialic acid and N-Acetylglucosamine (GlcNAc) sugar residues. Gangliosides contain one or 
more sialic acids in their glyco-chain; therefore, I utilised WGA as an indirect indicator of 
membrane ganglioside expression. Secondly, a Cholera Toxin Subunit B (CTxB) Alexa-
conjugated molecular probe was used to label the monosialoganglioside, GM1, both in the 
membrane and cytoplasmic regions. Ganglioside GM1 is highly abundant in the nervous 
system (Vajn et al., 2013) and localises to membrane lipid rafts (MLR). Disrupted MLR are 
associated with impaired neurotrophic signalling and consequent neurodegeneration (Sawada 
et al., 2019). Ganglioside expression was also evaluated in GLT8D1-ALS patient fibroblasts. 
I aimed to replicate my live imaging data in a neuronal model to place my findings in the 
context of the CNS, by re-programming GLT8D1-ALS patient and control fibroblasts into 
induced neurons (iNeurons) using a previously established method (Meyer et al., 2014).  
 
GLT8D1 contains an arginine-lysine motif in its cytoplasmic domain, which likely represents a 
Golgi localisation signal (Uemura et al., 2015). To test for this, I utilised the previously 
engineered GLT8D1-eGFP constructs (see section 3.3.1) to investigate the intracellular 
localisation of GLT8D1 in HEK293 and N2A cells via immunocytochemistry, and assessed 
whether the localisation signal was affected by the presence of GLT8D1 mutations. 
Glycosyltransferase-mediated Golgi fragmentation has previously been described (Petrosyan 
and Cheng, 2013); therefore, I investigated whether the presence of an R92C mutation in 
GLT8D1 causes fragmentation of the network. Importantly, fragmentation of the Golgi is a 





5.2. Aims and objectives for investigating the effects of an R92C variant in 
GLT8D1 on ganglioside expression and Golgi fragmentation  
 
1. Confirm tetracycline-inducible expression of GLT8D1 in isogenic HEK293-GLT8D1 
cells. 
2. Examine the effect of an R92C variant in GLT8D1 on the expression of sialic acid 
residues and N-Acetylglucosamine in isogenic HEK293-GLT8D1 cell membranes. 
3. Test whether the expression of sialic acid residues and N-Acetylglucosamine is 
reduced in GLT8D1-ALS patient fibroblasts compared to non-ALS controls.  
4. Examine the effect of an R92C variant in GLT8D1 on the expression of ganglioside 
GM1 in membrane and cytoplasmic regions of isogenic HEK293-GLT8D1 cells. 
5. Generate a neuronal cell model from GLT8D1-ALS patient and control fibroblasts for 
the live imaging of ganglioside dynamics. 
6. Examine the intracellular localisation of GLT8D1 in neuronal and non-neuronal cell 
lines via transient transfection.  
7. Investigate whether an R92C variant in GLT8D1 causes Golgi fragmentation in 





5.3.1. An R92C variant in GLT8D1 reduces the expression of sialic acid and N-
Acetylglucosamine (GlcNAc) residues in isogenic HEK293-GLT8D1 cell membranes  
 
The following sections of this chapter utilised isogenic HEK293-GLT8D1 cells (see section 
3.3.2) to test whether an R92C mutation affects membrane ganglioside expression. Isogenic 
HEK293-GLT8D1 cells were induced with tetracycline for 24 hours prior to live cell imaging 
with a WGA Alexa-conjugated molecular probe. The relative expression of WT and mutant 
GLT8D1 was assessed via immunoblotting for each biological repeat of the live imaging assay. 
Immunoblotting revealed a ~50% increase in the level of the mutant protein compared to the 
WT (n=3, t-test p=0.0197) (Figure 5.1). The selection pressure was sufficient to control gene 
transcription as basal levels of GLT8D1 were not within dynamic range of detectability in the 
un-induced (tetracycline-free) cells via immunoblotting. Protein bands in the un-induced cohort 
were only made visible following overexposure of the image (see appendix 12). 
Transcriptional control is important as leakiness (uncontrolled expression of the gene of 
interest) in the system may alter the cellular biochemistry. I observed a mutation-specific 
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reduction in the fluorescence intensity of WGA in isogenic HEK293-GLT8D1 plasma 
membranes across 3 biological repeats of the live imaging assay (n=3, unpaired t-test 
p=0.0145).  
 
In addition, overexpression of WT GLT8D1 modestly enhanced the membrane fluorescence 
intensity of WGA compared to Sham-transfected control lines. All fluorescence intensity 
values were plotted as a percentage of cell area and normalised to Sham-transfected controls 
(Figure 5.2). Cells were co-labelled with a CellMaskTM plasma membrane stain for accurate 
quantification of cell area (see appendix 14). WGA fluorescence intensity was also measured 
in the absence of tetracycline, showing a modest but non-significant decline in fluorescence 







Figure 5.1. GLT8D1-R92C expression is enhanced in isogenic HEK293-GLT8D1 cell 
lines compared to WT. (A) Representative blot showing tetracycline-induced expression of 
WT and mutant GLT8D1 in isogenic HEK293-GLT8D1 cells. Relative GLT8D1 expression was 
detected using an anti-FLAG antibody; ɑ-Tubulin was used as a loading control. Molecular 
weight markers are indicated (kDa). (B) Densitometric analysis shows enhanced levels of 
GLT8D1_R92C compared to GLT8D1-WT (unpaired t-test, p<0.05; n=3). Error bars represent 
mean ±SD. (TET – tetracycline; SHAM – sham-transfected; WT – wild-type; -ve – negative; 









Figure 5.2. ALS-linked R92C mutation in GLT8D1 reduces membrane sialic acid and N-
Acetylglucosamine (GlcNAc) expression in isogenic HEK293-GLT8D1 cells. 
Representative staining of sialic acid residues in isogenic HEK293-GLT8D1 cells 
overexpressing WT (A) and mutant (B) GLT8D1. Sialic acids were labelled using a WGA 
molecular probe (green). Nuclear counterstain (Hoechst 33342) is shown in blue. Scale bar = 
50μm. (WT – wild type). (C) Fluorescence intensity of sialic acid residues at membrane of 
isogenic HEK293-GLT8D1 cells (white arrows) is reduced by ~20% when mutant (R92C) 
GLT8D1 is overexpressed compared to overexpression of WT GLT8D1. Each data point is 
expressed as a percentage of control (sham-transfected) (n=3, unpaired t-test, * p<0.05). Error 
bars represent mean ±SD.   
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5.3.2. Overexpression of mutant GLT8D1 reduces membrane and cytoplasmic GM1 
expression in isogenic HEK293-GLT8D1 cells 
 
Cholera Toxin Subunit B (CTxB) has been used as a neuroanatomical tracer for the retrograde 
labelling of ganglioside GM1. Specifically, the larger B-subunit of CTxB contains 
choleragenoid, which binds to the GM1 receptor with high affinity, facilitating entry into the cell 
via endocytosis (Singh et al., 2003, Iglesias-Bartolome et al., 2009). Isogenic HEK293-
GLT8D1 cells were labelled with a CTxB Alexa-conjugated molecular probe for measuring 
membrane and cytoplasmic GM1 expression. The relative expression of WT and mutant 
GLT8D1 was assessed via immunoblotting for each biological repeat of the live imaging assay 
and again, mutant GLT8D1 expression was modestly enhanced compared to WT. I observed 
a mutation-specific reduction in the relative fluorescence intensity of membrane GM1 in the 
mutant (R92C) line compared to the WT line across 5 biological repeats of the assay (n=5, 
paired t-test p=0.0477). I observed a similar trend in cytoplasmic GM1 expression; however, 
these were data from 4 biological repeats and did not reach statistical significance (n=4, paired 
t-test p=0.12). All fluorescence intensity values were plotted as a percentage of cell area and 
normalised to Sham-transfected controls (Figure 5.3). As previously mentioned, cells were 
co-labelled with a CellMaskTM plasma membrane stain to identify cell regions and for accurate 
quantification of cell area (see appendix 14). The additional biological repeats were 
performed in order to analyse a similar number of cells to those analysed in the WGA live 















Figure 5.3. ALS-linked R92C mutation reduces membrane GM1 expression in isogenic 
HEK293-GLT8D1 cells. Representative staining of ganglioside GM1 (white arrows) in (A) WT 
and (B) mutant cells. GM1 was labelled using a CTxB molecular probe (red). Nuclear 
counterstain (Hoechst 33342) is shown in blue. Scale bar = 50μM. (WT – wild type). (C) 
Fluorescence intensity of membrane CTxB is reduced in mutant compared to WT (~10% 
reduction), (D) but unchanged in the cytoplasmic region. Each data point is expressed as a 
percentage of control (sham-transfected) (n=5, t-test, * p<0.05). Error bars represent mean 





5.3.3. GLT8D1-ALS patient fibroblasts did not successfully re-programme into induced 
neural progenitor cells 
 
My next aim was to replicate my live imaging data in a neuronal model to place my findings in 
the context of the CNS, which is relevant to ALS. This would be achieved by the re-
programming of GLT8D1-ALS patient fibroblasts into induced neurons (iNeurons) using a 
previously established protocol (Meyer et al., 2014). I had only one GLT8D1 patient-derived 
fibroblast line available, which did not successfully re-programme. The retroviral transduction 
of fibroblasts did produce cells representative of a pre-iNPC state; however, they immediately 
reached senescence before fully differentiating into iNPCs. Slowly dividing fibroblasts do not 
usually re-programme well; therefore, I cultured the fibroblasts in EMEM as opposed to DMEM 
to test whether their growth rate improved, however this slowed the rate of division further 





Figure 5.4. Poor growth rate was possibly a key factor preventing the direct conversion 
of GLT8D1-ALS patient fibroblasts into iNeurons. The growth rate of GLT8D1-ALS patient 
fibroblasts was evaluated in EMEM and DMEM. Cells were counted once per week over three 
consecutive weeks to compare the growth rate. Cells were split twice per week and re-seeded 
at the same density. Cells cultured in EMEM (blue line) displayed a reduction in growth rate 
compared to those cultured in DMEM (red line). Neither culture media improved the rate of 
cell division to a level required for successful re-programming. No statistical analysis was 
performed.   
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5.3.4. Membrane GlcNAc and sialic acid residue expression is unchanged in GLT8D1-
ALS patient fibroblasts compared to an age- and sex-matched control  
 
Due to the inability to generate a patient-derived neuronal model of GLT8D1, I designed tools 
for the CRISPR-mediated mutagenesis of a single age- and sex-matched control fibroblast 
line, which had been successfully re-programmed previously. Efforts to introduce the GLT8D1-
R92C mutation in these cells were deferred due to the ongoing coronavirus pandemic. Instead, 
I performed live imaging of sialic acid and N-Acetylglucosamine (GlcNAc) sugar residues using 
the WGA Alexa-conjugate molecular probe, as previously described, in GLT8D1-ALS patient 
and control fibroblasts. I did not observe a significant difference in the fluorescence intensity 
between the two groups, although there was a possible trend towards reduced membrane 







Figure 5.5. Membrane sialic acid and N-Acetylglucosamine (GlcNAc) expression is 
unchanged in GLT8D1-ALS patient fibroblasts compared to an age- and sex-matched 
control. Representative staining of sialic acid residues GLT8D1-ALS patient (A) and control 
(B) fibroblasts. Sialic acids were labelled using a WGA molecular probe (green). Nuclear 
counterstain (Hoechst) is shown in blue. Scale bar = 50μm. (C) Fluorescence intensity of 
membrane sialic acid residues is unchanged in patient cells compared to controls. Each data 
point in the patient group is expressed as a percentage of control (n=3, unpaired t-test, 




5.3.5. GLT8D1 is localised to the Golgi network when transiently overexpressed in 
HEK293 and N2A cells 
 
GLT8D1 is reported to be a type II Golgi glycosyltransferase and contains an arginine-lysine 
motif in its cytoplasmic domain, which likely represents a Golgi localisation signal (Uemura et 
al., 2015). To investigate localisation to the Golgi apparatus, neuronal (N2A) and non-neuronal 
(HEK293) cells were transfected with pEGFP-N1_GLT8D1-eGFP expression vectors (see 
section 3.3.1). GLT8D1-Golgi localisation was investigated prior to the generation of isogenic 
HEK293-GLT8D1 cell lines. Cells were fixed and co-stained using JL-8 to label GFP-tagged 
proteins, and TGN-46 that usually localises to the trans-Golgi network membrane. These 
antibodies were chosen based on their previously reviewed applications in 
immunofluorescence microscopy (van Galen et al., 2014, Mukai et al., 2005). Initial imaging 
was performed using a Nikon Eclipse Ni-U microscope and this revealed possible localisation 
between GLT8D1 and the Golgi network in N2A cells (Figure 5.6a, 5.6b). This signal was 
subsequently confirmed in HEK293 and N2A cells using confocal microscopy (Figure 5.6c, 
5.6d) to look at defined focal planes and eliminate out-of-focus signals to improve reliability 
(Nichols and Evans, 2011). The images shown (Figure 5.6) were acquired following 
transfection with a pEGFP-N1_GLT8D1-WT plasmid. The presence of an R92C mutation (as 
well as the G78W mutation presented in Chapter 3) in GLT8D1 did not affect the localisation 






Figure 5.6. When transiently over-expressed in HEK293 and N2A cells, GLT8D1 is 
localised to the Golgi network. (A, B) The intracellular localisation of GLT8D1 was initially 
investigated in N2A cells via multiphoton fluorescence microscopy (top panel), and (C, D) 
subsequently confirmed in HEK293 and N2A cells using confocal microscopy (bottom panel). 
In both instances, the Golgi network was imaged using anti-TGN46 (red); GLT8D1-GFP fusion 
protein was imaged using JL8 (green). Nuclear counterstain (DAPI) is shown in blue. Scale 
bars are 50µM. (UT – un-transfected; T – transfected). Figure adapted from (Cooper-Knock 




5.3.6. Overexpression of an R92C variant in GLT8D1 causes fragmentation of the 
Golgi network in isogenic HEK293-GLT8D1 cells 
 
Fragmentation of the Golgi network is a well-documented molecular consequence of ALS 
pathophysiology, yet the underlying mechanism remains unclear. Golgi fragmentation may 
result from inhibition of vesicular trafficking between the ER and Golgi, or from the Golgi to the 
plasma membrane (Sundaramoorthy et al., 2015). I have shown that GLT8D1 is localised to 
the Golgi network in neuronal and non-neuronal cell lines, and that the presence of either a 
G78W or an R92C mutation does not affect this localisation signal (see section 5.3.5). 
Glycosyltransferases are an essential component of the Golgi trafficking machinery (Martina 
et al., 2000); therefore, I hypothesise that mutant GLT8D1 may disrupt this trafficking, leading 
to fragmentation of the network.  
 
I investigated Golgi fragmentation in isogenic HEK293-GLT8D1 cells using two antibodies that 
target different regions of the network: TGN46 that localises to the trans-Golgi, and GM130 
that localises to the cis-Golgi. My preliminary data suggest enhanced fragmentation of both 
the trans- and cis-Golgi networks in isogenic HEK293-GLT8D1 cells overexpressing an R92C 
mutation compared to WT (Figures 5.7, 5.8). Overexpression of GLT8D1-WT caused a 
modest increase in Golgi fragmentation compared to sham-transfected control cells, but this 
was more profound following overexpression of GLT8D1-R92C. Overexpressing any WT gene 
can cause a mutant phenotype (Prelich, 2012) and my data are consistent with a mutation-
specific effect. Due to the ongoing coronavirus pandemic, only two biological repeats of the 
Golgi fragmentation analysis were performed; therefore, the data presented here do not 
contain any statistical analysis. ~2000 cells were analysed for each condition per biological 
















Figure 5.7. Preliminary data suggest that overexpression of GLT8D1-R92C causes 
fragmentation of the trans-Golgi network in isogenic HEK293 cells. Representative 
staining of the trans-Golgi network using a TGN46 antibody (red) in (A) HEK293-SHAM, (B) 
HEK293-GLT8D1-WT, and (C) HEK293-GLT8D1-R92C isogenic cell lines. The image 
segments outlined with a white box (upper) are magnified to delineate Golgi morphology 
(bottom). (D) The distance between the nearest neighbouring spot (μM) was measured for 
each condition. (E) Corrected spot intensity (568nm) was plotted for each condition. Each data 
point represents a technical repeat. Nuclear counterstain (Hoechst 33342) is shown in blue. 





Figure 5.8. Preliminary data suggest that overexpression of GLT8D1-R92C causes 
fragmentation of the cis-Golgi network in isogenic HEK293 cells. Representative staining 
of the cis-Golgi network using a GM130 antibody (red) in (A) HEK293-SHAM, (B) HEK293-
GLT8D1-WT, and (C) HEK293-GLT8D1-R92C isogenic cell lines. The image segments 
outlined with a white box (upper) are magnified to delineate Golgi morphology (bottom). (D) 
The distance between the nearest neighbouring spot (μM) was measured for each condition. 
(E) Corrected spot intensity (568nm) was plotted for each condition. Each data point 
represents a technical repeat. Nuclear counterstain (Hoechst 33342) is shown in blue. Scale 
bar is 50μM. (No statistical analysis was performed; n=2).  
  
































































































































5.4. Discussion  
 
The overarching aim of the work described in this chapter was to place GLT8D1 mutations in 
the context of an ALS disease pathway. As discussed in the introductory chapter, two distinct 
glycosyltransferase-associated mechanisms are prominent in neurodegenerative disorders: 
ganglioside synthesis and O-GlcNAcylation (Moll et al., 2020). I focused on the dysregulation 
of ganglioside biosynthesis, as this pathway encompasses a broader range of 
glycosyltransferase enzymes compared to O-GlcNAcylation, which is a well-characterised 
post-translational modification mechanism involving glycosyltransferases OGT and EOGT 
(Yang and Qian, 2017). To place GLT8D1 mutations in the context of an ALS disease 
pathway, live imaging of gangliosides was performed in isogenic HEK293 cell lines 
overexpressing WT and mutant GLT8D1. To replicate my findings into a neuronal model, I 
attempted to re-programme GLT8D1-ALS patient fibroblasts into induced neurons (iNeurons) 
using a previously established method (Meyer et al., 2014). Ganglioside biosynthesis occurs 
predominantly in the Golgi network (Maccioni et al., 2011); therefore, I investigated whether 
GLT8D1 localises to the Golgi in HEK293 and N2A cells. I subsequently investigated 
glycosyltransferase-mediated Golgi fragmentation in isogenic HEK293-GLT8D1 lines as a 
potential mechanism for perturbed ganglioside biosynthesis.   
 
 
5.4.1. An R92C variant in GLT8D1 reduces the expression of sialic acid and N-
Acetylglucosamine (GlcNAc) residues in isogenic HEK293 cell membranes  
 
Isogenic HEK293-GLT8D1 cells were used to characterise the early biochemical effects of the 
R92C variant in GLT8D1 through live cell imaging. In order to determine whether these early 
effects were mutation-specific and not due to enhanced levels of the mutant protein, 
immunoblotting was used to evaluate the relative expression of WT and mutant GLT8D1. 
Immunoblotting revealed that mutant GLT8D1 was expressed at a higher level than the WT, 
which may present a significant limitation. It might suggest that observed effects are due to 
enhanced expression of the mutant protein compared to WT (~50% increase). The double 
band in the mutant blot likely represents post-translational modification of GLT8D1 (Figure 
5.1). Post-translational modifications are essential to the regulation of protein folding, their 
interaction with ligands and, in the case of enzymes, their catalytic activity. Common forms of 
post-translational modifications are phosphorylation and glycosylation (see Chapter 1), both 
of which are essential for regulating the activity of enzymes. I have previously shown that a 
GLT8D1-R92C mutation reduces enzymatic activity, which was expected given that the 
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mutation is proximal to the substrate binding site (Cooper-Knock et al., 2019) (see Chapter 3). 
Therefore, it is possible that the GLT8D1-R92C protein is not undergoing the necessary 
phosphorylation or glycosylation required for proper enzymatic function, which may also cause 
protein misfolding, hence the observed double band in the blot. In the future, I plan to test for 
post-translational modification by treating the GLT8D1-R92C cell lysates with enzymes prior 
to immunoblotting. Such enzymes include alkaline phosphatase to remove phosphates (Seo 
and Lee, 2004), or PNGase F to remove N-linked oligosaccharides (Suzuki et al., 1995). 
Furthermore, my immunoblotting shows that selection pressure was maintained to a high 
standard, suggesting a limited effect on the cellular biochemistry, which was consistent 
between all isogenic HEK293-GLT8D1 cell lines prior to performing the live imaging assays. 
 
Lectins are carbohydrate- and glycoconjugate-binding proteins that are widely distributed 
throughout nature, whose primary function is to facilitate cell-to-cell contact. In vertebrates, 
there are two main classes of lectins: integral lectins of membranes, and soluble lectins 
present in intra and intercellular fluids. Lectins have a plethora of roles in animals including 
endocytosis, intracellular translocation of glycoproteins (Yamashita et al., 1999), 
glycoconjugate binding, apoptotic processes (Kilpatrick, 2002), defence mechanisms against 
microorganisms, as well as regulating the processes of cell adhesion and migration. In 
vertebrates, integral lectins facilitate the binding of glycoconjugates to cell membranes or 
vesicles, resulting in endocytosis or intracellular translocation (Sharon and Lis, 2004). WGA 
is a widely used lectin that binds specifically to N-acetyl-D-glucosamine and N-
acetylneuraminic acid (sialic acid) residues, both of which are ubiquitously expressed in 
neuronal cell membranes. WGA has also been demonstrated to interact with sialic acid 
residues on glyconjugates and oligosaccharides (Iqbal et al., 2019). The neuronal specificity 
of WGA makes it a useful tracer for the tracking of neural connections in all regions of the 
brain (Yoshihara, 2002).  
 
In the present study, WGA provided an indirect measure of plasma membrane integrity of 
isogenic HEK293 cells overexpressing WT and mutant GLT8D1. Membrane WGA expression 
was significantly reduced through overexpression of mutant GLT8D1 compared to WT, 
indicating a mutation-specific effect on the integrity of the plasma membrane (Figure 5.2). 
This was expected given that I previously observed enhanced levels of LDH in the culture 
media of cells transfected with GLT8D1-R92C plasmids compared to WT, which was indicative 
of reduced plasma membrane integrity (see section 3.3.6). It would be important to confirm 
this result via immunoblotting. These results suggest that an R92C mutation may alter the 
glycosylation profile of isogenic HEK293-GLT8D1 cells. However, to fully answer this 
question, lectin blotting could be used for the proteomic analysis of glycosylation patterns 
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within whole cell extracts (Cao et al., 2013) following overexpression of WT and mutant 
GLT8D1. Future work could utilise a panel of lectins including Maackia amurensis II and 
Sambucus nigra, both of which interact with N-Acetylneuraminic acid, the most prominently 
expressed sialic acid in mammalian cells (Wang and Brand-Miller, 2003).  
 
WGA may also provide an indirect measure of membrane ganglioside expression, as 
gangliosides contain a variable number of negatively charged sialic acid residues (Frey and 
Lee, 2013). However, to my knowledge, WGA has not previously been used as a ganglioside 
marker. Assuming the role of WGA as an indirect marker for ganglioside expression, I 
subsequently tested whether expression levels of ganglioside GM1 were affected in a similar 
way. GM1 was chosen based on its association with membrane lipid rafts, which are key 
determinants of neurotrophic signalling (see section 5.4.2). Moreover, this ganglioside is 
essential to maintaining neuronal function to prevent neurodegeneration (Chiricozzi et al., 
2020) and is strongly associated with neurodegenerative disorders (see Chapter 1).       
 
 
5.4.2. Overexpression of mutant GLT8D1 reduces membrane and cytoplasmic GM1 
expression in isogenic HEK293 cells 
 
Whilst ALS is not considered an autoimmune disorder, immunological phenomena are 
suggested to be involved. Over the past few decades, numerous studies have described the 
detection of antibodies against a variety of gangliosides in ALS patients, but with widely 
differing frequencies and titres (Pestronk et al., 1989, Lamb and Patten, 1991, Yuki et al., 
2014). As previously mentioned, it is noteworthy that autoantibodies against specific 
gangliosides produce an inflammatory disease of spinal motor neurons known as multifocal 
motor neuropathy with conduction block (Harschnitz et al., 2014), which is an important 
differential diagnosis for ALS (Cooper-Knock et al., 2019). However, a more recent study 
reported no statistically significant difference in the frequency of anti-ganglioside antibodies in 
ALS patients compared to controls (Kollewe et al., 2015). Although the role of anti-ganglioside 
antibodies in ALS is a controversial topic of debate, altered levels of gangliosides are widely 
reported in animal models of ALS and in post-mortem CNS tissue from ALS patients (Dodge 
et al., 2015, Ariga, 2014).  
 
Ganglioside GM1 is highly abundant in the nervous system and is localised to MLR, which are 
membrane micro-domains enriched in cholesterol and sphingolipids, with important roles in 
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cell signalling (Vajn et al., 2013). GM1 is internalised via caveolae, which are a type of lipid 
raft domain in the plasma membrane (Crespo et al., 2008). Gangliosides, particularly GM1, 
are shown to be responsible for the trafficking and maintenance of these caveolae domains 
(Singh et al., 2010). The association of GM1 with MLR makes this ganglioside a useful target 
for measuring lipid raft integrity. Disrupted MLR are associated with impaired neurotrophic 
signalling and consequent neurodegeneration (Sawada et al., 2019). Cholera toxin is a protein 
enterotoxin that belongs to the family of AB5 toxins and is capable of binding up to five 
molecules of GM1 at a time via its B-subunits. The CTxB-GM1 complex undergoes retrograde 
trafficking from the plasma membrane to the trans-Golgi network. It is then transported through 
the Golgi and delivered to the ER (Fujinaga et al., 2003). Once in the ER, the A-subunit 
dissociates from the B-subunit, unfolding the toxin and enabling retro-translocation to the 
cytosol to induce disease (Chinnapen et al., 2007). The CTxB molecular probe utilised in my 
study was completely free of the toxic A-subunit.  
 
In the present study, I observed a mutation-specific reduction in the fluorescence intensity of 
CTxB in the membrane of isogenic HEK293-GLT8D1 cells (Figure 5.3). Given the 
aforementioned role of ganglioside GM1 in the intracellular trafficking of cholera toxin, I also 
measured the relative expression of CTxB in cytoplasmic cell regions. Whilst a similar trend 
in fluorescence intensity was apparent, I did not observe a significant mutation-specific effect. 
I was unaware of the mechanisms regarding the internalisation of CTxB when performing the 
initial live imaging assay, hence the fewer biological repeats in cytoplasmic staining compared 
to membrane staining.  
 
CTxB and WGA have previously been used as probes for gangliosides GM1 and GM3, 
respectively; however, they have been shown to form cross-links with gangliosides, thus 
modifying ganglioside distribution and behaviour in the plasma membrane (Hammond et al., 
2005, Lingwood et al., 2008, Kaiser et al., 2009). Moreover, the specificity of these probes is 
under debate. A study using mouse embryonic neuroepithelial cells found that GM1 levels 
were barely detectable through thin-layer chromatography and immunoblotting. However, flow 
cytometry revealed that 80% of these cells were CTxB positive, indicating that the high affinity 
interaction between CTxB and GM1 in these cells may overestimate GM1 expression 
(Yanagisawa et al., 2006). Therefore, biochemical analysis such as immunoblotting should be 
performed in conjunction with CTxB cell staining to avoid mischaracterisation of the 
ganglioside species. This perhaps is not a limitation of my study, as I compared relative GM1 
levels rather than attempting to quantify GM1 expression exactly. My data indicate that GM1 
is expressed in HEK293 cells, which is inconsistent with a previous report that used high-
performance thin layer chromatography and indirect immunofluorescence to conclude that 
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GM1 is not expressed in this cell line (Cho, 2010). However, more recent studies using similar 
CTxB molecular probes have shown GM1 to be expressed in HEK293 cells (Sano et al., 2014, 
Fernandez-Perez et al., 2017), supporting the validity of my data. Recently, fluorescent 
analogues of GM1 and GM3, which were shown to behave similarly to their native 
counterparts, were synthesised to measure the dynamic behaviour of these gangliosides in 
living cells (Komura et al., 2016). Future use of these fluorescent analogues may enable more 
sensitive studies into the effect of ALS-linked GLT8D1 mutations on ganglioside trafficking.  
 
 
5.4.3. GLT8D1-ALS patient fibroblasts did not successfully re-programme into induced 
neural progenitor cells 
 
The next aim of my project was to replicate live cell imaging data in a neuronal model to place 
my findings in the context of the CNS. Induced neurons (iNeurons) can be generated from the 
direct re-programming of human fibroblasts. Examples include the work of Deng and 
colleagues who transformed somatic fibroblasts into a chemically induced intermediate XEN-
like state (a state that resembles extra-embryonic endoderm), bypassing the pluripotent stage 
(Li et al., 2017). This is a new and relatively untested re-programming method with narrow 
concentration windows and specific application durations required for small molecules to be 
effective. Therefore, I did not explore this method, but rather utilised methods previously 
developed by a member of our lab (Meyer et al., 2014).  
 
iNeuron technology can provide a fast and simple method for the generation of specific 
neuronal subtypes. Moreover, this technology may circumvent problems such as uncontrolled 
cell differentiation and tumour formation, which are associated with human induced pluripotent 
stem cells (hiPSCs) (Li et al., 2017). I had fibroblasts available from a single ALS patient with 
an R92C mutation; however, attempts to generate a patient-derived neuronal model were 
unsuccessful. Following retroviral transduction, a small proportion of cells successfully 
converted to a pre-iNPC state, but their growth rate soon declined and they reached relatively 
premature senescence. I was therefore unable to generate a pure population of cells 
resembling an iNPC lineage. When cultured in DMEM, the GLT8D1-ALS patient fibroblasts 
demonstrated a relatively slow rate of cell division for cells of this type, which usually suggests 
that they will not re-programme well. Almost all fibroblasts grow more quickly in DMEM, as 
this media contains almost twice the concentration of amino acids and four times the amount 
of vitamins as EMEM. By example, the amino acid arginine has been shown to enhance 
fibroblast proliferation and reduce apoptosis in vitro (Fujiwara et al., 2014). However, some 
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fibroblasts do exhibit a higher growth rate in EMEM, possibly due to the metabolic signature 
of the cells. Therefore, I tested the growth rate of the fibroblasts in DMEM vs EMEM over a 
period of three consecutive weeks, hypothesising that if the growth rate improved, they may 
re-programme successfully. Unfortunately, the growth rate declined further in EMEM (Figure 
5.4). It is possible that the R92C mutation is driving metabolic dysfunction; therefore, it would 
be interesting to investigate defective energy metabolism in this fibroblast line (Zhang et al., 
2012).  
 
Ageing is a leading risk factor for the development of neurodegenerative diseases such as 
ALS (Niccoli et al., 2017). It is important to recapitulate age-related characteristics by using 
motor neurons at relevant ages. Directly converted motor neurons have the advantage of 
preserving ageing-associated features from fibroblast donors, such as extensive DNA 
damage, loss of heterochromatin, and nuclear organization. An alternative method of 
generating motor neurons is via a pluripotent stem cell lineage, which resets the ageing 
phenotype (Tang et al., 2017). Therefore, directly reprogrammed motor neurons may be more 
suitable for modelling the late-onset pathogenesis of diseases such as ALS. Moreover, 
iAstrocytes derived from the direct conversion of ALS patient fibroblasts are selectively toxic 
to motor neurons (Haidet-Phillips et al., 2011, Meyer et al., 2014). This astrocyte-mediated 
motor neuron toxicity is lost when using the iPSC model. Due to these complications, I was 
unable to investigate whether iAstrocytes carrying a GLT8D1 mutation are selectively toxic to 
motor neurons. I do, however, have an age- and sex-matched control fibroblast line available, 
which has successfully been re-programmed into iNPCs previously. Fibroblasts were not 
available from additional patients with GLT8D1-ALS. I have additional fibroblasts from an 
individual with an R92C mutation; however, this patient has not been diagnosed with ALS, 
therefore was not included for experimentation. Future work will aim to utilise CRISPR/Cas9 
genome editing to introduce the R92C mutation into the single age- and sex-matched control 
fibroblast line. I have designed gRNAs to target regions proximal to the R92C mutation, but 
experiments were postponed due to the ongoing coronavirus pandemic.  
 
 
5.4.4. Membrane GlcNAc and sialic acid residue expression is unchanged in GLT8D1-
ALS patient fibroblasts compared to an age- and sex-matched control  
 
Due to the inability to directly convert GLT8D1-ALS patient fibroblasts into iNeurons, I decided 
to investigate sialic acid expression in the fibroblasts and compare with age- and sex-matched 
controls to place my findings in the context of the patients. Whilst I did observe a trend towards 
decreased sialic acid expression in the patient line, this experiment was limited by the lack of 
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available age- and sex-matched controls (Figure 5.5). Future experiments should include 
fibroblasts from at least three non-ALS controls, as well as from patients with mutations in 
other known ALS genes.  
 
Following on from my unsuccessful attempts to generate an iNeuron model, I attempted 
overexpressing WT and mutant GLT8D1 in mouse primary cortical neurons via nucleofection 
using a Lonza 4D NucleofectorTM System. The aim of this experiment was to test whether 
ALS-linked GLT8D1 mutations impair neurotrophic signalling via the disruption of MLR in the 
context of the CNS. Unfortunately, the neurons did not survive the transfection process and 
subsequently failed to adhere or develop neurites. For future work, the manufacturer 
recommends a recovery step immediately after nucleofection, if the observed mortality rate is 
high. This requires adding pre-equilibrated recovery medium to the cuvette (as opposed to the 
standard culture media), followed by a 5-10-minute incubation at 37°C, 5% CO2 prior to 
seeding (AmaxaTM 4D-NucleofectorTM Protocol for Primary Mammalian Neurons). I chose to 
use primary neurons because they are not tumour-derived, and therefore more accurately 
recapitulate the properties of neuronal cells in vivo (Gordon et al., 2013). I planned to confirm 
overexpression of mutant and WT GLT8D1 via immunoblotting, and assess the integrity of 
MLR using the live imaging techniques previously described in this chapter. I then planned to 
measure neurotrophic signalling by initially treating the neurons with neurotrophic factors such 
as BDNF, followed by an expression profile analysis of neurotrophin-mediated signalling 
targets including: P-TrkB, P-Akt, and P-ERK1/2 (Head et al., 2011). This would identify 
whether mutant GLT8D1 alters the expression of key receptors required for neurotrophic 
signalling, which may help to identify pathological mechanisms linking GLT8D1 mutations to 
the loss of motor neurons in ALS.  
 
 
5.4.5. GLT8D1 is localised to the Golgi network when overexpressed in HEK293 and 
N2A cells 
 
I observed localisation of GLT8D1 to the Golgi network in HEK293 and N2A cells (Figure 5.6); 
the presence of G78W and R92C mutations in GLT8D1 did not affect the observed localisation 
signal (see appendix 15). This suggests that the G78W and R92C mutation sites are not 
necessary for Golgi retention, which was expected given that the mutations are not localised 
to the cytoplasmic domain that contains the arginine-lysine motif representative of a Golgi 
localisation signal (Uemura et al., 2015) (Figure 1.4). Attempts to investigate GLT8D1-Golgi 
localisation via live-cell imaging were unsuccessful due to an undetectable eGFP signal. A 
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limitation of GFP is that it may lose its fluorescence during fixation (Swenson et al., 2007), 
hence the need for the JL-8 antibody. As previously discussed, GFP-tagging at either the N- 
or C-terminal domain can influence co-localisation (see section 3.4.1). Therefore, it is 
important to check the localisation of the endogenous protein with an antibody directed against 
the protein of interest. However, none of the available GLT8D1 antibodies demonstrated 
specificity in vitro (see appendix 16). Understanding protein subcellular localisation is 
essential to investigating protein function, cellular organisation, and identifying new disease 
pathways. For example, in the case of GLT8D1, the mutated forms of the protein may lead to 
dysfunction and/or fragmentation of the Golgi network, which is already proposed to be an 
early event in ALS (Sundaramoorthy et al., 2015, Gonatas et al., 1992). Golgi fragmentation 
was subsequently investigated as a potential GLT8D1-linked ALS pathogenic mechanism and 
is discussed in the following section.  
 
5.4.6. Overexpression of an R92C variant in GLT8D1 may cause fragmentation of the 
Golgi network in HEK293 cells 
 
The Golgi is an essential membrane-bound organelle that functions as a protein modification 
centre in the secretory pathway. It is comprised of three functional compartments: the cis-
Golgi, which receives newly synthesised proteins and lipids from the ER; the medial-Golgi, 
which is the site of post-translational modification; and the trans-Golgi, which dispatches 
proteins and lipids to distinct subcellular destinations (Marsh and Howell, 2002, Brandizzi and 
Barlowe, 2013). Ganglioside biosynthesis is compartmentalised in the Golgi network, and is 
organised in distinct units formed by associations of particular glycosyltransferases, which 
concentrate in different Golgi sub-compartments (Petrosyan et al., 2012). The cytoplasmic tail 
of glycosyltransferases determines Golgi localisation (Uliana et al., 2006, Ali et al., 2012). 
These cytoplasmic tails also bind to the cytoskeleton to stabilise the Golgi (Yamaguchi and 
Fukuda, 1995, Wassler et al., 2001). Studies have shown that glycosyltransferases are 
involved in the maintenance of the Golgi architecture. For example, a mutation of the 
membrane-spanning domain of N-acetylglucosaminyltransferase was shown to cause a loss 
of Golgi structure in HeLa cells (Nilsson et al., 1996). More recently, a high abundance of 
glycosyltransferases in the Golgi was shown to positively correlate with fragmentation of this 
organelle (Petrosyan and Cheng, 2013). The evidence for glycosyltransferase-mediated Golgi 
fragmentation, concurrent with the pathogenic role of Golgi fragmentation in ALS, formed the 




Golgi pathology is a feature of neurodegenerative disorders such as Alzheimer's (Sun et al., 
2008), Parkinson's (Fujita et al., 2006), and ALS (Sundaramoorthy et al., 2015). Importantly, 
Golgi fragmentation has been shown to occur early in the disease stage prior to apoptosis 
(Gosavi et al., 2002, Liazoghli et al., 2005, Atkin et al., 2014, van Dis et al., 2014), suggesting 
that fragmentation of the network could be a trigger for neurodegeneration rather than a 
consequence of the disease. Golgi fragmentation was first identified in ALS-patient motor 
neurons in 1992, appearing as disconnected punctate structures (Gonatas et al., 1992). Since 
then, Golgi fragmentation has been identified in up to 70% of fALS patient motor neurons 
(Fujita et al., 2000, Ito et al., 2011) and 10-50% of sALS patient motor neurons (Gonatas et 
al., 2006, van Dis et al., 2014) bearing SOD1, FUS or OPTN mutations. Larger human motor 
neurons of the cerebral cortex and anterior horn appear to undergo more prominent Golgi 
fragmentation (Fujita et al., 1999, Fujita et al., 2000). Precedent exists for a link between the 
cytoplasmic mislocalisation of TDP-43 and Golgi fragmentation (Fujita et al., 2008). Indeed, 
Golgi fragmentation has been observed in the transgenic rats expressing mutant TDP-43M337V 
(Tong et al., 2012), as well as in the SOD1G93A ALS mouse model (Mourelatos et al., 1996). 
Moreover, in the SOD1G93A model, Golgi fragmentation was shown to occur prior to the 
formation of SOD1 inclusions and neuromuscular denervation, suggesting it occurs upstream 
in the pathogenesis of ALS (van Dis et al., 2014). More recently, ALS-linked mutations in 
UBQLN2 were shown to inhibit protein transport from the ER to the Golgi in neuronal cells 
concurrent with fragmentation of both organelles (Halloran et al., 2019).  
 
The causes and consequences of Golgi fragmentation in ALS are not well understood. A 
possible cause of Golgi fragmentation is the inhibition of bi-directional protein trafficking 
between the ER and the Golgi (Nassif et al., 2010). Similarly, if vesicular trafficking from the 
Golgi to the plasma membrane is inhibited, proteins accumulate within the Golgi which, if 
prolonged, can cause fragmentation (Persson et al., 1992, Zolov and Lupashin, 2005, Zhou 
et al., 2013). Vesicular trafficking has been shown to be inhibited in cells expressing the ALS-
associated mutant proteins: SOD1, TDP-43, FUS and OPTN (Sundaramoorthy et al., 2015, 
Atkin et al., 2014, Soo et al., 2015). OPTN is involved in the maintenance of Golgi architecture, 
and functions specifically in membrane trafficking and exocytosis via interaction with myosin 
VI and Rab8 (Sahlender et al., 2005). It has also been shown to mediate post-Golgi trafficking 
to lysosomes, which is dependent on the Rab8-OPTN-htt complex (del Toro et al., 2009). 
Interestingly, FUS has been reported to interact with both myosin V1 (Takarada et al., 2009) 
and myosin V (Yoshimura et al., 2006). Therefore, impairment of intracellular trafficking of the 
complex including OPTN and/or FUS may cause pathological inclusions in ALS (Maruyama 
et al., 2010). Golgi fragmentation in ALS may also be linked to the disruption of autophagy. 
Autophagy is a natural regeneration process characterised by the proteolytic degradation of 
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cytosolic components at the lysosome (Glick et al., 2010). The roles of autophagy in ALS are 
unclear; however, multiple discovered ALS genes have been associated with dysregulated 
autophagy (Nguyen et al., 2019). That said, the association between glycosyltransferases and 
autophagy is not well founded.  
 
Brefeldin A is a fungal metabolite, which inhibits protein transport from the ER to the Golgi, 
inducing fragmentation of the Golgi cisternae. This process is reversible, making Brefeldin A 
a useful tool for the study of Golgi biogenesis (Langhans et al., 2007). Pharmacological 
induction of Golgi fragmentation with Brefeldin A has been shown to increase autophagosome 
biogenesis and induce the accumulation of autophagosomes (Naydenov et al., 2012). Finally, 
Golgi fragmentation in ALS may be associated with dysregulated axonal homeostasis 
(Sundaramoorthy et al., 2015). Motor neurons contain long axons that require biosynthetic 
output from the ER and Golgi for the maintenance of essential features, such as 
synaptogenesis, synaptic plasticity, and neurite outgrowth (Horton and Ehlers, 2004, Tuck and 
Cavalli, 2010). Proteins and lipids must travel large distances along axons; however, they are 
also synthesised locally within neurites. Brefeldin A-induced Golgi fragmentation has been 
shown to reduce synaptic potentiation (Broutman and Baudry, 2001) and axonal outgrowth 
(Jareb and Banker, 1997), highlighting the importance of the secretory pathway in neuronal 
integrity.  
 
My preliminary data indicate that an R92C mutation in GLT8D1 causes fragmentation of the 
cis- and trans-Golgi network in isogenic HEK293-GLT8D1 cell lines. These results are 
concurrent with a possible reduction in the relative fluorescence intensity of Golgi markers 
GM130 and TGN46 (Figures 5.7, 5.8). The most crucial aim moving forward is to obtain three 
biological repeats of these data, after which it would be interesting to investigate further the 
role of GLT8D1 in the stabilisation of the Golgi architecture. Golgi membranes are organised 
as stacks of multiple flat cisternae, which are further linked into a ribbon-like structure located 
in the perinuclear region (Klumperman, 2011). My images of the Golgi do not depict this 
ribbon-like structure because they were taken at 40x magnification. At a higher magnification, 
these structures would likely be more apparent. It would be interesting to test whether 
pharmacological induction of Golgi fragmentation using Brefeldin A is rescued following 
expression of WT GLT8D1 compared to its mutant form. This would help to determine whether 
GLT8D1 plays a role in the maintenance of the Golgi architecture.  
 
To my knowledge, the degree of Golgi fragmentation as a predictor for the severity of 
neurotoxicity via MLR disruption has not previously been explored. Of note, it has been 
proposed that the association of microtubules with exposed MLR could mediate fragmentation 
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of the trans-Golgi cisternae (Rodriguez-Boulan and Musch, 2005). It would be interesting to 
investigate whether the severity of Golgi fragmentation correlates with dysregulated MLR-
induced neurotoxicity. This could be tested via a dose-dependent treatment of primary neuron 
cultures with Brefeldin A to induce varying degrees of Golgi fragmentation. I would then test 
for a dose-dependent effect of Brefeldin A on the disruption of MLR using techniques 
previously described in this chapter. Neurotoxicity could be measured using techniques such 
as a multielectrode array (Bradley and Strock, 2019) or a neurite outgrowth assay (Filous and 





In summary, I have shown that an ALS-linked R92C mutation correlates with a reduction in 
the MLR integrity of isogenic HEK293-GLT8D1 cell lines, evidenced by mutation-specific 
reductions in membrane WGA and GM1 expression. This discovery places ganglioside 
metabolism upstream in the pathogenesis of GLT8D1-ALS. Gangliosides are associated with 
MLR integrity, and are responsible for the maintenance of caveolae. I explore novel ALS-
associated mutations in enhancers linked to the expression of caveolins 1 and 2 in Chapter 6. 
It is possible that GLT8D1 and caveolins 1 and 2 share a common pathophysiological pathway 
in ALS. Ganglioside biosynthesis occurs in the Golgi, and dysregulated trafficking of Golgi 
secretory proteins is associated with fragmentation of the network. I have shown that GLT8D1 
localises to the Golgi when transiently overexpressed in neuronal and non-neuronal cell lines, 
and my preliminary data suggest that the GLT8D1-R92C mutation causes fragmentation of 
the cis- and trans-Golgi network in isogenic HEK293-GLT8D1 cell lines. Future work should 
focus on completing a third biological repeat of the Golgi fragmentation analysis, as well as 
comparing fragmentation with transiently transfected models to confirm the validity of my 
findings. Moreover, it would be interesting to test whether chemically induced Golgi 








This chapter is an extended version of work currently under review (available at: 
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3606796). Experimental work 
presented within this chapter was performed in collaboration with Dr John Franklin, Helia 
Ghahremani Nezhad, and Samantha Allen. Genome-wide association studies suggest a 
significant proportion of missing heritability is distributed throughout non-coding chromosomal 
regions (van Rheenen et al., 2016). Indeed, 98% of all sequence (Elgar and Vavouri, 2008) 
and 85% of human DNA under evolutionary constraint (Ward and Kellis, 2012) is non-coding, 
suggesting an important role in all aspects of cellular function. To date, genetic discoveries 
within the non-coding genome have been limited by a shortage of appropriate methodology.  
Non-coding regulatory sequence includes enhancers, which are cis-acting DNA sequences 
that modulate expression of target genes primarily through the binding of transcription factors 
(TFs) (Koch et al., 2011). Physical interaction between an enhancer and the promoter of the 
target gene is mediated by DNA looping (Pennacchio et al., 2013). Recently, a novel pipeline 
for the identification of disease-associated variation within enhancers was designed (see 
section 1.8). Variants were aggregated according to function, filtered based on evolutionary 
conservation (Hujoel et al., 2019), and collapsed into a single burden test (Cirulli and 
Goldstein, 2010). Application of this pipeline in an unbiased genetic screen identified 
significant ALS-associated variation within enhancers linked to the expression of caveolin 1 
(CAV1) and caveolin 2 (CAV2) (see section 1.8).  
CAV1 and CAV2 are expressed together in a hetero-oligomeric complex (de Almeida, 2017) 
within membrane lipid rafts (MLR), and have a key role in the organisation of cell signalling 
(Sawada et al., 2019, Schmick and Bastiaens, 2014). CAV1 activity promotes neurotrophic 
signalling, leading to enhanced neuronal survival (Head et al., 2011, Mandyam et al., 2017). 
In contrast, loss of CAV1 accelerates neurodegeneration (Head et al., 2011, Head et al., 
2010). Finally, neuronal-targeted overexpression of CAV1 was shown to improve survival and 
reduce motor neuron death in the SOD1G93A ALS mouse model (Sawada et al., 2019) and is 
being developed as a novel therapy for ALS (www.cavogene.com).  
Burden testing derives power from aggregating mutations into a single statistical test; 
therefore, experimental evaluation is necessary to determine which individual mutations are 
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pathogenic. Indeed, it is likely that a significant proportion of variants are not pathogenic (Lee 
et al., 2012). To experimentally evaluate CAV1/CAV2-enhancer mutations, I acquired patient-
derived lymphoblastoid cells (LCLs) from two patients carrying ALS-associated CAV1/CAV2-
enhancer variants: CAV-ALS 1: chr7:116222625T>C; and CAV-ALS 2: chr7:115994269:C>T. 
LCLs are generated through infecting peripheral blood lymphocytes with Epstein Barr Virus. 
This process has been shown to immortalise human resting B cells in vitro, giving rise to an 
actively proliferating B cell population (Neitzel, 1986). Using these lines, I investigated 
CAV1/CAV2 expression at the mRNA and protein level. Reduced CAV1/CAV2 function is 
proposed to be toxic via disruption of MLR, leading to impaired cell signalling (Sawada et al., 
2019). Therefore, I tested whether ALS associated enhancer variants impair MLR formation. 
MLR integrity was measured by expression of GM1 gangliosides, as labelled by CTxB (Aman 
et al., 2001) (refer to section 5.3.2). 
Enhancers often act in a cell and tissue-specific manner (Andersson et al., 2014, Heinz et al., 
2015) and therefore LCLs may not be representative of expression changes in the CNS.  
However, CAV1/CAV2-enhancers were derived in a tissue-agnostic manner; therefore, I 
hypothesised that expression changes may be replicated across multiple cell types. To 
validate my findings in a CNS relevant cell type, I subsequently investigated CAV1/CAV2 
mRNA expression in differentiated SH-SY5Y cells, following CRISPR/Cas9 perturbation 
proximate to the chr7:116222625T>C patient-mutation.  
CRISPR/Cas9 is a naturally occurring bacterial defence mechanism that has been repurposed 
as a powerful RNA-guided DNA targeting platform for genome editing (Jiang and Doudna, 
2017). This technology can be used to precisely manipulate genomic sequences and relies 
on two main components: a Cas9 endonuclease, and an associated guide RNA (gRNA). 
gRNAs are duplexes constituting a crisprRNA (crRNA), which is a nucleotide sequence 
complementary to the target DNA sequence, and a tracrRNA, which acts as a binding scaffold 
for the Cas9 nuclease (Cong et al., 2013, Mali et al., 2013). The gRNA recognises the target 
DNA sequence of interest, directing the associated Cas9 endonuclease to transiently bind and 
induce sequence-specific cleavage in the form of a double strand break (DSB). Cas9 will not 
bind to or cleave the target DNA sequence without the presence of a downstream protospacer 
adjacent motif (PAM) (Mojica et al., 2009). The most commonly used Cas9 
from Streptococcus pyogenes (spCas9) recognizes PAM sites that contain a triplet NGG 
(where ‘N’ represents any nucleotide base). PAM sites are located immediately 3’ of the target 
sequence, and Cas9 endonucleases can be changed depending on which PAM sites are 
available (Jinek et al., 2012). The binding of Cas9 promotes unwinding of the two DNA strands 
immediately upstream of the PAM site, and the spacer sequence of the crRNA then binds with 
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the unwound DNA to form an RNA-DNA heteroduplex to initiate a DSB (Sternberg et al., 
2014). This DSB can subsequently be repaired by non-homologous DNA-end joining (NHEJ) 
or via homologous recombination (HR). The majority (up to 90%) of DSBs are repaired by 
NHEJ following cleavage by Cas9 (Liu et al., 2018). The NHEJ repair process is error prone, 
and thus random indels (insertion or deletion mutations) of unpredictable length may be 
introduced, disrupting gene function (Tuladhar et al., 2019). DSB repair via HR is less error 
prone and relies on a homologous donor template DNA to repair the break. Under 
physiological conditions, this usually comes from the sister chromatid. However, in 
CRISPR/Cas9 editing, this pathway can be leveraged to introduce specific desired sequence 
changes via the introduction of a pre-designed double- or single-stranded oligonucleotide 
template (Liu et al., 2018). 
CRISPR/Cas9 editing efficiency is usually estimated by measuring the proportion of an edited 
population of cells in which an indel mutation has been introduced. There are numerous ways 
of evaluating CRISPR editing efficiency. In the current project, I utilised two similar platforms 
that rely on Sanger sequencing trace data: TIDE (Tracking of Indels by DEcomposition) and 
ICE (Inference of CRISPR Edits). Both provide a simple, rapid and cost-effective strategy that 
accurately quantifies the editing efficiency of indels in a targeted cohort of cells, and predicts 
similar editing efficiencies to that of next generation sequencing (the gold standard for 
measurement of indel efficiencies) (Sentmanat et al., 2018). Both platforms require two 
parallel PCR reactions to amplify an approximate 400bp region around the predicted Cas9 cut 
site, followed by Sanger sequencing. The two sequencing traces that are generated are 
analysed using specially designed software (TIDE: available at http://tide.nki.nl; ICE: available 
at https://ice.synthego.com/#/) (Brinkman et al., 2014). TIDE is a well-established platform that 
has been shown to be superior to gel electrophoresis based assays such as the commonly 
used T7 endonuclease 1 mismatch-detection assay, however requires careful adjustment of 
specific parameters (e.g. alignment window, p-value, decomposition window) to obtain 
meaningful results. Furthermore, it can only accurately predict indels of a limited size of up to 
10bp (Brinkman et al., 2014, Sentmanat et al., 2018). Therefore, it is important to compare 
against alternative platforms to validate CRISPR editing efficiencies. ICE is a more recently 





6.2. Aims and objectives for experimentally evaluating ALS-associated 
CAV1/CAV2 enhancer variants 
1. Investigate the relative expression of CAV1 and CAV2 in patient-derived LCLs carrying 
ALS-associated CAV1/CAV2 enhancer variants via qRT-PCR and immunoblotting. 
2. Investigate the effect of identified enhancer mutations on MLR integrity in patient-derived 
LCLs via live cell imaging with CTxB. 
3. Use CRISPR/Cas9 genome editing to introduce an indel mutation proximal to the 
discovered chr7:116222625T>C (CAV-ALS 1) patient mutation site in SH-SY5Y cells. 
4. Evaluate CAV1/CAV2 expression in differentiated SH-SY5Y cells carrying a CAV1/CAV2 







6.3.1. CAV1 and CAV2 expression is reduced in patient-derived cells carrying an ALS-
associated enhancer variant 
Reduced CAV1 expression is toxic to neurons (Head et al., 2011, Head et al., 2010); therefore, 
I measured CAV1/CAV2 expression at the mRNA and protein level in LCLs derived from ALS 
patients carrying CAV1/CAV2 enhancer variants: chr7:116222625T>C (CAV-ALS 1) and 
chr7:115994269:C>T (CAV-ALS 2). Controls consisted of LCLs derived from three sALS 
patients without CAV1/CAV2 enhancer variants, and three neurologically normal controls (see 





Table 6.1. Summary of the LCLs used for characterising the relative expression of 
CAV1/CAV2 in patients carrying ALS-associated enhancer variants. Sample ID, age upon 
sample collection, sex, affectation status, enhancer variant, diagnosis, and age of disease 







A former member of our group had previously assessed the specificity of an anti-CAV1 
antibody through overexpression of CAV1 using a commercially available pEGFP-N1-CAV1 
construct (Addgene, plasmid #14433) in HEK293 cells. Targeted knockdown of CAV1 was 
performed via co-transfection with pcDNA6.2-EmGFP-miRNA vectors and pENTR/H1-TO-
MCS-shRNA vectors targeting CAV1. CAV1 protein bands were sized at a molecular weight 
of ~20kDa using GeneTools (Syngene). (Figure 6.1a).     
In cells carrying chr7:116222625T>C, CAV1 protein (n=3, 89% reduction, p=0.05, Mann-
Whitney test) (Figure 6.1b, 6.1c) and mRNA (n=3, 89% reduction, p=0.003, Welch’s t-test), 
(Figure 6.2a) was significantly reduced compared to mean expression in cells derived from 
neurologically normal controls. In addition, CAV2 mRNA (n=3, 93% reduction, p=0.002, 
Welch’s t-test) (Figure 6.2b) expression was significantly reduced compared to mean 
expression in cells derived from neurologically normal controls. Unfortunately, immunoblotting 
for CAV2 was not possible due to lack of a sufficiently specific antibody (see appendix 17). 
Expression of CAV1 protein and CAV1/CAV2 mRNA was not significantly reduced compared 
to ALS patients without an enhancer mutation (n=3, p>0.05, Welch’s t-test). Cells carrying 
chr7:115994269:C>T did not show significantly reduced expression of CAV1 protein or 
CAV1/CAV2 mRNA (n=3, p>0.05, Welch’s t-test), compared to neurologically normal controls, 
or compared to ALS patients without an enhancer mutation. Expression of CAV1 and CAV2 
mRNA was normalised to the housekeeping gene, RPL13A, which is stably expressed in LCLs 








Figure 6.1. An ALS-associated CAV1/CAV2-enhancer variant reduces CAV1 protein 
expression in LCLs. (A) Representative immunoblot showing reduction of CAV1 protein in 
HEK293 cells co-transfected with pEGFP-N1-CAV1 vectors, with or without pcDNA6.2-
EmGFP-miRNA and pENTR/H1-TO-MCS-shRNA vectors. The antibody used in this chapter 
detects CAV1 at a molecular weight of ~20kDa. Protein bands were sized using Gene Tools 
(Syngene). NaK ATPase served as a loading control (image kindly provided by Samantha 
Allen). (B) Representative immunoblot showing the relative expression level of CAV1 in non-
ALS controls, non-CAV-ALS controls, and CAV-ALS patient LCLs; α-tubulin served as a 
loading control. Molecular weight markers are indicated (kDa). Protein bands were sized 
between ~19-22kDa using Gene Tools (Syngene). (C) Densitometric analysis suggests CAV1 
expression is reduced in cells carrying a chr7:116222625T>C enhancer variant, compared to 
the mean CAV1 expression from neurologically normal controls (n=3, 89% reduction, p=0.05, 
Mann-Whitney test). CAV1 expression is not significantly reduced in cells carrying a 
chr7:115994269:C>T enhancer variant (n=3, p>0.05, Mann-Whitney test). Error bars 






Figure 6.2. An ALS-associated CAV1/CAV2-enhancer variant reduces CAV1 and CAV2 
mRNA expression in LCLs. qPCR measurement of (A) CAV1 and (B) CAV2 mRNA 
expression, relative to mean expression in neurologically normal controls; expression was 
normalised relative to the housekeeping gene, RPL13A (Hruz et al., 2011). Relative mRNA 
expression values were calculated using the 2-ΔΔCT method (Schmittgen and Livak, 2008). 
In cells carrying chr7:116222625T>C, CAV1 mRNA was reduced by 89% (n=3, p=0.003, 
Welch’s t-test), compared to mean expression in cells derived from neurologically normal 
controls (black line). CAV2 mRNA was reduced by 93% (n=3, p=0.002, Welch’s t-test), 
compared to mean expression in cells derived from neurologically normal controls. Data are 
presented on a logarithmic scale to account for wide-ranging numerical values. Error bars 







6.3.4. An ALS-associated CAV1/CAV2 enhancer variant impairs MLR integrity in LCLs 
Reduced CAV1/CAV2 function is proposed to be toxic via disruption of MLR, leading to 
impaired cell signalling (Sawada et al., 2019). Therefore, I tested whether an ALS-associated 
enhancer variant, which reduces CAV1/CAV2 expression, also impairs MLR formation. MLR 
integrity was measured by expression of GM1 gangliosides, as labelled by CTxB (Aman et al., 
2001). I initially attempted co-labelling the cells with a CellMaskTM plasma membrane stain in 
order to quantify CTxB fluorescence intensity relative to cell area. However, LCLs grow in 
clusters, making it difficult for automated software to distinguish individual cells accurately. 
Therefore, fluorescence intensity values presented in this chapter were not calculated relative 
to cell size. Representative images of CellMaskTM and CTxB staining are shown (Figure 6.3).  
 
 
Figure 6.3. A CellMaskTM plasma membrane stain was not suitable for determining cell 
area in LCLs. Healthy LCLs grow in clusters, which is problematic for the accurate 
quantification of cell size. Cells were co-labelled with CellMaskTM plasma membrane stain 
(green) and CTxB (orange). Nuclear counterstain (Hoechst 33342) is shown in blue. Scale 




Subsequent live imaging of CTxB in LCLs was performed in the absence of a plasma 
membrane marker. CTxB fluorescence was significantly reduced in LCLs carrying a 
chr7:116222625T>C (CAV-ALS 1) mutation, compared to cells derived from neurologically 
normal controls (n=6, Mann-Whitney test, p=0.008). Fluorescence intensity was not 
significantly reduced compared to ALS patients without a CAV1/CAV2 enhancer variant (n=6, 
Mann-Whitney test, p>0.05) (Figure 6.4). In all cell lines, GM1 expression and CAV1 protein 
expression are positively correlated (r=0.6246, p=0.0196, Pearson correlation) (Figure 6.5), 
which is consistent with direct dependence of MLR integrity on CAV1 function. Representative 






Figure 6.4. Patient-derived LCLs carrying an ALS-associated CAV1/CAV2 enhancer 
variant have disrupted MLR. (A) Representative images of ganglioside GM1 labelling with 
CTxB (orange) from a non-ALS control line, a non-CAV-ALS control line, and a CAV-ALS line. 
Nuclear counterstain (Hoechst 33342) is shown in blue. Scale bars are 50μm. (B) 
Fluorescence intensity of CTxB is reduced in cells carrying a chr7:116222625T>C variant 
(CAV-ALS 1), compared to cells derived from neurologically normal controls (n=6, p=0.008, 
Mann-Whitney test). Fluorescence intensity was not reduced compared to ALS patients 
without a CAV1/CAV2 enhancer variant (n=3, p>0.05, Mann-Whitney test). ~1000 cells were 
imaged per biological repeat from 15 fields of view, for each condition. Error bars represent 





Figure 6.5. CTxB fluorescence intensity and CAV1 protein expression are positively 
correlated. Relative CAV1 protein expression (% α-tubulin) (x-axis) was plotted against the 
mean CTxB fluorescence intensity (a.u) (y-axis) in the same cell line. A linear regression line 
was fitted (r=0.6246, p=0.0196, Pearson correlation), which shows a moderate, positive 







6.3.5. CRISPR/Cas9 enhancer editing reduces CAV1/CAV2 expression in 
differentiated SH-SY5Y cells 
 
Previous results suggest that patient-derived cells carrying an ALS-associated CAV1/CAV2 
enhancer mutation display reduced CAV1/CAV2 expression and disrupted MLR, which is 
likely to lead to neurotoxicity (Sawada et al., 2019). To confirm whether the 
chr7:116222625T>C enhancer mutation is responsible for observed down-regulation of CAV1 
at the mRNA and protein level, I planned initially to use CRISPR/Cas9 with homology-directed 
repair editing in an attempt to correct the mutant allele and restore genomic enhancer integrity 
and caveolin expression. Effective correction of the enhancer sequence would demonstrate 
whether discovered mutations are directly linked to observed changes in CAV1/CAV2 
expression. This approach would be technically challenging for three reasons: i) patient-
derived LCLs are difficult to transfect and grow from single cell clones, making them broadly 
unsuited to CRISPR experiments; ii) the targeted mutation is non-coding, which adds 
difficulties to using homology-directed repair, as the repair template cannot be edited to ablate 
the PAM site, thus permitting re-cleavage; iii) the lack of an appropriate PAM site in the 
immediate vicinity of chr7:116222625 would be likely to reduce homology-directed repair in 
these cells. 
To assess the feasibility of correcting the mutation, I first used a CRISPR/Cas9 plasmid 
(PspCas9(BB)-2A-Puro PX459) (Ran et al., 2013), and subsequently a spCas9/gRNA 
ribonucleoprotein (RNP) complex to target the chr7:116222625T>C patient mutation in LCLs. 
gRNAs were designed using the CRISPOR web tool (Haeussler et al., 2016) (available at: 
http://crispor.tefor.net), and three guides were chosen based on proximity to mutation, 
predicted on- and off-target effect, and the availability of suitable PAM sites. Single stranded 
oligonucleotide donor templates for homology-directed repair were designed using the 
Benchling CRISPR web tool (available at: https://www.benchling.com). 
Using the PX459 plasmid, I was unable to detect any editing as measured via TIDE or ICE 
using three different gRNA sequences (see appendix 19). One spCas9-gRNA RNP complex 
targeting the WT enhancer sequence 16bp downstream of the chr7:116222625T>C mutation 
site (gRNA sequence: 5-UUGUAAUCAGGAAUUUUCCA-3) was electroporated into non-ALS 
control-1 LCLs. Sanger sequencing and analysis using ICE at 7-days post electroporation, 
demonstrated only 6% editing efficiency (Figure 6.6). Given the technical challenges and the 
lack of a suitable PAM site, I did not continue with my efforts to correct the 
chr7:116222625T>C enhancer mutation in LCLs. Instead, I focused on disrupting the WT 
162 
 
enhancer sequence close to the mutation site (chr7:116222625) in a neuronal cell model to 




Figure 6.6. CRISPR-directed perturbation of a CAV-enhancer region proximate to a 
patient mutation in LCLs. (A) Sanger sequencing traces demonstrating spCas9 cut site 
adjacent to the PAM site, and subsequent waveform decomposition in enhancer-edited cells. 
The position of chr7:116222625T>C mutation is indicated. The black line indicates the gRNA 
sequence. (B) Indel distribution within the CAV-enhancer region in CRISPR-edited LCLs from 




To disrupt enhancer function in a CNS-relevant human neuronal cell, I used the same 
CRISPR/spCas9 RNP editing strategy to introduce an indel mutation proximal to the site of 
the chr7:116222625T>C mutation in immature SH-SY5Y cells, as permitted by the availability 
of PAM sites. SH-SY5Y cells were subsequently differentiated into neurons using an 
established protocol (Forster et al., 2016). The same gRNA (5-
UUGUAAUCAGGAAUUUUCCA-3) targeting a PAM site 16bp downstream of the 
chr7:116222625T>C mutation site, was used. Sanger sequencing and analysis using TIDE 
and ICE at 7-days post electroporation revealed 72% editing efficiency (both modalities) in 
undifferentiated SH-SY5Y cells, and the majority of introduced changes were a single 
nucleotide insertion (chr7:116222638T>TT) (Figure 6.7). To investigate the relative effect on 
caveolin expression, a commercially available gRNA targeting CAV1 exon 2 was chosen (to 
induce gene knockout via induction of a nonsense mutation) to serve as a positive control. In 
addition, a commercially available control gRNA targeting the hypoxanthine 






Figure 6.7. CRISPR-directed perturbation of a CAV-enhancer region proximate to a 
patient mutation in SH-SY5Y cells. (A) Sanger sequencing traces demonstrating spCas9 
cut site adjacent to the PAM site, and subsequent waveform decomposition in enhancer-edited 
cells. The position of chr7:116222625T>C mutation is indicated. The black line indicates the 
gRNA sequence. (B) Indel distribution within the CAV-enhancer region in CRISPR-edited SH-




CRISPR/SpCas9-edited SH-SY5Y cells were differentiated into a neuronal phenotype (Forster 
et al., 2016). Differentiation was evaluated through expression of PAX6 and measurements of 
total neurite length. Preliminary immunocytochemistry data suggest that PAX6 expression is 
reduced in differentiated SH-SY5Y cells (n-2, no statistical analysis was performed) (Figure 
6.8a, 6.8b, 6.8e). qRT-PCR data show variable PAX6 mRNA expression between 
differentiated and undifferentiated cells, with a significant reduction in the enhancer-edited line 
(n=3, p=0.0001, un-paired t-test). Reductions in PAX6 mRNA were not observed in 
differentiated HPRT control or CAV1 exon 2-targeted cells, compared to undifferentiated cells 
(Figure 6.8g). Alterations in neurite length were assessed via immunostaining for α-tubulin, 
followed by semi-automated quantification using the Simple Neurite Tracer plugin for FIJI. 
Total neurite length was increased in differentiated cells, compared to undifferentiated (n=4, 
p=0.01, paired t-test) (Figure 6.8c, 6.8d, 6.8f). Differentiated cells were harvested, and RNA 
was extracted for qPCR. I confirmed reduced expression of CAV1 (n=4, >99% reduction, 
p<0.0001, Welch’s t-test) and CAV2 (n=4, >99% reduction, p<0.0001, Welch’s t-test) mRNA 
in enhancer edited cells. CAV1/CAV2 mRNA expression was normalised relative to the 
housekeeping gene, GAPDH, which has previously been used as an internal reference in SH-
SY5Y cells (Fan et al., 2016) (Figure 6.9). CAV2 mRNA expression was reduced in the 
context of enhancer editing, but also by CAV1-coding editing, which likely reflects 





Figure 6.8. Increased dendrite length and altered PAX6 expression suggests successful 
neuronal differentiation of SH-SY5Y cells. Representative images of PAX6 staining in (A) 
un-differentiated and (B) differentiated SH-SY5Y cells with a CRISPR-induced enhancer 
perturbation. (C, D) Representative images of α-tubulin (green) staining in undifferentiated and 
differentiated SH-SY5Y cells carrying a CRISPR-induced enhancer perturbation. Nuclear 
counterstain (Hoechst 33342) is shown in blue. Scale bars are 50μm. (E) Quantification of 
PAX6 fluorescence intensity for the whole cell; no statistical analysis was performed (n=2). (F) 
Differentiated SH-SY5Y cells show increased total neurite length, based on α-tubulin staining 
(n=4, *p<0.05, paired t-test). (G) qRT-PCR data suggest PAX6 expression is reduced in 
differentiated enhancer-edited cells compared to undifferentiated enhancer-edited cells (n=3, 
p<0.001, un-paired t-test). Error bars represent mean ±SD (*p<0.05; ***p<0.001). 
Representative images of PAX6 and α-tubulin staining from all experimental conditions are 




Figure 6.9. qPCR measurement of CAV1 mRNA and CAV2 mRNA reveals reduced 
expression in CAV-enhancer and CAV1-exon CRISPR-edited neurons, compared to 
CRISPR editing of HPRT. CRISPR-induced CAV-enhancer and CAV1-exon mutations 
correlated with reduced expression of (A) CAV1 (n=4, >99% reduction, p<0.0001, Welch’s t-
test) and (B) CAV2 (n=4, >99% reduction, p<0.0001, Welch’s t-test) mRNA. Expression was 
normalised relative to the housekeeping gene, GAPDH (Fan et al., 2016). Relative mRNA 
expression values were calculated using the 2-ΔΔCT method (Schmittgen and Livak, 2008). 
Data are presented on a logarithmic scale to account for wide-ranging numerical values. Error 







CAV1 and CAV2 are integral membrane proteins located in caveolae in the outer cell 
membrane. They are also present intracellularly in the ER, Golgi apparatus, and transport 
vesicles (de Almeida, 2017). CAV1 and CAV2 form a stable hetero-oligomeric complex, which 
enables CAV2 to be trafficked to the plasma membrane. In the absence of CAV1, CAV2 forms 
monomers and dimers that localise to the Golgi network and become a target for degradation. 
Therefore, whilst CAV1 and CAV2 are often co-expressed, CAV2 expression in caveolae is 
largely dependent on the formation of the hetero-oligomeric complex with CAV1 (de Almeida, 
2017).  
CAV1 functions prominently in cell signalling and in the transport of cholesterol (Quest et al., 
2008). Cell signalling mediated by CAV1 function includes neurotrophic signalling with 
important implications for neuronal cell death (Head et al., 2011, Mandyam et al., 2017). 
Indeed, premature apoptosis has been implicated in motor neuron loss in ALS (Guegan and 
Przedborski, 2003). In addition, dysregulated cholesterol metabolism is well described in ALS. 
High levels of cholesterol are toxic to neurons, and lower levels of cholesterol provide a 
neuroprotective phenotype (Abdel-Khalik et al., 2017). Interestingly, neuron-specific up-
regulation of CAV1 in the SOD1G93A ALS mouse model has been shown to extend survival 
and improve motor function (Sawada et al., 2019). Up-regulation of CAV1 is also 
demonstrated to improve cognition and hippocampal plasticity in aged mice, as well as 
promote axonal and dendritic growth in primary neurons, making it an area of interest for 
therapies targeting neurodegenerative disorders (Head et al., 2011, Mandyam et al., 2017).  
  
6.4.1. CAV1 and CAV2 expression are reduced in patient-derived cells carrying an 
ALS-associated enhancer variant 
In the present study, I hypothesised that discovered ALS-associated CAV1 enhancer 
mutations contribute to pathogenicity via downregulation of functional CAV1 protein. 
Therefore, immunoblotting was used to evaluate whether there was a difference in CAV1 
protein expression between control and patient samples. Initially, the relative expression of 
CAV1 protein was explored using LCLs, as this was the only biological material available from 
patients with ALS-associated CAV1 enhancer mutations. LCLs are relatively simple to 
maintain, they exhibit a minimal somatic mutation rate during continuous culture, and they 
provide an unlimited source of biomolecules, which makes them useful for genetic screening, 
genotype-phenotype correlation studies, and functional assays (Mohyuddin et al., 2004, 
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Hussain and Mulherkar, 2012). An important caveat to their use is the fact that they are not 
neuronal, which limits their applicability for modelling diseases such as ALS. 
LCL lysis for subsequent CAV1 immunoblotting was initially performed using IP lysis buffer; 
however, I did not detect a signal when probing with a validated anti-caveolin-1 antibody (see 
appendix 22). CAV1 is a membrane-bound protein; therefore, I hypothesised that the absence 
of the signal was due to CAV1 being expressed in an insoluble membrane fraction. I decided 
to trial urea buffer, which is capable of dramatically enhancing the solubility of membrane-
bound proteins (Molloy et al., 1998, Harris et al., 2017). Use of this buffer meant it was not 
possible to quantify total protein within cell lysates accurately using a Bradford protein assay, 
which is incompatible with urea at a concentration higher than 3.0M (Gotham et al., 1988). 
However, I found the BCA assay to be compatible, as it provided an accurate quantification of 
total protein within lysates (Krieg et al., 2005). Had I still been unable to detect a signal 
following urea-based cell lysis, I would have considered subcellular fractionation (de Araujo 
and Huber, 2007) to isolate the membrane region of LCLs in order to provide a more accurate 
detection of potentially low abundant CAV1.  
A previous member of our group had assessed the specificity of the anti-CAV1 antibody, 
following overexpression and targeted knockdown of CAV1 in HEK293 cells. The CAV1 
protein signal was detectable when overexpressed in lysates that had been generated using 
IP lysis buffer. I speculate that the CAV1 signal is not within the dynamic range at endogenous 
levels in LCLs, where expression is low relative to kidney-derived cells 
(https://www.proteinatlas.org). This antibody detected CAV1 at the predicted molecular weight 
of ~20kDa (Figure 6.1a), which gave me confidence in the use of this antibody moving 
forward. In the present study, I observed a reduction in CAV1 expression at the protein level 
in cells with a chr7:116222625T>C enhancer mutation, compared to neurologically normal 
controls (n=3, 89% reduction, p=0.05, Mann-Whitney test), but not compared to ALS patients 
without a CAV1 enhancer mutation (n=3, p>0.05, Mann-Whitney test). In contrast, cells 
carrying an ALS-associated chr7:115994269:C>T mutation did not show reduced expression 
of CAV1 protein (n=3, p>0.05, Mann-Whitney test) (Figure 6.1b, 6.1c). I speculate that the 
latter mutation may influence transcription only in CNS cells, or alternatively this variant may 
be non-functional. Attempts to evaluate CAV2 expression at the protein level were not possible 
due to lack of a validated commercially available antibody (see appendix 22).   
The observed reduction in CAV1 protein expression in the patient with a chr7:116222625T>C 
enhancer mutation does not confirm malfunction at the transcriptional level, which is a 
necessary prediction of the present model of enhancer dysfunction. Therefore, qRT-PCR was 
used to evaluate the relative expression of CAV1 and CAV2 at the mRNA level in LCLs. My 
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qRT-PCR data shows a similar trend in CAV1 mRNA expression compared to immunoblotting, 
concurrent with a significant reduction in cells with the chr7:116222625T>C mutation (n=3, 
p=0.003, Welch’s t-test) (Figure 6.2a). Moreover, I observed CAV2 to follow a similar 
expression pattern across the various cohorts, with reduced expression level in the cells 
harbouring a chr7:116222625T>C mutation compared to neurologically normal controls (n=3, 
p=0.002, Welch’s t-test) (Figure 6.2b). From these data, it can be inferred that CAV1/CAV2 
expression is affected at both the transcriptional and translational level, which led me to 
investigate this further using CRISPR/Cas9 genome editing. 
 
6.4.2. Patient-derived LCLs carrying an ALS-associated CAV enhancer variant have 
disrupted MLR 
Prior to genome editing, I investigated ganglioside metabolism (see Chapter 5) as a potential 
mechanism linked to ALS-associated CAV1/CAV2 enhancer variants. As previously 
mentioned, ganglioside GM1 is highly expressed in the CNS and is localised to MLR, which 
are important for transmembrane signalling (Vajn et al., 2013). GM1 is internalised via 
caveolae (Crespo et al., 2008), and is shown to be responsible for the trafficking and 
maintenance of caveolae domains (Singh et al., 2010). The association of GM1 with MLR 
makes this ganglioside a useful target for measuring MLR integrity. My data indicate that CTxB 
expression may influence CAV1 expression (Figures 6.4, 6.5) and, by extension, MLR 
integrity may be influenced by CAV1 expression. This is consistent with previous work 
demonstrating that neuron-specific upregulation of CAV1 increases CTxB expression in the 
spinal cord of the SODG93A ALS mouse model (Sawada et al., 2019).     
The use of CTxB for the labelling of ganglioside GM1 and MLR has been discussed previously 
(see section 5.4.2). Live imaging of ganglioside GM1 using a CTxB molecular probe was 
challenging, as LCLs are non-adherent. To encourage cell adherence, I tested three different 
factors used for coating culture plates prior to seeding: fish gelatin (Huang et al., 2018), type 
I collagen (Heino, 2007), and plasma fibronectin (Hsiao et al., 2017). Of these factors, plasma 
fibronectin most effectively encouraged cell adherence following a 30-minute incubation at 
5µg/mL, whereas cells were mobile when visualised under the microscope for plates pre-
coated in fish gelatin or type 1 collagen. Plasma fibronectin is an extracellular matrix 
glycoprotein present in blood plasma and is a key modulator of cellular adhesion (Hsiao et al., 
2017). When measuring the fluorescence intensity of cells, it is ideal to display the data as a 
percentage of cell area to account for variability in cell sizes between groups. Therefore, I 
attempted co-labelling the LCLs with CellMaskTM, a fluorescent lipophilic membrane dye 
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(Takov et al., 2017), to calculate cell size. However, LCLs grow in clusters, making it difficult 
for automated software to detect individual cells (Figure 6.3). This perhaps limits the reliability 
of my data, as it suggests that the mean fluorescence intensity is not representative of 
individual cells. However, my results were consistent across all biological repeats of this 
assay, despite variations between the sizes of the cell clusters. I have previously linked an 
ALS-associated GLT8D1 mutation to disrupted MLR (Chapter 5), and the results in the present 
chapter may suggest a convergence between GLT8D1- and CAV1-ALS disease pathways.  
 
6.4.3. CRISPR/Cas9 genome editing of human cells 
To determine whether the chr7:116222625T>C enhancer mutation is responsible for observed 
down-regulation of CAV1 at the mRNA and protein level, I planned to use CRISPR/Cas9 
genome editing to correct the mutation and restore genomic enhancer integrity. Effective 
correction of the enhancer sequence would demonstrate whether discovered mutations are 
directly linked to observed changes in CAV1/CAV2 expression.   
LCLs have a relatively low transfection efficiency, and to my knowledge, the highest reported 
editing efficiency in this cell line using the CRISPR system to induce homology-directed 
recombination, was ~20% (Johnston et al., 2019). This study utilised a Cas9-GFP-gRNA 
plasmid, but there are key limitations to plasmid-based approaches for CRISPR-induced 
editing. For example, cells must be amenable to transfection, plasmids may randomly 
integrate into the host genome, off-target effects can occur due to prolonged Cas9 expression, 
and plasmids demonstrate variable CRISPR editing efficiencies (Kim et al., 2014). The authors 
recommended delivering Cas9-RNP-gRNA complexes (Johnston et al., 2019), which was 
previously shown to be feasible in LCLs (Jiang et al., 2018). Delivery of Cas9-RNP complexes 
has been shown to provide more efficient on-target cleavage and reduce off-target cleavage, 
compared to plasmid transfection (Kim et al., 2014, Liang et al., 2015). Moreover, the Cas9-
gRNA-RNP complex can be electroporated into the cell and is degraded over time, which limits 
the potential for off-target effects (Schumann et al., 2015). Overall, studies that have used the 
RNP delivery system have consistently reported high editing efficiencies across a variety of 
cell lines (Hendel et al., 2015, Lin et al., 2014).   
Initially, I planned to correct the chr7:116222625T>C enhancer mutation in LCLs via 
CRISPR/Cas9-based editing. To assess the feasibility of this, I used the RNP delivery system 
to target the WT enhancer sequence, by introducing an indel mutation in LCLs from a 
neurologically normal patient. Analysis using TIDE (Brinkman et al., 2014) demonstrated only 
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achieved 6% editing efficiency (Figure 6.6). In order to generate a pure population of CRISPR-
edited cells, the LCLs would need to be serially diluted into single cell colonies, and 
subsequently expanded over several months. Unfortunately, LCLs do not readily expand from 
single cell colonies, rather they aggregate into clusters to remain healthy, and at lower 
concentrations, their death rate increases (Hussain and Mulherkar, 2012). However, a recent 
study described an efficient method of generating of a pure population of CRISPR-edited LCLs 
via fluorescent activated cell sorting, allowing for the expansion of transfected groups of cells 
in a matter of weeks (Johnston et al., 2019). This is a new approach that I may have 
considered pursuing with more time.  
Given the technical challenges and the lack of a suitable PAM site, I did not continue with my 
efforts to correct the chr7:116222625T>C enhancer mutation in LCLs. Instead, I focused on 
targeting the WT enhancer sequence 16bp downstream of the chr7:116222625T>C mutation 
site in a neuronal model to place this mutation in the context of the CNS. I chose SH-SY5Y 
cells, a human neuroblastoma line that has been extensively used in Parkinson’s and 
Alzheimer’s research (Xicoy et al., 2017, Agholme et al., 2010). There are several advantages 
to the use of SH-SY5Y cells; for example, their continuous proliferation at the undifferentiated 
stage enables the user to generate a large biomass of post-mitotic neurons with relative ease 
and minimal cost. Moreover, SH-SY5Y cells are human-derived; therefore, they express many 
human-specific proteins and protein isoforms, which are not inherently present in primary 
rodent cultures (Kovalevich and Langford, 2013). 
I used the RNP complex delivery system to introduce an indel mutation proximal (16bp 
downstream) to the patient enhancer mutation site in SH-SY5Y cells. My experiments did not 
include a DNA repair template, as I was aiming to disrupt the WT enhancer. CRISPR edits 
were evaluated through a combination of Sanger sequencing and waveform decomposition 
analysis (Brinkman et al., 2014). Both TIDE and ICE analysis platforms demonstrated similarly 
high levels of editing efficiency (~72%) in my SH-SY5Y model (Figure 6.7). Efficiently edited 
cell pools are acceptable alternatives to clonally isolated cells with specific knockouts and are 
more easily attainable (Ran et al., 2013). However, edited pools have some limitations: DNA 
double strand breaks are often associated with undesired off-target effects such as 
translocations (Kosicki et al., 2018), or the activation of p53 (Haapaniemi et al., 2018), which 





6.4.4. Generation of a CRISPR-edited neuronal model 
My next aim was to differentiate the CRISPR-edited SH-SY5Y cells into neurons, in order to 
model CAV1-ALS in the context of the CNS. Differentiated SH-SY5Y cells are morphologically 
similar to primary neurons, displaying extended processes, decreased proliferation rate, and 
increased expression of neuron-specific markers (Gordon et al., 2013). There are numerous 
methods of inducing SH-SY5Y neuronal differentiation, and the best characterised is through 
the addition of 10µM retinoic acid to the culture media. Retinoic acid is a vitamin A derivative 
with known growth-inhibiting and cellular differentiation-promoting properties (Melino et al., 
1997).  
In order to generate a neuronal model, CRISPR-edited human SH-SY5Y neuroblastoma cells 
were differentiated into neurons over a one-week period, as previously described (Forster et 
al., 2016). Neuronal differentiation was initiated one-week post nucleofection. Successful 
differentiation was initially evaluated via PAX6 expression. Fully differentiated neurons are 
post-mitotic, and PAX6 expression is usually discontinued in the precursor progeny following 
cell cycle exit. Therefore, post-mitotic neurons do not normally express detectable levels of 
the protein (Hsieh and Yang, 2009, Sebastian-Serrano et al., 2012). Preliminary staining for 
PAX6 suggests reduced expression in differentiated cells, compared to undifferentiated (n=2, 
no statistical analysis was performed) (Figure 6.8). However, PAX6 reduction was confirmed 
at the mRNA level in enhancer-edited cells (n=3, p<0.001, un-paired t-test) (Figure 6.9). Co-
staining for other neuronal markers such as NeuN (Gusel'nikova and Korzhevskiy, 2015) 
would have strengthened the characterisation of this model; however, additional readouts 
were investigated. Differentiated cells presented with extended neuritic processes (n=4, 
p=0.01, paired t-test) (Figure 6.8). I also observed reductions in growth rate and cell 
clustering, which is consistent with previous studies (Forster et al., 2016). An overview of the 







Figure 6.10. Schematic representation of the generation of a neuronal model of CAV-
associated ALS. Cas9-gRNA complexes targeting the CAV-WT enhancer sequence were 
electroporated into SH-SY5Y cells at day 0 and cells were subsequently expanded over a 
period of one week. At day 7, editing efficiency was evaluated via Sanger sequencing, TIDE, 
and ICE, and cells were differentiated into a neuronal phenotype as previously described 
(Forster et al., 2016). At day 14, differentiated neurons were characterised via 
immunocytochemistry and measurements of total neurite length; and CAV1/CAV2 expression 




CAV1 has been shown to inhibit neuronal differentiation by decreasing neurite outgrowth and 
branching in PC12 cells (Gaudreault et al., 2005). In addition, CAV1 is shown to block the 
formation of neurites and phosphorylation of ERK in bFGF-treated N2A cells (Kang et al., 
2006). However, PC12 and N2A cells are derived from rat and mouse, respectively (Hu et al., 
2018, Namsi et al., 2018); therefore, to be consistent with my previous work, I chose to model 
the CAV1-enhancer variant in a human-derived neuronal cell line. CAV1 has been 
demonstrated to inhibit neuronal differentiation of neural progenitor cells via the 
downregulation of VEGF signalling and the inhibition of p-p44/42MAPK, p-Akt and p-Stat3 (Li 
et al., 2011). In the current study, CAV1 enhancer-edited SH-SY5Y cells did not display 
enhanced neurite development, compared to HPRT controls and unedited cells (n=3, p>0.05, 
paired t-test) (Figure 6.8). However, PAX6 expression was significantly reduced in the 
differentiated cells carrying a CAV1 enhancer perturbation, compared to CRISPR control cells 
with edited HPRT (n=3, p=0.0294, un-paired t-test) (Figure 6.8). This result suggests that a 
reduction in CAV1 expression improves neuronal differentiation, which is consistent with 
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previously published work (Kang et al., 2006, Li et al., 2011). It would be expected, therefore, 
that disruption of the CAV1 exon would have a similar effect on PAX6 expression; however, 
this was not the case in the present study. This may be because of unmeasured effects on 
additional genes under control of the same enhancer. 
In my neuronal model, I observed reductions in CAV1 (n=4, p<0.0001, Welch’s t-test) and 
CAV2 (n=4, >99%, p<0.0001, Welch’s t-test) mRNA, consistent with a functional effect of the 
enhancer on expression (Figure 6.7). Reductions in CAV1/CAV2 expression greater than the 
editing efficiency are notable; however, phenotypic change in excess of editing efficiency is 
well described and may be a consequence of CRISPR interference (Gaj et al., 2017). 
Importantly, this mutation does not mimic exactly the one seen in the patient, and it is possible 
that observed effects on expression are a result of an artefact. However, it is unlikely that an 
unpredictable off-target effect produced the exact changes predicted by our other lines of 
evidence. It is very difficult to determine whether there were any off-target effects resulting 
from my experiment, although use of the RNP delivery system will have helped to mitigate this 
(Lin et al., 2014). One consideration would be to utilise bulk RNA-sequencing; however, this 
usually reflects the average gene expression across thousands of cells by combining genomic 
readouts from individual cells to generate an overall representation. As such, single-cell RNA 
(scRNA) sequencing has become more favourable for studying the key biological questions 
of cell heterogeneity, although this technology is still in its developmental stage. Compared to 
bulk RNA sequencing, scRNA sequencing produces nosier and more variable data. Both 
methodologies introduce amplification errors, which often leads to imbalanced proportions or 
complete lack of variant alleles (Chen et al., 2019).  
Until recently, it was challenging to introduce or correct disease-causing genetic variants 
efficiently without causing excess by-products (Jinek et al., 2012, Cong et al., 2013, Mali et 
al., 2013, Kosicki et al., 2018). However, prime editing has since been described, which is a 
‘search-and-replace’ genome editing technology that mediates targeted indels as well as all 
12 possible base-to-base conversions in human cells without requiring double-strand breaks 
or donor DNA templates (Anzalone et al., 2019). This CRISPR technology could be applied to 
efficiently correct the chr7:116222625T>C enhancer mutation and determine whether it is 
responsible for the downregulation of CAV1. I am planning to pursue this strategy in the future.  
 
 6.4.5. Summary 
Genetic discoveries in ALS have focused on high effect variants within coding genes in 
patients with autosomal dominant inheritance. The non-coding genome is thought to contain 
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missing heritability (Pallares, 2019). A new approach was developed to discover genetic 
association within gene enhancer-elements. This new methodology successfully identified and 
validated ALS-associated genetic variation within enhancer and coding regions associated 
with CAV1, suggesting CAV1 is a new ALS gene.  
This work builds upon previous observations that CAV1 function is neuroprotective in 
neurodegenerative disease (Head et al., 2010, Head et al., 2011) and in ALS in particular 
(Sawada et al., 2019). Until now, it was not clear whether CAV1 dysfunction was a cause or 
effect of neuronal toxicity. However, discovery of genetic risk associated with CAV1/CAV2 
expression places this pathway upstream in the development of disease. Using patient-
derived cells, I have shown that ALS-associated genetic variation within CAV1/CAV2 
enhancers reduces the expression of CAV1 and CAV2 and disrupts MLR, which is consistent 
with impaired neurotrophic signalling and consequently neurodegeneration (Sawada et al., 
2019). Moreover, CRISPR/SpCas9 perturbation proximate to this mutation reduced CAV1 and 
CAV2 expression in human neuronal cells, suggesting that this enhancer-region is functional 
within the CNS. Future work should investigate CTxB expression in my CRISPR-edited 
neuronal model to validate the findings in LCLs regarding the role of CAV1/CAV2 on MLR 
integrity. Data presented in this chapter provide links with my previous work, as both CAV1 
and GLT8D1 appear to function prominently in the maintenance of MLR. Together, these 
results place perturbed ganglioside metabolism upstream in the pathogenesis of ALS (see 
Chapter 5). 
Enhancer function is thought to depend on the binding of TFs (Koch et al., 2011). Current 
understanding of function within enhancer regions is limited (Levo et al., 2015), in part because 
of a paucity of variants with validated biological impact. This incomplete understanding is 
reflected in our failure to link a TF to observed changes in CAV1/CAV2 expression (data not 
shown). The discovery of ALS-associated CAV1/CAV2 enhancer variations forms a platform 
for improved understanding of molecular function within these regions. Moreover, the 
discovery of disease-associated genetic variation is a means of overcoming a reliance on un-
physiological in vitro assays to understand enhancer biology (Gasperini et al., 2020). 
The premise of personalised medicine for complex disease is that gene-environment 
interactions leading to disease are likely to be heterogeneous (Li et al., 2019). It is possible 
that in a significant number of ALS patients, genetic mutations leading to reduced CAV1/CAV2 
function are a cause of neuronal toxicity. Upregulation of CAV1 is in development as a 
therapeutic tool (Head et al., 2011) (www.cavogene.com), and data presented here suggest 









ALS is a universally fatal and relatively common neurodegenerative disease. 
Neurodegenerative diseases exhibit late age of onset and it is therefore reasonable to assume 
that genetic mutations are upstream in disease pathogenesis. Discovery of genetic variants of 
ALS have been instrumental in elucidating pathological mechanisms that cause motor neuron 
loss (Renton et al., 2014). Here I describe the discovery and characterisation of novel ALS-
associated genes: GLT8D1, CAV1, and CAV2. This project has focused primarily on the 
generation of cell and animal models to experimentally evaluate the pathogenicity of 
discovered variants. GLT8D1 is part of a large family of proteins called glycosyltransferases, 
and members of this protein group have been previously implicated in neurodegenerative 
diseases, including ALS (Ariga, 2014, Dodge et al., 2015). Moreover, I have provided new 
evidence that genetic mutations within the glycosyltransferase, EOGT, are significantly 
associated with sALS (Moll et al., 2020). CAV1 function is already implicated in the 
pathogenesis of ALS (Sawada et al., 2019), and is currently being developed as a novel ALS 
therapy (www.cavogene.com).   
 
7.1.1. ALS-associated GLT8D1 mutations act via a dominant-negative mechanism 
 
The majority of this project focused on understanding how newly discovered ALS-associated 
G78W and R92C variants in GLT8D1 cause loss of motor neurons, and identifying potential 
therapeutic targets for neuroprotection. Initially, I engineered plasmid constructs expressing 
WT and mutant forms of GLT8D1 for transient overexpression in neuronal and non-neuronal 
cells. Overexpression of GLT8D1-R92C produced the more toxic phenotype in MTT and LDH 
assays, which is in line with the observed clinical severity. Observed in vitro cellular toxicity is 
still consistent with an age-of-onset disease because my overexpression model does not 
reflect the physiological expression of mutant GLT8D1 in the patients. Rather, GLT8D1-ALS 
patients are likely to present with lower levels of the mutant protein, which may be 
counteracted by homeostatic mechanisms for decades prior to disease onset.  
 
The plasmid constructs expressing FLAG-tagged WT and mutant GLT8D1 were used to 
engineer stable isogenic HEK293 cells with tetracycline-inducible expression of GLT8D1-WT 
and GLT8D1-R92C. These lines were initially generated for the production of purified 
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recombinant protein for the assessment of glycosyltransferase function. I hypothesised that 
the presence of either mutation would impact enzymatic activity, as ALS-linked GLT8D1 
mutations cluster proximal to the proposed ligand-binding site (Cooper-Knock et al., 2019). I 
was the first to publish information regarding the substrate specificity of GLT8D1, and in doing 
so, I observed a mutation-specific reduction in enzymatic activity with UDP-galactose as the 
target substrate. I validated my findings following immunoprecipitation of recombinant protein 
from HEK293 cells transiently transfected with FLAG-tagged GLT8D1-WT, GLT8D1-G78W, 
and GLT8D1-R92C constructs. Similarly, I observed reductions in enzyme activity for both 
mutations compared to WT with UDP-galactose as the target substrate, with R92C producing 
the greater effect. In both instances, reduced enzyme velocity was commensurate with 
increased substrate affinity, which could impair cycling of the substrate through the enzyme. I 
propose that higher substrate affinity could cause competitive antagonism of WT function and 
a dominant negative effect, which would explain why ALS-associated GLT8D1 mutations are 
autosomal dominant. 
 
Precedence exists for dominant-negative mutations in other ALS-associated genes, notably 
TARDBP and OPTN (Shen et al., 2015, Guerrero et al., 2019). I cautiously note the example 
of SOD1 mutations that were originally thought to cause ALS through loss-of-function but were 
subsequently shown to cause a gain-of-function toxicity arising from misfolding of the SOD1 
protein (Boillee et al., 2006). It is possible that G78W and R92C mutations in GLT8D1 increase 
the proteins’ propensity to misfold. My discovery implicates dysregulated glycosyltransferase 
function in the pathogenesis of ALS, making it an attractive new therapeutic target. 
 
The next stage of the project was to investigate whether GLT8D1 mutations are toxic within a 
whole organism. Using zebrafish as the model organism, I overexpressed human mutated and 
WT GLT8D1 mRNA. Whilst embryo survival was unaffected, motor function was specifically 
impaired in zebrafish larvae expressing either the GLT8D1-R92C or GLT8D1-G78W mutated 
mRNA at 5dpf. This is consistent with a specific effect on the motor system. Further supporting 
a role for GLT8D1 in motor function, knockdown of the endogenous glt8d1 orthologue in 
zebrafish embryos produced a specific deficit of motor function without observed 
morphological abnormalities at 5dpf. Overlap between the effects of glt8d1 knockdown and 





7.1.2. GLT8D1 mutations fragment the Golgi and disrupt ganglioside-containing 
membrane lipid rafts 
 
The final stages of my work on GLT8D1 focused on linking discovered mutations to a disease 
pathway. The most likely candidate was ganglioside metabolism, as various 
glycosyltransferases are shown to be key modulators of this pathway (Moll et al., 2020). 
Gangliosides are sialic acid-containing glycosphingolipids that are particularly abundant within 
the CNS (Vajn et al., 2013). Gangliosides within the CNS are typically synthesized in the ER 
from a lactosylceramide precursor and are remodelled during transit from the cis- to the trans-
Golgi network by a series of glycosyltransferase enzymes that incorporate galactose and 
GalNAc groups (Moll et al., 2020). Consistent with a role in this process, GLT8D1 shows 
prominent CNS expression; moreover, GLT8D1 carries a Golgi localisation signal and is able 
to accept galactose as a substrate. Mature gangliosides are carried to the cell surface where 
they function prominently in cell signalling (Yu et al., 2012) as well as enhance neurite 
outgrowth and survival (Kittaka et al., 2008). Interestingly, autoantibodies against specific 
gangliosides produce an inflammatory disease of spinal motor neurons known as multifocal 
motor neuropathy with conduction block (Harschnitz et al., 2014), which is a common 
differential diagnosis of ALS. Altered levels of gangliosides have been reported in animal 
models of ALS and in post-mortem CNS tissue from ALS patients (Dodge et al., 2015, Ariga, 
2014). The role of gangliosides in maintaining CNS integrity, coupled with various lines of 
evidence implicating their role in neurodegenerative disease, suggests that dysregulation of 
this pathway would likely explain the loss of motor neurons in our patient cohort.   
 
I investigated ganglioside expression in stable isogenic HEK293 cells expressing GLT8D1-
WT and GLT8D1-R92C, and showed that an R92C mutation reduced the fluorescence 
intensity of sialic acid marker, WGA, and ganglioside GM1 marker, CTxB, at the plasma 
membrane. I propose that the reduction in glycosyltransferase activity caused by the GLT8D1 
mutations negatively impacts on ganglioside signalling. Gangliosides are important 
constituents of membrane lipid rafts (MLR), which have a key role in the organisation of cell 
signalling and neuronal survival. Disrupted MLR are associated with impaired neurotrophic 
signalling and consequent neurodegeneration (Sawada et al., 2019, Schmick and Bastiaens, 
2014). My findings place dysregulated ganglioside metabolism upstream in the pathogenesis 
of GLT8D1-ALS, and provide justifiable cause to investigate gangliosides, and GM1 in 
particular, as a potential therapeutic target in patients with ALS-linked GLT8D1 mutations. 
Indeed, gangliosides have previously been explored as potential therapeutic targets in a 
variety of neurodegenerative disorders, including ALS (Knight et al., 2015, Schneider et al., 
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2015a, Henriques et al., 2017). Future work will focus on confirming whether discovered ALS-
associated GLT8D1 mutations do indeed impair neurotrophic signalling and whether this is 
key to the development of neurodegeneration.   
 
GLT8D1 contains an arginine-lysine motif in its cytoplasmic domain, which likely represents a 
Golgi localisation signal (Uemura et al., 2015). To test for this, I transiently overexpressed 
GFP-tagged constructs expressing WT GLT8D1 sequences in HEK293 and N2A cells, and 
observed localisation to the Golgi network. The presence of G78W or R92C mutations in 
GLT8D1 did not affect the localisation signal. Glycosyltransferases have previously been 
shown to influence Golgi architecture (Nilsson et al., 1996, Petrosyan and Cheng, 2013). 
Moreover, Golgi fragmentation is a well-described feature of neurodegenerative diseases, 
including ALS, and is associated with the dysregulated trafficking of Golgi secretory proteins 
(Sundaramoorthy et al., 2015). Based on these lines of evidence, I hypothesised that 
mutations within GLT8D1 would cause fragmentation of the Golgi network. To investigate this, 
I stably overexpressed GLT8D1-WT and GLT8D1-R92C in isogenic HEK293 cells and 
performed immunocytochemistry using cis- and trans-Golgi markers GM130 and TGN46, 
respectively. My preliminary data indicate that an R92C mutation causes fragmentation of both 
the cis- and trans-Golgi compartments. This result may explain the aforementioned mutation-
specific impairment of ganglioside metabolism, as ganglioside biosynthesis is 
compartmentalised in the Golgi and is organised in distinct units formed by associations of 
particular glycosyltransferases (Giraudo and Maccioni, 2003). Therefore, I propose that 
fragmentation of the Golgi network may cause dysregulated ganglioside metabolism, both of 
which may be an upstream cause of impaired glycosyltransferase function. I have summarised 
my key findings from the experimental evaluation of ALS-associated GLT8D1 mutations in 





Figure 7.1. Graphical summary of key findings from the characterisation of pathogenic 
variants in GLT8D1. Exosome sequencing in an autosomal dominant ALS pedigree identified 
heterozygous p.R92C mutations in GLT8D1 that co-segregate with disease. Targeted 
sequencing in 103 familial and young sporadic ALS patients from the North of England 
identified five additional patients with two missense mutations in GLT8D1: p.R92C and 
p.G78W. Sequencing of an ALS international cohort confirmed significant ALS-association 
with genetic variation in exon 4 of GLT8D1 in familial ALS patients, including three additional 
rare deleterious missense mutations. G78W and R92C variants are toxic to HEK293 and N2A 
cells when overexpressed, and an R92C change disrupts MLR integrity. Preliminary data 
suggest an R92C mutation causes fragmentation of the Golgi network. Both G78W and R92C 
mutations in GLT8D1 impair the glycosyltransferase activity of the enzyme. Knockdown of 
endogenous glt8d1, and overexpression of mutant human GLT8D1 mRNA, produces motor 
deficits in zebrafish larvae 5dpf. These data indicate a loss of function mechanism and a 




7.1.3. CAV1/CAV2 enhancer mutations also disrupt membrane lipid rafts 
 
The final stage of my project was to investigate novel ALS-associated enhancer variants in 
CAV1 / CAV2. CAV1 and CAV2 are integral membrane-bound proteins located in the caveolae 
of the plasma membrane. Together they form a stable hetero-oligomeric complex, suggesting 
that they are often co-expressed (de Almeida, 2017). CAV1 functions prominently in 
neurotrophic signalling, and dysregulated cell signalling has important implications for 
neuronal cell death (Head et al., 2011, Head et al., 2010, Mandyam et al., 2017). The role of 
CAV2 is far less studied than CAV1 (de Almeida, 2017). Enhancers are non-coding regulatory 
sequences that modulate expression of target genes through the binding of transcription 
factors (Koch et al., 2011). Physical interaction between an enhancer and the promoter of the 
target gene is mediated by DNA looping (Pennacchio et al., 2013).  
 
I investigated two CAV1/CAV2 enhancer variants in patient-derived LCLs by evaluating the 
expression of CAV1 and CAV2 at the mRNA and protein levels. One of the enhancer 
mutations (chr7:116222625T>C) correlated with a reduction in the expression of CAV1 mRNA 
and protein, as well as a reduction in CAV2 mRNA. A second enhancer mutation 
(chr7:115994269:C>T) did not affect the expression of CAV1 or CAV2 at either the mRNA or 
protein level. I speculate that this variant may influence transcription only in CNS cells, or 
alternatively this variant may be non-functional.  
 
To validate whether the chr7:116222625T>C mutation causes a reduction in CAV1/CAV2 
expression, I utilised CRISPR/Cas9 genome editing to disrupt the WT enhancer in a human 
neuronal model to place my findings in the context of the CNS. Guide RNAs were designed to 
specifically target a region proximal to the patient mutation site (~16bp downstream) in SH-
SY5Y cells. I demonstrated 72% editing efficiency in immature SH-SY5Y cells via analysis 
using two similar platforms: TIDE and ICE. CRISPR-edited SH-SY5Y cells were subsequently 
differentiated into neurons using a previously established method (Forster et al., 2016), and 
successful differentiation was confirmed through alterations in Pax6 expression and total 
neurite length, which was quantified through staining with α-tubulin. Fully differentiated 
neurons showed reductions in CAV1 and CAV2 expression at the mRNA level, supporting the 
above correlation as possible cause that the enhancer is important for CAV1/CAV2 
expression.  
 
The discovery that an enhancer mutation within CAV1/CAV2 causes downregulation of 
CAV1/CAV2 mRNA and protein builds on previous lines of work highlighting CAV1 as potential 
therapeutic target for neurodegenerative disease. For example, neuron-specific up-regulation 
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of CAV1 in the SOD1G93A ALS mouse model has shown to extend survival and improve motor 
function (Sawada et al., 2019). Up-regulation of CAV1 is also demonstrated to improve 
cognition and hippocampal plasticity in aged mice, as well as promote axonal and dendritic 
growth in primary neurons (Head et al., 2011, Head et al., 2010, Mandyam et al., 2017).  
 
As previously mentioned, CAV1 and CAV2 are structural components of caveolae, which are 
small vesicular invaginations of MLR that are important for signal transduction (Sowa et al., 
2001). Therefore, I hypothesised that the observed mutation-specific reduction in CAV1 and 
CAV2 expression would negatively impact MLR integrity. To test for this, I performed live 
imaging of ganglioside GM1 using CTxB in patient-derived LCLs as a measure of MLR 
integrity. I observed a reduction in CTxB expression in the chr7:116222625T>C patient line 
compared to neurologically normal control patients without a CAV1/CAV2 enhancer variant. 
Strikingly, CAV1 protein expression was shown to positively correlate with the fluorescence 
intensity of CTxB, suggesting a direct dependence of CAV1 expression on MLR integrity. 
Indeed, gangliosides, particularly GM1, are shown to be responsible for the trafficking and 
maintenance of these caveolae domains (Singh et al., 2010). I propose a convergence 
between GLT8D1- and CAV-ALS disease pathways via disrupted MLR integrity and 
subsequently dysregulated neurotrophic signalling.  
 
 
7.1.4. Identified genetic risk factors converge on disruption of neurotrophic signalling  
 
Neurotrophic factors are endogenous signalling proteins that promote the survival and integrity 
of specific neuronal populations, as well as stimulating neuronal differentiation (Ekestern, 
2004). Impaired neurotrophic signalling pathways, and the brain-derived neurotrophic factor 
(BDNF) signalling pathway in particular, is a well described feature in ALS pathophysiology 
(Bronfman et al., 2007, Sleigh et al., 2019, Pradhan et al., 2019). Various neurotrophic growth 
factors are shown to promote neuronal survival and stimulate regeneration in the CNS. For 
example, co-administration of ciliary neurotrophic factor (CNTF) and BDNF in the ALS wobbler 
mouse was shown to arrest disease progression (Mitsumoto et al., 1994). Moreover, the BDNF 
agonist, 7,8-dihydroxyflavone, improved motor neuron deficits in SOD1G93A ALS mice 
(Korkmaz et al., 2014). ALS patient motor neurons express high levels of the BDNF receptor’s 
truncated isoform, TrkB.T1. Targeted deletion of TrkB.T1 has been demonstrated to slow the 
onset of motor neuron degeneration, as well as delay the development of muscle weakness 




Despite these encouraging pre-clinical studies, no neurotrophins have yet succeeded in a 
clinical phase III trial, possibly due to low blood-brain-barrier penetrance or limited biological 
half-life (Henriques et al., 2010). Interestingly, the most effective ALS treatment, Riluzole, is 
an anti-excitotoxic substance that has been demonstrated to stimulate the synthesis of 
neurotrophins BDNF and GDNF in cultured mouse astrocytes (Mizuta et al., 2001). Indeed, 
early synaptic hyper-excitability of MNs is thought to enhance BDNF-mediated signalling, thus 
causing glutamate excitotoxicity, and motor neuron death. Therefore, manipulation of BDNF 
may provide a viable therapeutic option in the future (Pradhan et al., 2019). My work suggests 
that this therapy may need to be applied in a personalised fashion to patients with relevant 
genetic risk.   
 
My work builds upon previous observations that CAV1 function is neuroprotective in 
neurodegenerative disease (Head et al., 2010) and in ALS in particular (Sawada et al., 2019). 
Until now, it was not clear whether CAV1 dysfunction was a cause or effect of neuronal toxicity. 
However, discovery of genetic risk associated with CAV1/CAV2 expression places this 
pathway upstream in the development of disease. My proposed mechanism of 
neurodegeneration resulting from ALS-associated CAV1/CAV2 enhancer variants is 





Figure 7.2. Graphical summary of key findings from the characterisation of pathogenic 
enhancer variants in CAV1 and CAV2, and a proposed ALS disease pathway. A reduction 
in CAV1/CAV2 expression within neurons may cause disruption of MLR, which leads to 




7.2. Future directions 
 
At present, it is still not fully understood how mutations in the glycosyltransferase domain of 
GLT8D1 cause ALS. I have suggested that ALS-associated GLT8D1 variants may increase 
the propensity of the protein to misfold, thus reducing enzymatic activity. Therefore, future 
work should consider defining the crystal structure of the WT and mutant GLT8D1 protein in 
order to identify potential mutation-specific structural alterations. With more time, my main 
focus would be to complete a third biological repeat of the Golgi fragmentation analysis. 
Indeed, my GLT8D1 in vitro data was generated primarily through the use of HEK293 cells, 
which are useful tools for providing insights into potential pathogenic mechanisms; however, 
this work requires validation in a neuronal model to place these findings in the context of the 
CNS. Therefore, I would re-attempt the nucleofection of primary neurons with mutant GLT8D1 
constructs for the subsequent assessment of MLR integrity and measurements of 




My zebrafish data suggest that GLT8D1 is involved in motor system function. However, to fully 
characterise the effect of mutant GLT8D1 within a whole organism, future work should aim to 
create a transgenic zebrafish line using CRISPR/Cas9 genome editing; this technology has 
developed considerably in the past few years alone. The generation of a transgenic line is 
important for modelling an age-related disorder such as ALS. Moreover, neuropathological 
analysis should be performed in this line in order to fully characterise GLT8D1 as a new ALS 
gene. Routine neuropathological investigations should include measurements of motor neuron 
loss, TDP-43 pathology, neuromuscular junction defects, and oxidative stress.  
 
As with any disease-associated genetic discovery, it is extremely important to scan larger 
patient cohorts to identify additional ALS-linked GLT8D1 and CAV1/CAV2 variants, as this 
would determine the true frequency of the mutations within the population. This search may 
lead to the discovery of additional patient material such as fibroblasts, which would aid in my 
previously unsuccessful attempts to generate a co-culture model to address the potential for 
astrocyte-mediated motor neuron toxicity. If additional fibroblast samples were not obtainable, 
my focus would be to genetically manipulate control fibroblast lines using CRISPR/Cas9 prior 
to direct conversion into iNPCs. Recent advancements in this technology such as the 
CRISPR-prime editing method (Anzalone et al., 2019) would suggest that mutations can be 
introduced with high precision, and may also be applicable to my proposed GLT8D1 zebrafish 
model (Liu et al., 2020a).   
 
In conclusion, ALS is a complex multifactorial disease with several known dysregulated 
biological pathways. Understanding the various mechanisms involved in the pathogenesis is 
key to the development of effective treatments. Therefore, effective treatment of the disease 
will likely require modulation of more than one target, and possibly a personalised medicine 
approach. Finally, the rapid degeneration of motor neurons in ALS patients suggests that 
successful early diagnosis is critical in treating the disease effectively, and therefore the 
development of better biomarkers will be necessary. My work on two new genetic variants 
discovered using two different methodologies is remarkable in that it converges on a single 





Figure 7.3. ALS-associated GLT8D1 and CAV1/CAV2 enhancer variants likely converge 
on the same pathological mechanism of disrupted neurotrophic signalling. A reduction 
in CAV1/CAV2 expression within neurons causes disruption of MLR. Impaired enzyme activity 
of GLT8D1 is also linked to disruption of MLR. This proposed mechanism would lead to 
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Appendix 1. Mutations in EOGT found in ALS patients: 
 
ALS-associated missense changes found within EOGT in 4493 sporadic ALS patients and 
1924 controls. Mutations are listed 5’ to 3’; EOGT has 15 exons and is encoded on the reverse 









Appendix 3. Aggregated enhancers linked to all genes within the ‘amyotrophic lateral 











Appendix 5. There is significant overlap between enhancers and ALS-associated variants 





Appendix 6. Sanger sequencing traces of pEGFP-N1_GLT8D1-eGFP vectors. Sequencing 


















Appendix 8. Sanger sequencing traces of pcDNA5/FRT/TO_3xFLAG-GLT8D1 vectors. 














Appendix 9. Representative blot using a commercially available anti-GLT8D1 antibody 
(GeneTex; #GTX123636) to assess specificity following targeted knockdown of GLT8D1 in 







Appendix 10. Sanger sequencing traces of PCS2+_GLT8D1 vectors for the in vitro synthesis 
of capped mRNA for zebrafish embryo microinjection. Sequencing was performed using a 















Appendix 11. Zebrafish survival data presented in the form of Kaplan-Meier survival curves. 
 


























































Appendix 12. Protein bands in un-induced stable HEK293 cells expressing GLT8D1-WT and 






Appendix 13. WGA fluorescence intensity was also measured in the absence of tetracycline, 
showing a modest but non-significant decline in fluorescence intensity in the mutant line 






Appendix 14. Representative images of sham-transfected HEK293 cells, and stable isogenic 
HEK293 cells with tetracycline induced expression of GLT8D1-WT and GLT8D1-R92C. Cells 
were co-labelled with a CellMaskTM plasma membrane stain (red) to identify cell regions and 





Appendix 15. The presence of either a G78W or R92C mutation in GLT8D1 does not affect 





Appendix 16. Representative immunostaining of GLT8D1-ALS patient and age- and sex-
matched control fibroblasts using a commercially available anti-GLT8D1 antibody (green) 







Appendix 17. Representative immunoblot for CAV2. Multiple bands detecting inconsistent 

















Appendix 19. CRISPR editing efficiency in LCLs using the PX459 plasmid. Sequencing traces 









Appendix 20. Representative images of Pax6 staining in undifferentiated and differentiated 








Appendix 21. Representative images of α-tubulin staining in undifferentiated and 
differentiated SH-SY5Y cells. Images show unedited cells or cells with a CRISPR-mediated 













Appendix 22. Representative blot following lysis of LCLs using IP lysis buffer. A signal was 
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